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Abstract 
Best vitelliform macular dystrophy (BVMD) is a rare form of macular dystrophy 
involving degeneration of the retinal pigment epithelium (RPE). It is characterised by 
accumulation of fluid and lipofuscin in the macula region, and consequently shares 
similarities with one of the leading causes of blindness, age-related macular 
degeneration. BVMD is known to be caused by mutations in the BEST1 gene, which 
encodes for the Bestrophin-1 (BEST1) protein. Over 100 BVMD-causing BEST1 
mutations have been reported including the F305S mutation. The aim of this thesis 
was to characterise a new and unreported human embryonic stem (ES) cell line 
containing the F305S BEST1 mutation to better understand the molecular pathology 
of BVMD. The first experimental chapter focused on characterising the pluripotent 
properties of the F305S-mutant BEST1 human ES cell line and its capacity to 
differentiate into RPE. The results revealed the F305S-mutant BEST1 human ES 
cells were highly similar to normal human ES cells, and that RPE derived from both 
normal and F305S-mutant BEST1 human ES cells displayed defining RPE properties 
including: pigmentation, polygonal morphology and expression of important RPE 
genes and proteins. A key finding was that BEST1 protein in the F305S-mutant 
BEST1 RPE was shown to be localised predominantly within the cells compared to 
BEST1 in the normal RPE, which was localised predominantly at the plasma 
membrane. In the second experimental chapter, whole-cell patch clamp 
electrophysiology showed that RPE derived from the F305S-mutant BEST1 human 
ES cells had similar voltage-gated sodium and potassium currents compared to RPE 
derived from normal human ES cells. As heterologous overexpression systems 
suggest BEST1 protein may regulate chloride (Cl
-
) and calcium (Ca
2+
) movements, 
the third experimental chapter used whole-cell patch clamp to compare Cl
-
 and Ca
2+
 
    
 
xvii 
 
currents in RPE derived from normal and F305S-mutant human ES cells. These data 
revealed reduced Cl
-
 and Ca
2+
 conductance in the F305S-mutant BEST1 RPE 
compared to normal human ES cell-derived RPE. These data suggest that in human 
RPE BEST1 can i) act as a Ca
2+
-activated Cl
-
 channel, and ii) regulate intracellular 
Ca
2+
. Importantly, while these data are consistent with data from heterologous 
overexpression systems, they are also biologically more relevant as they were 
obtained from human RPE expressing endogenous levels of BEST1 protein without 
BEST1 overexpression. Overall, the data presented in this thesis begin to define the 
molecular consequences of BEST1 mutation on both Ca
2+
 and Cl
-
 conductance in 
human RPE. The data also indicate further investigation of human ES cell-derived 
RPE will provide new molecular insights and potentially identify different treatment 
options for BVMD and age-related macular degeneration.  
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1.1. Disease modelling using human pluripotent stem cells 
1.1.1. Best vitelliform macular dystrophy 
Macular degeneration involves the progressive dysfunction of the retina and the 
underlying retinal pigment epithelium (RPE) that results in loss of high acuity vision, 
particularly in the central macula region of the retina (Bressler et al., 1988). Best 
vitelliform macular dystrophy (BVMD) is a rare disease, with the incidence reported 
in Denmark (1.5:100,000) and a county in Sweden (0.2:1000) (Nordstrom, 1974, 
Bitner et al., 2012) as well as case studies from other countries including Australia. 
(Stone et al., 1992, Marquardt et al., 1998, Caldwell et al., 1999, Kramer et al., 2000, 
White et al., 2000, Wabbels et al., 2006, Marchant et al., 2007, Cohn et al., 2011). 
BVMD is an autosomal dominant disorder with an early juvenile onset, where the 
penetrance is incomplete and its development is highly variable as different patients 
within the same family can show a number of clinical manifestations (Marmorstein 
et al., 2000, Seddon et al., 2003, Wabbels et al., 2006, Marchant et al., 2007, Cohn et 
al., 2011). BVMD is characterised by an accumulation of yellow pigment known as 
lipofuscin (degraded lipids and proteins) within and beneath the RPE and central 
macula, in addition to a decreased, slow light peak seen in the electro-oculogram 
(EOG) (Petrukhin et al., 1998, Rosenthal et al., 2006, Marmorstein et al., 2006, 
Arden and Constable, 2006, Marchant et al., 2007). Currently, there is no cure for 
BVMD. 
Mutations in the BEST1 gene are responsible for BVMD, with over 100 
disease-causing BEST1 gene mutations, mostly missense mutations, having been 
identified including the F305S BEST1 mutation (Marquardt et al., 1998, Petrukhin et 
al., 1998, Caldwell et al., 1999, Kramer et al., 2000, White et al., 2000, Seddon et al., 
  Chapter 1: Introduction 
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2003, Wabbels et al., 2006, Marchant et al., 2007). The BEST1 gene encodes for the 
Bestrophin-1 (BEST1) protein found to be expressed in RPE cells. Despite this 
knowledge the molecular mechanisms of BVMD remain unclear, indicating a real 
need to define the affected disease pathways in order to identify therapeutic targets 
that might reverse or delay BVMD disease progression. It is thought that obtaining a 
more detailed understanding of how BEST1 functions in human RPE will help 
provide mechanistic links between BEST1 mutations and characteristic BVMD 
symptoms, such as an abnormal light peak seen in patient EOG and the accumulation 
of lipofuscin and fluids around the RPE and macula (Petrukhin et al., 1998, Marchant 
et al., 2007, Arden and Constable, 2006, Marmorstein et al., 2006, Thompson et al., 
2015). BVMD can also be a model for age-related macular degeneration as both 
diseases share characteristics such as the abnormal accumulation of water and 
lipofuscin (i.e., protein and lipid products) within the retina that results in a loss of 
visual acuity (Marquardt et al., 1998, Bressler et al., 1988, Stone et al., 1992). 
Therefore an increased understanding of the molecular mechanisms of BEST1 
function could lead to improved treatments for both RPE-based blinding disorders. 
 
1.1.2.  An unlimited source of human cells from human pluripotent stem cells 
Human pluripotent stem (PS) cells are defined as cells that can both self-renew 
indefinitely in vitro and produce any cell type within an organism (Thomson et al., 
1998). These PS cells include human embryonic stem (ES) cells (derived from pre-
implantation embryos) and human induced PS cells which are produced by 
reprogramming adult cells (somatic cells) back to an embryonic-like state (Figure 
1.1) (Thomson et al., 1998, Takahashi et al., 2007). When derived from genetically 
  Chapter 1: Introduction 
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normal embryos, human ES cells are defined by their normal karyotypes, expression 
of telomerase activity, expression of particular cell surface antigens associated with 
pluripotent cells (e.g., TRA-1-81, TRA-1-60) and expression of specific pluripotency 
genes such as OCT4, NANOG, SOX2, FOXD3 (Thomson et al., 1998, International 
Stem Cell et al., 2007, Bradley et al., 2010, O'Connor et al., 2011, Ungrin et al., 
2007).  
In culture, human ES cells can be manipulated to differentiate into specific 
cell types. This process can be aided by understanding the intrinsic and extrinsic 
factors involved in normal development of a specific cell type, in order to be able to 
introduce these factors into the cell culture at the appropriate time to direct the 
differentiation process (Hirano et al., 2003, Meyer et al., 2009). Since the discovery 
of human ES cells, a great deal of effort has been put into understanding and 
exploiting their crucial characteristic of being able to differentiate into any cell type. 
There are a large number of studies investigating phenotypic and functional 
characteristics of cell types such as enterocytes (Spence et al., 2011), cardiomyocytes 
(Mummery et al., 2002), endocrine and neuronal cells (Schuldiner et al., 2000, 
Schuldiner et al., 2001, D'Amour et al., 2006) and RPE (Meyer et al., 2009, Brandl et 
al., 2014, Klimanskaya et al., 2004).  
Multiple studies have demonstrated that the human PS cells in vitro can 
generate retinal progenitors and RPE (Meyer et al., 2009, Singh et al., 2013a, 
Klimanskaya et al., 2004, Singh et al., 2013b, Idelson et al., 2009, Carr et al., 2009, 
Hirami et al., 2009). Currently, human foetal RPE is the culture standard for 
comparison of human PS cell-derived RPE (Buchholz et al., 2009, Singh et al., 
2013b). Notably, there are characteristics that define human ES cell-derived RPE 
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such as: cell morphology (i.e., monolayer of pigmented, cuboidal cells), key 
expression of RPE proteins and genes (i.e., BEST1, RPE65, and ZO-1), 
transepithelial resistance and the ability to phagocytose photoreceptor outer segments 
(Singh et al., 2013a, Klimanskaya et al., 2004). 
The strong similarities between human PS cell-derived RPE and primary 
human RPE, coupled with the ability to generate large numbers of normal human 
cells make ES cells a powerful source of cells for transplantation therapies, as shown 
by clinical trials underway with human ES cell-derived RPE to treat macular 
degeneration (Schwartz et al., 2015). Importantly, human ES cells provide a unique 
tool to study the development and function of human ES cells to RPE to better 
understand the molecular mechanisms of normal development and disease 
progression. Therefore, these advances in stem cell research will help in the 
development of new and or improve cell therapies and treatment for RPE-based 
blinding disorders such as BVMD and age-related macular degeneration.  
  
  Chapter 1: Introduction 
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Figure 1.1: Sources of human PS cells in embryonic development Human ES 
cells are derived from the blastocyst and human induced PS cells are derived 
from somatic cells after re-expression of pluripotency genes reprograms them to 
possess the self-renewal and differentiation capacities of ES cells (Carr et al., 
2013). 
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1.1.3. Human pluripotent stem cells: a new paradigm for disease modelling 
Studies show that human induced PS cells possess similar characteristics to human 
ES cells such as: morphology, expression of pluripotency genes, expression of cell 
surface antigens and the ability to form teratomas containing endodermal, 
mesodermal and ectodermal cell types (Chin et al., 2009, Takahashi et al., 2007, Yu 
et al., 2007a). Advantages of human induced PS cells include the elimination of 
embryos required to generate human ES cells, the ability to generate disease-specific 
cells for which no embryos are available, and the ability to generate patient-specific 
cells in order to reduce immune rejection in cell replacement transplantation 
therapies (Yu et al., 2007a, Takahashi et al., 2007, Chin et al., 2009). Conversely, 
disease-specific human ES cells provide an opportunity to study human diseases in 
human cells without requiring any genetic manipulation or erasing of epigenetic 
marks that occurs with human induced PS cells. 
Moreover, human ES cell lines that contain mutations to specific diseases can 
be shown to possess pluripotent characteristics such as expression of pluripotent cell 
surface antigens and also pluripotency genes that are unaffected by the genetic 
mutation (Bradley et al., 2011, Dumevska et al., 2016). The use of disease-specific 
human ES cells thus provides an opportunity to study the development of diseased 
tissue using cells in which no genetic manipulation has been required for generation 
of the pluripotent cell. It is therefore reasonable to predict that disease-specific 
human ES cells will more closely model disease progression than heterologous 
overexpression systems, and in doing so can provide an opportunity to better 
understand currently untreatable diseases.  
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1.2. Importance of the RPE 
The RPE is a monolayer of pigmented polygonal epithelial cells, where its apical 
membrane is facing the photoreceptor outer segments and the basolateral membrane 
faces the choroid (Figure 1.2) (Strauss, 2005, Wimmers et al., 2007, Swaroop et al., 
2009). The RPE becomes a functional unit with photoreceptors when its apical 
microvilli extend and surround the extended photoreceptor outer segments in the 
subretinal space to allow close interaction (Strauss, 2005). The position of the RPE is 
essential for the support and preservation of retinal integrity and visual function of its 
surrounding tissue (Strauss, 2005). The retinal integrity is maintained by the RPE 
through secretion of growth factors (e.g., PEDF and VEGF) to the choroid (Strauss, 
2005). RPE has many functions which include: the transport of ions and nutrients 
from choroidal circulation (i.e. a network of blood vessels) to the retina; stray light 
absorption via the RPE pigment; formation of the blood retinal barrier; and recycling 
of damaged retinal photoreceptors (Rosenthal and Strauss, 2002, Strauss, 2005). 
 
1.2.1. RPE function 
1.2.1.1. Absorption of light 
During the visual cycle, light entering the eye through the cornea and the lens is 
focused onto the macula. Photons of light not absorbed by the photoreceptors (stray 
light) are absorbed by the pigmentation of the RPE (Strauss, 2005). This light energy 
triggers functions such as: the regeneration of all-trans retinal, the phagocytosis of 
photoreceptor outer segments (POS) and the homeostasis of ions and water within 
the subretinal space (Thompson and Gal, 2003). Another response to the detection of 
7.7 µm 
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light is the metabolism of vitamin A and the cycling of retinoids between the 
photoreceptors and the RPE; this process is important for the formation of visual 
pigments that allow the absorption of light (Thompson and Gal, 2003). The 
expression of RPE65 is essential for the conversion of vitamin A to 11-cis retinal; if 
it was absent, an accumulation of trans-retinal esters would occur resulting in the 
blocking of the retinoid process, thus RPE65 is often used as a marker of mature 
RPE. The reduced ability to absorb/detect light is causatively linked to retinal 
diseases (i.e., Leber congenital amaurosis and retinitis pigmentosa) (Gu et al., 1997, 
Lorenz et al., 2000, Thompson and Gal, 2003). 
It is thought that phagocytosis of the POS may be activated through photo-
oxidative damage to the proteins, lipoproteins and lipids within the POS (Strauss, 
2005). Clinically, RPE function is detected using an EOG and is used to examine the 
RPE in patients with BVMD, retinitis pigmentosa and Leber congenital amaurosis 
(Whatham et al., 2014, Arden and Constable, 2006). Potentials are generated by eye 
movements, these potentials are recorded during changes in light (i.e., dark phase to 
light phase) (Arden and Constable, 2006). In healthy eyes, during the dark phase the 
potentials reduce with time, in contrast during the light phase the potentials peak - 
hence the light peak generated by the EOG (Arden and Constable, 2006, Whatham et 
al., 2014). The light peak in the EOG is thought to be caused by the depolarisation of 
a basolateral membrane chloride (Cl
-
) channel in the RPE (Gallemore and Steinberg, 
1993, Arden and Constable, 2006). Cl
-
 and calcium (Ca
2+
) are thought to play key 
roles in RPE functions such as phagocytosis of shed POS and the generation of the 
light peak seen in the EOG (Muller et al., 2014, Singh et al., 2013b, Marmorstein et 
al., 2006).  
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1.2.1.2. Transepithelial transport and ion homeostasis in the subretinal space 
Transepithelial transport by the RPE is essential for the homeostasis of ions and 
water within the subretinal space (Wimmers et al., 2007). To control the volume in 
the subretinal space the RPE mediates the movement of fluid to the choroid 
(Wimmers et al., 2007, Strauss, 2005). The movement of ions occurs when 
extracellular stimuli cause an increase in intracellular free Ca
2+
, which in turn 
activates Ca
2+
-activated Cl
-
 and potassium (K
+
) channels (Strauss, 2005, Wimmers et 
al., 2007). Also the presence of a sodium (Na
+
)/ K
+
-ATPase pump in the apical 
membrane and a Cl
-
 channel in the basolateral membrane of RPE cells allows for the 
absorption of extra Na
+
 ions (moving out of the RPE) and secretion of Cl
-
 ions 
(moving into the RPE) from the subretinal space (Wimmers et al., 2007, Kunzelmann 
et al., 2007, Jaffe et al., 1989). 
K
+
 and Na
+
 are regulated by different ion channels, co-transporters, pumps 
and exchangers that are found in the RPE; these function to maintain cell pH as well 
as ion and fluid homeostasis (Quinn and Miller, 1992, Strauss, 2009, Fox et al., 1988, 
Hughes and Takahira, 1996). The K
+
 channels are the most extensively studied ion 
channels in the RPE, and have been implicated in RPE functions such as the Na
+
/K
+
 
pump, which play a role in transepithelial transport and the regulation of the ion 
composition of the subretinal space via the RPE (Fox et al., 1988, Hughes and 
Takahira, 1996, Strauss et al., 1993). The Na
+
/K
+
 pump on the apical membrane 
returns Na
+
 to the subretinal space to help the photoreceptors function properly. 
Understanding the ion homeostasis properties in RPE is important, given the key 
functions that ion gradients perform in driving transport of fluid and ions to support 
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RPE and maintain the photoreceptor outer segments and the choroid (Wimmers et 
al., 2007, Carr et al., 2009, Klimanskaya et al., 2004).  
 
1.2.1.3. Phagocytosis of shed photoreceptor outer segments 
One of the most important roles of the RPE is the phagocytosis of shed POS. This 
process occurs daily within the RPE, with the POS estimated to be renewed every 11 
days. To do this the RPE has been estimated to ingest over 25,000 shed 
photoreceptor discs per day (Muller et al., 2014, Fischmeister and Hartzell, 2005, 
Young, 1967). As mentioned above, the RPE and photoreceptors are in close 
interaction with one another to maintain the structural integrity of the eye (Young 
and Bok, 1969). A disruption in this process can lead to an accumulation of 
lipofuscin (end products of oxidative damage caused by degraded POS) within the 
subretinal space, leading to the degeneration of the RPE and photoreceptors, and thus 
leading to a diseased state (Muller et al., 2014, Singh et al., 2013b, Strauss et al., 
2016). 
A number of hypotheses exist for the activation of phagocytosis activity. For 
example, one activator is thought to be the second messenger inositol triphosphate 
(Heth and Marescalchi, 1994). Another is thought to be an interaction between 
BEST1 and L-type Ca
2+
 channels (Rosenthal et al., 2006, Muller et al., 2014).  
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B C A 
Figure 1.2: RPE location and morphology A) A schematic diagram of the location of the RPE in the eye. B) A diagram showing the location of the 
RPE between the photoreceptors and choroid (Swaroop et al., 2009) and C) Human ES cell-derived RPE displaying its characteristic polygonal 
morphology and pigmentation (scale bar = 20 µm). 
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1.3.  Bestrophin-1 protein in focus  
1.3.1. The structure and function of the Bestrophin protein 
The BEST1 gene is located on chromosome 11q13 encoding for the BEST1 protein, 
which contains 585 amino acids and has a molecular mass of 68 kDa (Petrukhin et 
al., 1998, Marchant et al., 2007). BEST1 mRNA shows expression in a number of 
tissues, but in humans the protein appears to be exclusively expressed in the RPE 
(Marchant et al., 2007, Petrukhin et al., 1998).  
X-ray crystallography structures of BEST1 protein have been constructed for 
both chicken BEST1 (sharing 74% sequence identity with human BEST1) and for 
the bacteria klebsiella pneumonia (Kp) Best1, which shares 14% identity with human 
BEST1 (Yang et al., 2014, Kane Dickson et al., 2014). Both studies show that 
BEST1 forms a pentamer of transmembrane protein units, suggesting there are 5 
BEST1 subunits that form the active protein. These studies suggest that BEST1 can 
form a Ca
2+
-activated anion channel capable of transporting anions such as Cl
-
 (Yang 
et al., 2014, Kane Dickson et al., 2014).  
A number of studies using non-RPE heterologous overexpression systems 
such as HEK293 human kidney cells and Madin-Darby canine kidney (MDCKII) 
cells suggest it may act as (i) a Cl
-
 channel activated by Ca
2+
 (Sun et al., 2002, 
Kunzelmann et al., 2009), (ii) a regulator of voltage-gated Ca
2+
 channels (Muller et 
al., 2014, Reichhart et al., 2010, Rosenthal et al., 2006, Yu et al., 2008), (iii) a 
volume regulator (Fischmeister and Hartzell, 2005, Milenkovic et al., 2015), or (iv) a 
multifunctional protein, where BEST1 may function as a Cl
-
 channel and a regulator 
of Ca
2+
 in a feedback loop (Rosenthal et al., 2006, Hartzell et al., 2008).  
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BEST1 localises predominantly at or near the plasma membrane (where it 
may be located close to endoplasmic reticulum) of the RPE, suggesting that BEST1 
plays a role in the BVMD phenotype (Klimanskaya et al., 2004, Marmorstein et al., 
2000, Milenkovic et al., 2011b, Davidson et al., 2009, Bakall et al., 2003, Singh et 
al., 2013b). For example, a BEST1 localisation study was conducted in MDCKII 
cells (Milenkovic et al., 2011b). The expression of wild-type BEST1 was shown to 
be strongly localised to the plasma membrane by immunofluorescence (Milenkovic 
et al., 2011b). In contrast, the 13-associated BEST1 missense mutations also 
investigated in this study showed defective localisation to the plasma membrane 
compared to wild-type BEST1 (Milenkovic et al., 2011b). One of the mutations 
investigated in this study was the F305S BEST1 missense mutation; it was shown 
that the MDCKII expressing BEST1 with this mutation had one of the most severe 
trafficking defects of all the mutant BEST1 proteins studied (Milenkovic et al., 
2011b). The F305S-mutant BEST1 protein was shown to be partially retained within 
the golgi complex, endoplasmic reticulum and in early endosomes, indicating that 
they fail to undergo proper processing (Milenkovic et al., 2011b). Other experiments 
that measured the fluorescence intensity caused by anion fluxes in HEK293 
heterologous overexpression system revealed reduced anion permeability resulting 
from different BEST1 mutations including the F305S BEST1 mutation (Milenkovic 
et al., 2011b). These data suggest that the defective trafficking observed by BEST1 
mutations leads to a reduction in anion function.  
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1.3.2. Electrophysiological reports of BEST1 function  
1.3.2.1. BEST1 a newly defined Cl
-
 channel activated by Ca
2+
 
Cl
-
 channels are anion channels that can conduct multiple anions such as Cl
-
, 
bicarbonate, bromide, iodide, nitrate and thiocyanate (Suzuki et al., 2006). Cl
-
 
channels can be modulated in a number of ways including through phosphorylation, 
intracellular Ca
2+
, various ligands (e.g., ATP) and changes in cell volume (Suzuki et 
al., 2006). In the RPE, Cl
-
 channels function to maintain homeostasis through the 
movement of fluid and ions to its surrounding tissues: specifically the photoreceptors 
and choroid (Hu et al., 1996, Weng et al., 2002, Wills et al., 2000). The Cl
- 
channels 
are thought to be involved in RPE volume regulation (Milenkovic et al., 2015, 
Fischmeister and Hartzell, 2005, Wills et al., 2000) and in the generation of the light 
peak seen in the EOG (Marmorstein et al., 2002, Gallemore and Steinberg, 1989). 
Multiple Cl
-
 channels have been previously identified in the RPE, these include: 
cystic fibrosis transmembrane conductance regulator (CFTR), Cl
-
 channel (ClC)-2, -
3, -5 and -7 and volume-activated Cl
-
 channels (Weng et al., 2002, Wills et al., 2000, 
Botchkin and Matthews, 1993, Sun et al., 2002). 
Overexpression data suggests BEST1 is a Ca
2+
-activated Cl
-
 channel (CaCC) 
(Sun et al., 2002). BEST1 has been shown to exhibit specific characteristics of 
CaCCs such as: (i) the ability to produce distinct current-voltage (I-V) relationships 
suggesting BEST1 is responsible for part or all of the conductance seen in 
electrophysiology studies, (ii) ion selectivity of the proposed channel (i.e., Cl
-
 < Br
-
 < 
I
-
 < NO3
-
), (iii) increased activity with Ca
2+
, (iv) ability to form pentamers, (v) 
normal but not mutant BEST1 Cl
-
 conductance can be inactivated by sulfhydryl-
reactive agents MTSET
+
 and MTSEA
-
 (these reagents are used to study protein 
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structure and activity), and vi) BEST1 mutations inhibit the Cl
-
 conductance (Sun et 
al., 2002, Tsunenari et al., 2003, Yang et al., 2014, Kane Dickson et al., 2014, 
Marmorstein et al., 2015, Qu and Hartzell, 2008, Yu et al., 2007b).  
Electrophysiological studies after overexpression of BEST1 sequences from 
various species such as humans, Caenorhabditis elegans and Drosophila 
melanogaster have been shown to result in whole-cell Cl
-
 conductance that was 
voltage-dependent, and a resting potential near zero (Marmorstein et al., 2015, Sun et 
al., 2002, Qu and Hartzell, 2008, Liu et al., 2015). The Cl
-
 conductance seen in these 
cells was blocked by the reversible Cl
-
 channel inhibitor 4,4’diisothiocyanostilbene-
2,2’-disulfonate (DIDS) (Liu et al., 2015, Sun et al., 2002). Further 
electrophysiological studies have shown BEST1 Cl
-
 conductance is sensitive to Ca
2+
 
in overexpression systems (Sun et al., 2002, Liu et al., 2015). The whole-cell Cl
-
 
conductance increased with an increase of intracellular Ca
2+
, suggesting that BEST1 
is a CaCC (Sun et al., 2002, Liu et al., 2015). 
Importantly, the light peak seen in the EOG is thought to be mediated via 
basolateral Cl
-
 conductance through an internal second messenger (i.e., Ca
2+
) (Arden 
and Constable, 2006). Accordingly, BEST1 is thought to play a key role in the 
generation of the light peak due to its ability to regulate both Cl
-
 and Ca
2+
 currents. 
Thus the decrease in Cl
-
 conductance seen with overexpression of mutant BEST1 
compared to wild-type BEST1 may result in the reduced light peak seen in the EOG 
in BVMD patients as a consequence of these mutations (Sun et al., 2002). 
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1.3.2.2.  BEST1 plays an integral role in Ca
2+ 
regulation 
Ca
2+
 has many functional roles that are involved in the initiation or stimulation of 
certain cell functions due to its ability to bind and modify proteins. Within cells 
including the RPE a low concentration of intracellular Ca
2+
 is essential for 
proliferation, migration, apoptosis and differentiation (Zhang et al., 2011a). In the 
RPE, intracellular free Ca
2+
 regulates: differentiation of RPE, transepithelial 
transport of ions and water, secretion of growth factors, dark adaptation activity and 
phagocytosis of photoreceptors to maintain homeostasis of the RPE, as well as the 
structural integrity of its surrounding tissue (Muller et al., 2014, Rosenthal et al., 
2007, Rosenthal and Strauss, 2002, Wimmers et al., 2008, Rosenthal et al., 2006). 
One family of Ca
2+
 channels that has been described in the RPE is voltage-dependent 
Ca
2+
 channels (VDCC). It has been shown that RPE cells express L-type Ca
2+
 
channels which are a subtype of VDCC (Mergler et al., 1998, Muller et al., 2014, 
Reichhart et al., 2010, Rosenthal et al., 2006, Strauss et al., 1997, Strauss et al., 2016, 
Yu et al., 2008). Other Ca
2+
 channels described in the RPE include ligand-gated Ca
2+
 
channels and transient receptor potential channels (Wimmers et al., 2007). 
Expression profiling studies have shown human RPE expresses certain 
subunits of L-type and T-type voltage- dependant Ca
2+
 channels. The expression of 
their pore-forming (i.e., α2δ1-α2δ4) and auxillary subunits (i.e., β1-β4) has also been 
shown (Wimmers et al., 2008). In heterologous overexpression systems co-
immunoprecipitation and co-localisation studies have shown that BEST1 and the L-
type Ca
2+
 channel β-subunit bind and form a complex together with CaV1.3 through 
its binding with the β-subunit (Wimmers et al., 2008). It has also been demonstrated 
that the C-terminus of BEST1 has a proline rich region, and within this region are 
  Chapter 1: Introduction 
18 
 
predicted SH3 binding domains, which could associate with the SH3 domain of 
CaV1.3 L-type Ca
2+
 channel (Rosenthal et al., 2006, Yu et al., 2008, Milenkovic et 
al., 2011a). These findings suggest that BEST1 can interact with and modulate the 
pore activity of VDCC CaV1.3 L-type Ca
2+
 channel (Milenkovic et al., 2011a). There 
is also evidence that L-type channels in the RPE are modulated by the protein 
tyrosine kinase (PTK), pp60
c-src
, with the help of protein kinase C (PKC) (Strauss et 
al., 1997). Whole-cell patch clamp electrophysiology performed on cultured rat and 
human RPE showed that L-type Ca
2+
 channel activity can be reduced or increased 
depending on the activity of PKC on PTK (Strauss et al., 1997). It has also been 
suggested that L-type Ca
2+
 channels may be involved in the secretion of growth 
factors within the RPE (Rosenthal et al., 2007), and so BEST1 activity may also 
impact on this important RPE function. 
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1.4.  Hypothesis and Aims 
1.4.1. Hypothesis 
This study investigated a newly established human ES cells line, GENEA069 that 
contains the clinically-relevant F305S BEST1 gene mutation known to cause BVMD. 
The underlying hypothesis for this thesis was that F305S-mutant BEST1 human ES 
cells possess defining molecular characteristics of pluripotent cells, and that 
comparison of RPE-derived from normal and the F305S-mutant BEST1 human ES 
cells will provide molecular insights into BVMD. 
 
1.4.2. Aims 
The aims of this project were:  
1. To characterise the pluripotency phenotype and RPE differentiation capacity 
of F305S-mutant BEST1 human ES cells relative to normal human ES cells. 
 
2. To characterise the Na+ and K+ currents in RPE derived from normal and 
F305S-mutant BEST1 human ES cells and to compare these to Na
+
 and K
+
 currents 
in primary human RPE.  
 
3. To investigate Cl- and Ca2+ conductance in RPE-derived from normal and 
F305S-mutant BEST1 human ES cells that express endogenous levels of BEST1 
protein. 
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Experiments using human embryonic stem (ES) cells were performed in accordance 
with national guidelines with oversight by the Western Sydney University Human 
Research Ethics Committee (approval H10950) and Biosafety and Radiation Safety 
Committee (approval B8022 and B10355). 
 
2.1. Human ES cell lines 
2.1.1. Cell line details 
MEL-1 human ES cells supplied by StemCore, University of Queensland, were 
generated in accordance with the Australian National Health and Medical Research 
Council Licensing Committee (Licence #309709). The GENEA069 human ES cells 
(containing the BVMD-causing F305S mutation) were produced and provided by 
Genea Biocells (Sydney, Australia) under licence in compliance with relevant 
legislation (Licence #309710). 
 
2.1.2. Genomic characterisation of the GENEA069 cells 
Characterisation assays performed by Genea Biocells on the GENEA069 cells as part 
of their routine cell line production process included: DNA fingerprinting and 
comparative genomic hybridisation (CGH) karyotyping, as well as mycoplasma and 
sterility testing. 
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2.1.3. Human ES cell line maintenance 
All human ES cell lines were cultured using previously described conditions 
optimised for human ES cell maintenance (O'Connor et al., 2008). Briefly, human ES 
cells were cultured in 60 mm tissue culture plates coated for 30 minutes (room 
temperature) with a 1 mg/mL solution of the extracellular matrix Matrigel (BD 
Biosciences, Sydney, Australia). The extracellular matrix was added to aid in cell 
attachment. The cells were cultured in the defined, feeder-free medium mTeSR1™ 
(StemCell Technologies Inc., Melbourne, Australia) with daily medium changes 
(Ludwig et al., 2006a, Ludwig et al., 2006b). Once the human ES cells reached 
confluence, the plates were washed with 2 mL phosphate buffered saline (PBS; 
StemCell Technologies, Melbourne, Australia), incubated (37°C, 5% CO2) for 3-4 
minutes in 1 mg/mL dispase (StemCell Technologies), to harvest the cells as 
aggregates. The cells were washed three times with 3 mL of PBS before being 
collected in 2 mL of Dulbecco’s Modified Eagle’s Medium (DMEM, StemCell 
Technologies). The cells were scraped off the plate using a cell scraper (Greiner Bio-
One, Melbourne, Australia) and transferred to a 15 mL tube (Greiner Bio-One). The 
culture dish was washed with 3 mL of PBS, which was then transferred to the 15 mL 
tube containing the human ES cells and the cells pelleted by centrifugation (300 x g 
for 5 minutes) using an Allegra X 15R centrifuge (Beckman Coulter, Sydney, 
Australia). The supernatant was removed and the cells were gently resuspended in 1 
mL of mTeSR1™. The cells were replated as aggregates in mTeSR1™ on Matrigel-
coated tissue culture plates for continued maintenance, with daily mTeSR™ medium 
changes. 
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2.1.4. Human ES cell differentiation to RPE 
Differentiation of human ES cells to RPE was performed similar to that described by 
Meyer et al. (Meyer et al., 2009). Briefly, on Day 0 of differentiation the pluripotent 
cells were incubated for an hour with 10 µM Rho-associated kinase (ROCK) 
inhibitor Y-27632 (Merck, NSW, Australia). The cells were then washed with 2 mL 
PBS, incubated (7-10 minutes, 37°C, 5% CO2) in 1 X TrypLE™ (Thermo Scientific, 
Melbourne, Australia) to harvest as single cells. The cells were collected and 
transferred to a 15 mL tube; the plate was washed with 3 mL of PBS and this wash 
transferred to the 15 mL tube before centrifugation (300 x g for 5 minutes). The cells 
were resuspended in ES cell medium consisted of DMEM/F12, 15% knockout serum 
replacer, 2 mM L-glutamine and 1% non-essential amino acid (NEAA) 
supplemented with 10 µM Y-27632. Embryoid bodies (EB) are aggregates of stem 
cells. To form EBs approximately 1.5 x 10
6
 cells were transferred to each AggreWell 
800 insert (StemCell Technologies Inc.) in 6-well plates and centrifuged (300 x g for 
5 minutes), these single cells were then cultured to form EBs over a 2 day period. On 
day 2 the EBs were transferred to a 60 mm non-adherent petri dishes in fresh ES cell 
medium. Two days later the EBs were transferred to a neural induction (NI) medium 
containing: DMEM/F12, 1% N2 supplement, 2 mM L-glutamine and 1% NEAA. 
After a further 2 days (i.e., on day 6 of RPE differentiation) the EBs were made 
adherent by transferring them to tissue culture plates previously coated with 1 
mg/mL Matrigel for 30 minutes. Thereafter the NI medium was changed every three 
to four days until day 16 of differentiation. On day 16 the medium was changed to 
retinal differentiation medium (RDM) which contained DMEM/F12, 2% B27 
supplement 2 mM L-glutamine, 1% NEAA and 10 mM nicotinamide (Sigma-Aldrich 
Pty. Ltd., Sydney, Australia) (Idelson et al., 2009). From day 40 onwards, the 
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medium was changed to foetal retinal pigment epithelium (FRPE) medium that 
consisted of alpha Minimum Essential Media (α-MEM), 15% foetal bovine serum 
(FBS), 1% N1 supplement, 1% NEAA, 2 mM L-glutamine 20 µg/L hydrocortisone, 
250 mg/L taurine, 0.013 µg/L triiodo-thryonine and 1% penicillin streptomycin 
(Maminishkis et al., 2006).  
 
2.1.5. Isolating human ES cell-derived RPE 
Throughout differentiation the cells were observed using an Olympus CKX41 
inverted microscope (Olympus, Melbourne, Australia). Areas of pigmentation were 
harvested for downstream experiments typically from days 60 – 90 of differentiation. 
To do this, pigmented areas from differentiating cultures of normal and F305S-
mutant BEST1 human ES cells were manually excised by removing non-RPE areas 
surrounding the pigmented areas with a needle. The pigmented cells were scraped off 
the plate and collected with a p20-200 pipette, transferred to a 1.5 mL microfuge 
tube and centrifuged using a QikSpin microfuge (2000 x g for 1 minute; Edwards, 
Sydney, Australia). Excess media was removed and the cells were resuspended in 
500 µL of TrypLE™ and incubated (37°C, 5% CO2) for 7 minutes. After incubation 
cells were centrifuged in a Microfuge® 22R centrifuge (Beckman Coulter, Australia) 
at 300 x g for 5 minutes. The supernatant was removed and the pigmented cells were 
either: 
1. Resuspended and triturated in 200 µL FRPE medium, then plated as single 
cells on Matrigel-coated Thermanox™ glass coverslips (Thermo Scientific, 
Melbourne, Australia) or glass bottom tissue culture dishes (14 mm diameter, 
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glass #0, MatTek, Massachusetts, USA) and incubated overnight for patch 
clamp and single cell immunofluorescence respectively OR 
2. Resuspended in Lysis Buffer RLY and 1% β-mercaptoethanol to collect RNA 
for Affymetrix arrays and PCR. 
 
2.2. Quantitative polymerase chain reaction  
2.2.1. RNA collection 
Cells were collected from normal and F305S-mutant BEST1 human ES cell-derived 
RPE for RNA was purified using a Bioline Isolate II RNA Mini-kit (Bioline, Sydney, 
Australia). Briefly, cells were resuspended in Lysis Buffer RLY containing 1% β-
mercaptoethanol, and RNA purified as per the manufacturer’s instructions. Further 
purification of the RNA was performed by adding 12 µL of DNase and 8 µL of 10 X 
DNase Reaction Buffer (Promega, Sydney, Australia) to each sample and run in the 
Mastercycler® thermal cycler (Eppendorf, Sydney, Australia) at 37°C for 30 
minutes. A stop solution was then added to each sample, the samples were placed 
back in the thermal cycle at 65°C for 10 minutes. After DNase treatment, the 
concentration of all RNA samples was taken in triplicates using a NanoPhotometer
TM
 
(Integrated Sciences, Sydney, Australia). The volume of RNA needed to provide 500 
ng of RNA for cDNA synthesis was calculated. All purified RNA was stored in a -
80°C freezer, until further analysis. 
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2.2.2. cDNA synthesis via reverse transcription 
The initial step of cDNA synthesis involved combining 500 ng of RNA, 2 µL of 25 
µg random hexamer (Bioline) and RNase-free water, to a total volume of 15 µL in a 
1.5 mL microtube (Interpath). The reaction was gently mixed, and centrifuged using 
a Qikspin (2000 x g for 1 minute). The samples were placed in a Mastercycler® 
thermal cycler at 70°C for 5 minutes. For each RNA sample, 3 cDNA reactions were 
performed: (i) the first sample included RNA and reverse transcriptase (+ RT) to 
generate cDNA; (ii) the second sample tested for genomic DNA contamination of the 
RNA by not including reverse transcriptase (-RT); and (iii) a no RNA control was 
included that tested for DNA contamination of the PCR reagents (Figure 2.1). Each 
PCR reaction master mix A consisted of 6 µL of 5 X Reaction buffer, 1.5 µL of 10 
mM dNTPs , 1.5 µL of 40 U/uL RNase Inhibitor and 6 µL DNase and RNase-free 
water with a final total of 15 µL. Bioscript enzyme (4 µL of 200 U/µL; Bioline) was 
added to the +RT and no RNA control samples, but not the – RT samples. The 
samples were gently mixed, and centrifuged using a Qikspin (2000 x g, 1 minute). 
PCR was performed using the Mastercycler® thermal cycler at the following 
settings: cycle step 1: 42°C for 60 minutes and cycle step 2: 70°C for 10 minutes. 
The cDNA samples were used for PCR amplification of specific mRNA transcripts. 
 
Master Mix A 
RNA 
Bioscript 
Master Mix A 
RNA 
 
Master Mix A 
Bioscript 
Figure 2.1: cDNA sample set up 
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2.2.3. Primer design 
Forward and reverse primers for specific genes of interest were designed using the 
Primer3 web interface (http://frodo.wi.mit.edu/primer3/) and exon sequences for 
specific genes were obtained using the UCSC genome browser 
(http://genome.ucsc.edu/). A sequence spanning from one end of one exon to the start 
of the next exon was input into Primer3 and primer design initiated using the 
following parameters: 60°C melting temperature, and 80 – 120 base amplicon length. 
The resulting predicted primers were then searched against the entire known human 
genome and transcriptome using the Blast nucleotide web interface 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?) to check whether predicted primers bound 
anywhere else in the genome. If they did, the primer design process was repeated 
until unique primers were acquired (Table 2.1). Primers were obtained from 
GeneWorks (Thebarton, South Australia) 
 
 
 
Table 2.1: Primer sequences (5’ to 3’) 
Gene Forward primer sequence Reverse primer sequence 
BEST1 TTTGCCAACCTGTCAATGAA GGTGTTCATCTCGTTCAGCA 
RPE65 GAAACTTGGGTTTGGCAAGA GCTCACCACCACACTCAGAA 
MITF CGAAAGTTGCAACGAGAACA GAGCCTGCATTTCAAGTTCC 
PAX6 CCGGCAGAAGATTGTAGAGC TCTCGTAATACCTGCCCAGAA 
GAPDH ATTGCCCTCAACGACCACT ATGAGGTCCACCACCCTGT 
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2.2.4. PCR amplification of mRNA transcripts 
PCR reactions were tested between 55°C and 60°C in order to find out the optimal 
working temperature of each primer set. Each PCR reaction contained 40 cycles of: 
high temperature to separate cDNA strands test temperature to allow primers to bind 
to the cDNA, then cDNA transcript extension at 72°C. The PCR products were 
assessed for amplicon length by running on a 2% agarose gel run at 100 V, 300 mA, 
50 W for 40 minutes. Gels were imaged on a GelDock transiluminator (Fisher Biotec 
Pty. Ltd., WA, Australia) using the E-Box software and analysed to ensure only one 
product was produced and that this was of the predicted size.  
 
2.2.5. Real-time PCR 
Semi-quantitative real-time PCR was performed using primers that passed the above 
validation steps. The master mix used for real-time PCR consisted of SYBR® Select 
Master Mix (ThermoFisher Scientific) and 1 µL of 6.25 µM forward and reverse 
primers. Each real-time PCR reaction was performed in triplicates in a 96-well flat 
top low profile ultraflex PCR plate (Interpath, Victoria, Australia) and contained: 6 
µL of the master mix containing appropriate primers and 4 µL of cDNA (either +RT, 
-RT or NTC). The plate was centrifuged (1000 x g, 1 minute) before being placed in 
a Mx3005P real-time-PCR System (Aligent Technologies, Sydney, Australia) and 
programmed using the MxPro real-time-PCR software (Figure 2.2). 
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2.2.6. Analysis of relative quantitation of gene expression 
Cycle threshold (Ct) values were obtained for real-time PCR reactions based on 
SYBR green fluorescence crossing a threshold level during the extension phase of 
the real-time PCR reaction. The Ct values were generated for each gene of interest 
(GOI) such as MITF, PAX6, RPE65 and BEST1 using the MxPro real-time-PCR 
software. The delta delta Ct (ΔΔCt) value for each reaction was used in calculating 
the relative gene expression for each GOI this was normalised to the expression of 
GAPDH to determine the ΔCt, this was applied to all biological replicates, which 
were then exponentially transformed (2
-ΔCt
). The exponentially transformed values 
obtained from the biological replicates were averaged to provide a mean ΔCt value 
and standard error of the mean (SEM) ΔCt values for each GOI. To calculate the 
ΔΔCt values, the mean ΔCt from the F305S-mutant BEST1 RPE GOI were 
normalised to normal human ES cell-derived RPE mean ΔCt, this was repeated for 
normalising the SEM ΔΔCt.  
 
Figure 2.2: Schematic of the cycle steps using the MxPro real-time-PCR 
software 
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2.3. Flow cytometry 
2.3.1. Antibody staining for flow cytometry 
Undifferentiated human ES cells were harvested as single cells. After collection via 
TrypLE, a cell pellet was obtained using a Microfuge® 22R centrifuge (300 x g for 5 
minutes), the supernatant was removed, and a small volume was left to break up the 
pellet before fixing the cells so they did not become fixed as one large cell aggregate. 
To fix the cells, 200 μL of 2% paraformaldahyde (PFA) in phosphate buffered saline 
(PBS) was added; the cells were gently mixed and put on ice for 15 minutes. The 
cells were centrifuged (300 x g for 5 minutes), supernatant was removed and the 
pellet was resuspended in 10% foetal bovine serum (FBS; ThermoFisher Scientific) 
in PBS. A cell count was performed and the samples used for intracellular staining 
were permeabilised using 0.1% Saponin (100 mg of Saponin, 100 mL of PBS and 1 
mL of 10% bovine serum albumin; BSA; Amresco, OH, USA) for 15 minutes at 
room temperature. The intracellular samples were centrifuged (300 x g for 5 
minutes), the supernatant removed, and the cells resuspended in 100 µL of 0.1% 
Saponin. The primary antibodies used were; 2 µg/µL TRA-1-60 (Sapphire 
Bioscience, Sydney, Australia), 2 µg/µL TRA-1-81 (Sapphire Bioscience, Sydney, 
Australia) and 0.25 µg/µL OCT4 (BD Biosciences, Sydney, Australia). These 
primary antibodies were added to their appropriate samples, mixed gently and 
incubated on ice for 20 minutes. After incubation the samples were washed with 
1mL of their appropriate buffers, centrifuged (300 x g for 5 minutes), and the 
supernatant removed without disturbing the cell pellet. For a 1/10 dilution of the 
secondary antibodies; 1 µL of appropriate secondary antibody was diluted in 1 mL 
of 2% BSA in PBS. The secondary antibodies used were: Alexa Fluor-488 anti-
mouse IgG (Thermo Fisher Scientific, Scoresby, Australia) for the intracellular 
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samples; and Alexa Fluor-488 anti-mouse IgM (Invitrogen) secondary antibody used 
for the extracellular sample. All samples were mixed gently and incubated on ice for 
20 minutes. After incubation, samples were washed with their appropriate buffers 
and centrifuged (300 x g for 5 minutes). The supernatant was removed without 
disturbing the pellet, and the cells were resuspended in either 200 μL of 0.1% 
Saponin (intracellular samples) or 10% BSA in PBS (extracellular samples) for 
analysis. 
 
2.3.2. Flow cytometry data acquisition 
Antibody stained samples were analysed using a MACSquant flow cytometer 
(Miltenyi Biotec, Australia Pty. Ltd.). Three plots were used for data acquisition: (i) 
forward scatter (FSC-area) versus side scatter (SSC-area) with gating of human ES 
cell population; (ii) analysis of human ES cells via FSC-area vs FSC-height to limit 
the analysis to single cells (i.e. not doublets); and (iii) histogram analysis of the 
single cells to detect secondary antibody fluorescence. The final plot, the gating used, 
designated 99.9% of the events detected in the secondary-only antibody stained 
sample as negative events (i.e. ~ 0.1% of the events designated as real positive events 
to account for possible non-specific binding of the secondary antibody to the cells). 
The flow cytometer detector voltages were adjusted using a secondary only stained 
sample, to ensure proper positioning of the cells within the graphs. This was used as 
a control for the primary and secondary stained samples. The primary and secondary 
stained samples were then analysed using these 3 plots and the identical gate settings 
established for their relevant control samples.  
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2.4. Colony forming assay for undifferentiated human ES cells 
To perform the alkaline phosphatase (AP)-based colony forming cell (CFC) assay 
undifferentiated human ES cells were harvested as single cells. After collection via 
TrypLE the cells were filtered through a 40 µm cell strainer (BD Biosciences) to 
remove cell aggregates. The human ES cells were pelleted by centrifugation (300 x g 
for 5 minutes), the supernatant was removed, and the cells were gently resuspended 
in 1 mL of mTeSR1™ with 10 µM Y-27632 inhibitor. Two independent cell counts 
were performed. Undifferentiated cells were plated in separate Matrigel™-coated 
wells of a 6 well tissue culture plate at three different densities (5x10
3
, 1x10
4
 and 
5x10
4
); within the linear detection range for this assay (O'Connor et al., 2008). 
Thereafter, 1 mL of mTesR1™ medium changes were performed daily. After 7 days 
the medium was removed and the wells were washed with 2 mL of PBS. Cells were 
fixed and stained for AP activity using the AP Leukocyte Kit following the 
manufacturer’s instructions (Sigma-Aldrich, Sydney, Australia). Counts of stained 
colonies containing greater than 30 cells were performed using an Olympus CKX41 
inverted microscope (Olympus, Melbourne, Australia). The percentage of the colony 
frequency was calculated by dividing the number of colonies by the density the cells 
were plated. 
 
2.5. Teratoma Assay 
The GENEA069 human ES cells used for this assay were replated in T25 cell culture 
flasks (Greiner Bio-one, Interpath services, Victoria, Australia) and maintained in 
mTeSR1™. The cells were shipped overnight at room temperature to StemCore 
(Stem Cells Limited, Queensland) where the teratoma assay was performed. The 
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F305S-mutant BEST1 human ES cells were harvested using Collagenase IV 
treatment, washed in DMEM/F12 and resuspended in injection buffer supplemented 
with 10% FBS and 30% Matrigel™. Cells were injected intramuscularly into the 
hind leg of CB17-SCID mice at a concentration of approximately 1x10
6
 cells in 50 
μL. After 14 weeks, they were removed, fixed and stained for histopathological 
analysis (Wesselschmidt, 2011, International Stem Cell et al., 2007, Thomson et al., 
1998, O'Connor et al., 2011). 
 
2.6. Immunofluorescence 
Monolayer and isolated RPE cells from both normal and F305S-mutant BEST1 
human ES cell-derived were plated as single cells on glass bottom tissue culture 
plates (14 mm diameter, glass #0, MatTek). Cells plated for monolayer 
immunofluorescence were grown for a month before being fixed and stained. In 
contrast RPE for single cell immunofluorescence were fixed 24 hours after replating. 
For immunofluorescence both monolayer and single cells were fixed with 2% 
paraformaldahyde (PFA) in PBS for 10 minutes at room temperature. Cells were 
permeabilised using 0.2% Triton X-100 in PBS for 30 minutes at room temperature. 
After this time the cells were washed 3 x 10 minutes with PBS. Non-specific binding 
sites were then blocked on the cells using 2% BSA in PBS for one hour. The primary 
antibodies and their concentrations used were: 2.5 µg/mL ZO-1 (ThermoFisher 
Scientific), 5 µg/mL RPE65 (Merck Millipore) and 5 µg/mL BEST1 (Merck 
Millipore), each being diluted to their specific working concentrations using 1% 
BSA/PBS. Permeabilised cells were incubated overnight at 4°C with 200 µL primary 
antibody, after which it was removed and the cells were washed 3 x 10 minutes with 
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PBS. Secondary antibodies and their concentration used for indirect fluorescent 
imaging were: 2 mg/mL Alexa Fluor 488 Goat anti-rabbit IgG secondary antibody 
for ZO-1; and 2 mg/mL Alexa Fluor 488 Goat anti-mouse IgG secondary for both 
RPE65 and BEST1. Cells were stained with 200 µL secondary antibody at room 
temperature for 30 minutes. The cells were then washed 3 x 10 minutes with PBS 
before the nuclear stain Hoechst 33342 (ThermoFisher Scientific) was added to the 
cells at a concentration of 2 µg/mL and incubated for 10 minutes at room 
temperature. The Hoechst was removed and the cells were washed with PBS 3x 10 
minutes. Using the LSM-5 Pascal Confocal Microscope system (Zeiss, Sydney, 
Australia) the localisation of these proteins was imaged. Single cell analysis of 
multiple fluorescent images included a frequency cell count of single cells expressing 
fluorescence at the membrane and cytoplasm or in the cytoplasm only. The Fishers 
exact test (n < 100) was calculated in GraphPad prism (GraphPad Software, 
California, USA) to calculate the probability between protein localisation in RPE 
derived from normal and F305S-mutant BEST1 human ES cells. 
 
2.7. Electrophysiology 
2.7.1. Whole-cell patch clamp data collection 
Single human ES cell-derived RPE cells were plated at low density on Matrigel-
coated Thermanox™ glass coverslips (ThermoFisher Scientific) and the cells chosen 
for whole-cell patching were highly pigmented. Whole-cell currents were recorded at 
room temperature, with an Axon MultiClamp700B amplifier connected to a Digidata 
1440A data acquisition system with pClamp 10 software (Molecular Devices, CA, 
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USA). The cells were viewed under a BX51 fixed-stage upright microscope 
(Olympus) using a 40X objective lens. The series resistance (Rs) was monitored 
throughout the experiment and was in the range of 15 – 25 MΩ. Micropipettes were 
pulled from thick-walled borosilicate glass pipettes with filament (1.5 mm x 0.86 
mm x 10 cm; SDR scientific, Sydney Australia) using a glass puller (P-97, Sutter 
Instruments, CA, USA), giving the electrode a resistance of 5 - 10 MΩ. Recordings 
from isolated cells were made in voltage-clamp mode, where data was sampled at a 
rate of 10 kilohertz and filtered by a 6 kilohertz low pass filter. In the pClamp 
software P/N leak subtraction was enabled, this removed capacitive and the passive 
membrane currents (leakage currents) from the whole-cell current to allow 
assessment of voltage-dependent currents. P/N leak subtraction protocol was set to: 4 
subsweeps, of polarity the same as waveform to occur before each individual sweep, 
with a minimum start-to-start time and 100 ms settling time. 
 
2.7.2. Solutions 
2.7.2.1. Whole-cell Na
+
 and K
+
 currents 
To study whole-cell Na
+
 and K
+
 currents, the external solution consisted of (in mM): 
140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 glucose and 10 Na-HEPES (Sun et al., 
2002). The internal solution consisted of (in mM): 30 KCl, 100 potassium gluconate, 
15 KHCO3, 0.5 CaCl2, 1 MgCl2, 5-5 EGTA-KOH, 1 ATP-Na2 and 1 GTP-Na2 with 
an osmolarity of 263 mOsm (Wen et al., 1993, Wen et al., 1994). Pharmacological 
blockers were dissolved in external solution at the following concentrations for the 
K
+
 channel blockers were: 5 mM 4-aminopyridine (4-AP) and 20 mM 
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tetraethylammonium (TEA). The concentration of the hyperpolarising activated 
cation channel blocker was 2.5 µM 4-ethylphenylamino-1,2-dimethyl-6-
methylaminopyrimidinium chloride (ZD7288) and Na
+
 channel blocker 50 nM 
tetrodotoxin (TTX). All blockers were added individually or in combination to the 
external solution. All reagents were purchased from Sigma Aldrich (Sydney, 
Australia). 
 
2.7.2.2. Whole-cell Cl
-
 and Ca
2+
 currents 
Whole-cell chloride currents were recorded between the voltage ranges of - 120 mV 
to + 120 mV using voltage steps of 10 mV or 20 mV, with a holding potential of - 50 
mV. All reagents were purchased from Sigma Aldrich (Sydney, Australia). The 
external solution consisted of (in mM): 130 tetramethylammonium chloride (TMA-
Cl), 2 NaH2PO4, 2 CaC12, 1 MgSO4, 5 glucose and 10 Na-HEPES , the internal 
solution consisted of (in mM): 130 TMA-Cl, 0.2 CaCl2, 3 MgSO4, 2 EGTA, 10 
HEPES, 3 Na-ATP with an osmolarity of 300 and 275 mOsm respectively and a pH 
of 7.4 (Wills et al., 2000). Pharmacological blockers were dissolved in external 
solution at the following concentrations 0.5 mM 4,4'-diisothiocyanato-stilbene-2,2'-
disulphonic acid (DIDS) and 1 mM Cadmium chloride (CdCl2).  
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2.7.3. Analysis of whole-cell patch clamp data 
The approximate membrane capacitance and resting membrane potentials were 
recorded and averaged (mean ± SEM) for both normal and F305S-mutant BEST1 
human ES cell-derived RPE. These values were compared to published primary 
human foetal RPE and adult RPE using an unpaired t-test (GraphPad Software), with 
comparison of the mean, standard deviation and the number of cells analysed. The 
Fishers exact test (n < 100) was used to calculate the difference in the frequency of 
voltage-gated Na
+
 and K
+
 channels between the normal and F305S-mutant BEST1 
RPE. Statistical analysis of the Na
+
 current density values from human ES cell-
derived RPE was compared to primary human RPE using an unpaired t test, with the 
following values used for analysis: mean, standard deviation and the number of cells. 
The recorded voltage-gated currents were analysed offline using AxoGraph X 
(CA, USA) and Microsoft excel. The current (nA) values from the raw traces of the 
voltage-dependent currents across all voltage ranges (- 120 mV to + 120 mV) were 
measured at the steady state. The current densities were normalised by dividing the 
current (nA) with membrane capacitance (pF) and averaged (mean ± SEM) for both 
normal and F305S-mutant BEST1 human ES cell-derived RPE currents. A two-way 
ANOVA was conducted to compare the difference in current densities between 
normal and F305S-mutant BEST1 RPE (GraphPad). The same statistical analysis 
was conducted on the current densities on data collected before and after the 
application of Na
+
, K
+
, Cl
-
 and Ca
2+
 blockers on normal and F305S-mutant BEST1 
human ES cell-derived RPE.  
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2.8. Affymetrix gene expression analysis 
2.8.1. Affymetrix microarray analysis 
Three biological replicate RNA samples were collected from RPE-derived from both 
normal (i.e. MEL1) and F305S mutant (i.e. GENEA069) human ES cells. The RPE 
was harvested as single cells, RNA was collected and purified and then DNAse 
treated; 500 ng of RNA from each of the 6 samples (i.e. 3 for each cell line) was sent 
to the Ramaciotti Centre for Gene Function Analysis (University of New South 
Wales, Australia) for Affymetrix microarray analysis. Each sample underwent 
quality control procedures (e.g. spectrophotometer and Agilent Bioanalyzer) to 
assess the purity and integrity of the RNA samples before they were analysed using 
Human Gene 2.0ST microarrays. The microarray results were uploaded as ‘.CEL’ 
files, and processed using the online bioinformatics tool GenePattern (Kuehn et al., 
2008).  
 
2.8.2. Identifying RPE gene expression data 
The GenePattern module ‘Expression File Creator’ was used to create a ‘.RES’ file 
(i.e., tab-delimited text file) from the microarray ‘.CEL’ files. The ‘.RES’ file 
contained a row for each Affymetrix transcript identification (ID) number, as well as 
a column for each RNA sample indicating a gene name corresponding to the 
Affymetrix ID and another column indicating whether the transcript was detected as 
present (‘P’) or absent (‘A’). The data was exported to Microsoft Excel where 
duplicate gene entries (e.g. due to each gene having multiple Affymetrix probe ID 
numbers) were removed from each sample. The data from all 6 samples was then 
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sorted based on ‘P’ and ‘A’ values to generate a gene expression (i.e., ‘3P’) list for 
the MEL1-derived RPE and another for the GENEA069-derived RPE. 
 
2.8.3. Analysis of published human foetal and adult RPE datasets 
Publically-available gene expression datasets obtained from fresh and cultured 
human fRPE and adult RPE (aRPE) were retrieved from the Gene Expression 
Omnibus (GEO; accession number: GSE18811). The datasets were analysed using 
GenePattern in the same way as described for human ES cell-derived RPE datasets. 
The ‘3P’ lists generated for the primary human fRPE and aRPE datasets were then 
compared with the ‘3P’ lists obtained for the normal and F305S-mutant BEST1 
human RPE. 
 
2.8.4. Identifying Gene ontology categories in human ES cell-derived RPE 
The online Database for Annotation, Visualisation and Integrated Discovery 
(DAVID) was used to classify genes based on their biological processes. The gene 
ontology (GO) Biological Process 5 was selected, as it categorised genes that are 
highly associated to specific biological processes (Huang da et al., 2009b, Huang da 
et al., 2009a). Analyses were conducted on shared gene lists identified in human ES 
cell-derived RPE and primary human RPE; statistical GO term categories were 
selected based on their P-value (≤ 0.05) calculated by DAVID.  
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2.8.5. Identifying ion channels in the expressed gene lists  
A keyword search for ion homeostasis genes was performed on the ‘3P’ gene lists to 
identify ion channels expressed by human ES cell RPE and primary human RPE. For 
the RPE list of identified ion channels was analysed using the online Protein 
Analysis Through Evolutionary Relationships (PANTHER) database, to identify 
particular families of ion homeostasis proteins (Thomas et al., 2003).  
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3.1. Introduction 
Human embryonic stem (ES) cells are a unique tool that were first described in 1998 
by Thomson et al., in the hopes they may provide new information on the molecular 
mechanisms responsible for normal and pathological development in all cell types, as 
well as using stem cells as an alternative treatment in cell replacement therapy 
(Thomson et al., 1998). Human ES cells are pluripotent cells derived from the inner 
cell mass of the blastocyst obtained using donated embryos from in vitro fertilisation 
programs (Thomson et al., 1998). Human ES cells possess the ability to be 
maintained in a proliferative state for prolonged periods of time (i.e. self-renewal), 
while retaining the capacity to differentiate into any cell type in the body (i.e. they 
are pluripotent) (Thomson et al., 1998).  
Specific criteria are used to ensure that newly established human ES cell lines 
are pluripotent. These include the ability to (i) form colonies from individual cells 
that have a high nucleus to cytoplasm ratio and express the pluripotency marker 
alkaline phosphatase, (ii) express certain pluripotency genes, such as transcription 
factors (i.e., OCT4, NANOG, SOX2, FOXD3) and cell surface markers (i.e., TRA-1-
81, TRA-1-60) and (iii) form a teratoma in vivo containing derivatives of endoderm, 
mesoderm and ectoderm (International Stem Cell et al., 2007, Thomson et al., 1998, 
O'Connor et al., 2011, O'Connor et al., 2008, Ungrin et al., 2007).  
In culture, human ES cells can be manipulated to differentiate into specific 
cell types e.g., lens progenitor cells, endocrine and neuronal cell types (Schuldiner et 
al., 2000, Schuldiner et al., 2001, D'Amour et al., 2006, Hirano et al., 2003, Yang et 
al., 2010). Furthermore, studies have demonstrated that the differentiation of human 
pluripotent stem (PS) cells in vitro can generate retinal progenitors and retinal 
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pigment epithelium (RPE) (Klimanskaya et al., 2004, Singh et al., 2013a, Meyer et 
al., 2009, Idelson et al., 2009, Carr et al., 2009, Lu et al., 2009). The RPE is a 
monolayer of pigmented, polygonal epithelial cells that function to maintain its 
surrounding tissue (i.e., photoreceptor outer segments and choroid) (Carr et al., 2009, 
Klimanskaya et al., 2004, Strauss, 2005). RPE functions include: the transport of 
fluid and ions, absorption of stray light and phagocytosis of shed photoreceptor outer 
segments (Carr et al., 2009, Klimanskaya et al., 2004, Strauss, 2005). Disruption to 
these essential RPE functions can result in the accumulation of debris within and 
beneath the RPE, leading to the degeneration of the RPE and the photoreceptors, thus 
causing irreversible blindness (Tombran-Tink, 2007, Strauss, 2005).  
Currently, human ES cell-derived RPE is in Phase I/II clinical trials 
investigating the safety and efficacy of these cells in patients with age-related 
macular dystrophy and Stargardt’s macular dystrophy (Schwartz et al., 2015). These 
advances in stem cell research will help in the development of new and/or improve 
cell therapies for RPE-based blinding disorders.  
An alternative way to identify potential treatment for RPE blindness disorders 
is through in vitro studies utilising human PS cells. Further study of human PS cell 
progression into functional RPE may provide new information to better understand 
the development of normal and diseased (e.g. Best vitelliform macular dystrophy; 
BVMD) RPE. This study aimed to characterise the pluripotency phenotype and RPE 
differentiation capacity of F305S-mutant BEST1 human ES cells relative to normal 
human ES cells. The combined analyses showed that the F305S-mutant BEST1 
human ES cells have a similar pluripotent phenotype to normal human ES cells, they 
are capable of differentiating into RPE, and the RPE generated from them has shared 
 Chapter 3: Characterisation of a novel human ES cell line containing the F305S BEST1 mutation 
44 
 
gene expression with both normal human ES cell-derived RPE and primary human 
foetal RPE (fRPE). This new, BVMD-specific human ES cell line thus provides a 
suitable and highly novel model system to study the development and progression of 
BVMD.  
 
3.2. Results 
3.2.1. GENEA069 cells possess the disease-causing F305S BEST1 mutation 
Sequencing of the BEST1 gene by Genea Biocells using cells extracted from the 
originating GENEA069 embryo revealed the T to C base change (Figure 3.1 A) 
known to cause BVMD (Bakall et al., 1999). This mutation results in a phenylalanine 
(F) to serine (S) amino acid change at position 305 in the BEST1 protein. To 
investigate whether the GENEA069 cells contained other genomic abnormalities, the 
cells were further profiled using comparative genomic hybridisation. This approach 
revealed there were no genomic copy number changes detected within the 200 
kilobase resolution of the arrays (Figure 3.1 B).  
 
3.2.2. F305S-mutant BEST1 human ES cells display typical pluripotency 
phenotypes 
To determine whether the GENEA069 cells are truly pluripotent, a variety of 
phenotypic characterisation assays were performed. Morphological assessment 
showed the F305S-mutant BEST1 cells displayed the typical morphology of 
undifferentiated human pluripotent cells. Light micrographs showed the cells were 
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able to form circular growth areas (Figure 3.2 A) consisting of tightly packed cells 
with a high nucleus to cytoplasm ratio (Figure 3.2 B).  
The expression of known pluripotency genes OCT4, NANOG, SOX2 and 
FOXD3 was investigated in the GENEA069 human ES cells via PCR. The results 
showed expression of all of these key pluripotency genes in the F305S-mutant 
BEST1 human ES cells (Figure 3.2 C). Further molecular characterisation using flow 
cytometry showed that, when maintained in conditions that support maintenance of 
human PS cells, the vast majority of cultured GENEA069 cells (~ 90% or greater) 
expressed high levels of the extracellular pluripotency-associated antigens TRA-1-60 
(90.0% ± 4.4%; n = 5) and TRA-1-81 (96.1% ± 3.7%; n = 5), as well as the key 
pluripotency transcription factor OCT4 (88.0% ± 3.3%; n= 6) (Figure 3.2 D).  
 
3.2.3. F305S-mutant BEST1 human ES cells are functional human ES cells 
Functional assays commonly used to assess human ES cells include the alkaline 
phosphatase-based CFC assay and the teratoma assay. The CFC assay has been 
shown to be capable of reliably quantifying the presence of self-renewing human ES 
cells through their ability to express alkaline phosphatase, which is a marker of 
pluripotency (O'Connor et al., 2008). Alkaline phosphatase is highly expressed in 
cells of the inner cell mass of human blastocysts. Furthermore, these alkaline 
phosphatase positive human ES cells are able to generate cell types representative of 
all three germ layers, which is another indicator of pluripotency (O'Connor et al., 
2008). A CFC assay was used to estimate the frequency of functional pluripotent 
stem cells within the F305S-mutant BEST1 human ES cell cultures. This assay was 
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chosen as it quantifies the frequency of pluripotent single cells capable of forming 
colonies containing alkaline phosphatase-expressing cells over a seven day period 
(Figure 3.3 A) (O'Connor et al., 2008), and this frequency can be compared with that 
obtained for highly-characterised human ES cell lines. Using this assay the 
GENEA069 cultures were shown to contain an average of 4.4% ± 3.6% CFCs, a 
figure consistent with well characterised human ES cell lines (O'Connor et al., 2008). 
 
3.2.4. F305S-mutant BEST1 human ES cells form teratomas 
The teratoma assay was performed using the GENEA069 human ES cells to 
determine if they have the ability to differentiate into cells from all three embryonic 
germ layers, i.e.: endoderm, mesoderm and ectoderm. The results of this assay 
showed production of representative ectodermal cells (e.g., squamous and 
neuroepithelium cells; Figure 3.3 B), mesodermal cells (e.g., smooth muscle and 
cartilage cells; Figure 3.3 C) and endodermal cells (e.g., glandular epithelium cells; 
Figure 3.3 D). 
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Figure 3.1: Genetic characterisation of GENEA069 human ES cells A) 
DNA sequence showing the T to C base change that causes the phenylalanine 
to serine amino acid change at position 305 in the Bestrophin 1 (BEST1) 
protein. B) Comparative genetic hybridisation (CGH) array detected no 
changes in copy number variation. A CGH array detects chromosomal changes 
such as gains and losses that are indicated by deviations in the data plot line 
above each chromosome. The absence of significant variations in any of these 
plot lines show no copy number changes greater than 200 kilobases were 
detected. 
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Figure 3.2: Phenotypic characterisation of undifferentiated GENEA069 
human ES cells A) Light micrographs showing a representative circular 
growth area present in culture plates (scale bar = 156 µm). B) GENEA069 
cells displayed tightly packed undifferentiated cells with a high nuclei to 
cytoplasm ratio (black arrow) (scale bar = 7.7 µm). C) Expression of known 
pluripotent genes detected using PCR. D) Average expression levels of 
pluripotent antigens TRA-1-60 and TRA-1-81 and the transcription factor 
OCT4 were detected using flow cytometry.  
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Figure 3.3: Functional characterisation of undifferentiated GENEA069 
human ES cells A) Colony derived from a single cell GENEA069 cell shows 
strong and uniform alkaline phosphatase positive CFC assay indicated by the 
blue alkaline phosphatase staining (scale bar = 31µm; inset shows higher 
magnification) of B - D) Brightfield images of the three germ layers; 
ectodermal cells (squamous and neuroepithelium cells); mesodermal cells 
(smooth muscle and cartilage cells) and endodermal cells (glandular 
epithelium cells) respectively. 
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3.2.5. Characterisation of F305S-mutant BEST1 RPE relative to normal RPE 
Experiments were undertaken to generate and characterise RPE from both normal 
and F305S-mutant BEST1 human ES cells. Phenotypic and functional features of the 
RPE were examined through a number of assays. Normal and F305S-mutant BEST1 
human ES cells were differentiated using a published protocol (Meyer et al., 2009) 
that has been reported to mimic aspects of RPE development in vivo. Both normal 
and F305S-mutant BEST1 human ES cells generated clusters of pigmented cells with 
polygonal morphology representative of RPE (Figure 3.4 A & C), these were found 
within cultures of mixed phenotypes. Manual excision of these pigmented cell 
clusters generated pure populations of pigmented cells for downstream experiments 
(Figure 3.4 B & D). 
The F305S-mutant BEST1 RPE was investigated for expression of the mature 
RPE genes BEST1, RPE65, PAX6 and MITF by real-time PCR. The results showed 
that the F305S-mutant BEST1 RPE expressed the same mature RPE genes as normal 
human ES cell-derived RPE with no statistical difference detected at the level of 
gene expression (Figure 3.4 E). Overall, there were no differences observed in the 
capacity for different human ES cells to produce RPE efficiently. Both cell lines 
were able to produce clusters of RPE cells that displayed similar expression levels 
for genes known to be expressed by mature RPE. 
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3.2.6. Altered BEST1 localisation in the F305S-mutant BEST1 RPE 
To further characterise the F305S-mutant BEST1 human ES cell-derived RPE an 
immunofluorescence assay was performed to localise the expression of RPE protein 
markers. Manually excised RPE was cultured for one month to enable establishment 
of confluent monolayers of pigmented cuboidal cells. The cells were then fixed, 
stained and imaged. As expected, the normal human ES-derived RPE expressed ZO-
1 at the cell membrane, BEST1 at the plasma membrane and RPE65 in the cytoplasm 
(Figure 3.5 A, C & E). In comparison, the F305S-mutant BEST1 RPE showed a 
similar expression pattern for ZO-1 and RPE65 (Figure 3.5 B & D), however, less 
BEST1 protein was localised at the plasma membrane with most of the protein 
appearing to show intracellular localisation (Figure 3.5 F).  
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Figure 3.4: Characterisation of RPE derived from normal and F305S-
mutant BEST1 human ES cells A & C) Images of RPE derived from normal 
(A) and F305S-mutant BEST1 (C) human ES cells respectively (black scale bar 
= 1 cm), B & D) Non-phase contrast images taken at Day 85 of culture showing 
pigmented, polygonal RPE morphology from normal (B) and F305S-mutant 
BEST1 RPE (D) (white scale bar = 20 µm). E) Real-time PCR analyses showed 
the relative quantitation of RPE genes MITF, PAX6, RPE65 and BEST1 
expression between normal and F305S-mutant BEST1 human ES cell-derived 
RPE. 
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Figure 3.5: Localisation of RPE proteins in normal and F305S-mutant 
BEST1 human ES cell-derived RPE (left to right) A/B) ZO-1 staining at the 
cell membrane was present in both normal and F305S mutant human ES cell-
derived RPE. C/D), RPE65 for both normal and F305S-mutant RPE showed 
staining in the cytoplasm and E/F) The expression of BEST1 in normal human 
ES cell-derived RPE was at the plasma membrane whereas the F305S-mutant 
BEST1 RPE showed intracellular expression of BEST1 (F) (scale bar 100 µm). 
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3.2.7. F305S-mutant BEST1 and normal RPE have similar Affymetrix gene 
expression 
Affymetrix-based gene expression profiling was conducted on F305S-mutant BEST1 
RPE to identify large-scale gene expression changes in comparison to normal human 
ES cell-derived RPE. The Affymetrix analysis of normal human ES cell-derived RPE 
showed expression of 19,886 genes across all 3 samples analysed, while the F305S-
mutant BEST1 human ES cell-derived RPE expressed 20,762 genes in all 3 samples 
tested (Figure 3.6 A). Comparing these datasets showed that the F305S-mutant 
BEST1 human ES cell RPE shared ~ 95% (19,705) expression of genes with normal 
human ES cell-derived RPE, revealing that ~ 5% (1,058) of these genes were 
differentially expressed. Similarly, normal human ES cell-derived RPE shared ~ 99% 
of its expressed genes (19,705) with the F305S-mutant BEST1 RPE, with only ~ 1% 
(181) of its genes differentially expressed compared to F305S-mutant BEST1 RPE. 
Thus the Affymetrix gene expression profile of F305S-mutant BEST1 RPE was 
shown to be highly similar to that of normal human ES cell-derived RPE. 
 
3.2.8. GO analysis reveals biological processes in human ES cell-derived RPE 
Gene lists generated based on the ‘3P’ criteria for both normal and F305S-mutant 
BEST1 human ES cell-derived RPE were processed via DAVID GO analysis at the 
level of biological processes category 5. The analyses of statistically significant (≤ 
0.05) GO terms revealed that RPE-derived from human ES cells shared 50 GO terms 
out of 66 for F305S-mutant BEST1 RPE and 50 out of 61 for normal human ES cell-
derived RPE (Table 3.1). These shared GO terms revealed biological process 
 Chapter 3: Characterisation of a novel human ES cell line containing the F305S BEST1 mutation 
55 
 
categories important in RPE function such as: ‘anion transport’ and ‘inorganic anion 
transport’. The F305S-mutant BEST1 RPE showed 16 statistically significantly 
different GO term categories compared to normal human ES cell-derived RPE, 
though these GO terms did not appear related to RPE-specific functions (Table 3.2). 
In comparison, the review of the 11 GO terms only identified in the normal human 
ES cell-derived RPE identified one biological process related to RPE-specific 
function (i.e., ‘ion homeostasis’; Table 3.2). Of the 382 genes in this ‘ion 
homeostasis’ GO category, 380 genes were also expressed by the F305S-mutant 
BEST1 RPE (Appendix Table A.1). The 2 ‘ion homeostasis’ genes differentially 
expressed in normal human ES cell-derived RPE but not in F305S-mutant BEST1 
RPE were: CCL23 and PROK2. 
Further analysis of the 11 GO categories specific to normal human ES cell-
derived RPE revealed 2,302 genes, of which 2,293 were expressed by the F305S-
mutant BEST1 RPE; the 9 genes that were differentially expressed by normal RPE 
were not related to ion channel or ion transport functions (Table 3.3). Analysis of the 
16 GO categories specific to F305S-mutant BEST1 human-ES cell-derived RPE 
identified 1,789 genes, of which 1,723 were also expressed by the normal human ES 
cell-derived RPE. Analysis of the 66 differentially expressed genes identified only 1 
gene: C1QTNF2 implicated in ion homeostasis (Table 3.4). Taken together, the 
various GO analysis data demonstrated that normal and F305S-mutant BEST1 
human ES cell-derived RPE have a highly similar gene expression profile and that 
these genes are associated with key biological processes to human RPE. 
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Figure 3.6: Comparison of gene expression profiles obtained from RPE datasets 
A) Comparison of normal and F305S-mutant BEST1 human ES cell-derived RPE 
Affymetrix gene expression lists and B) Comparison of primary human foetal and 
adult RPE Affymetrix gene expression lists. 
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Table 3.1: GO categories (Biological Processes 5) 
expressed by normal and F305S-mutant BEST1 human ES cell-derived RPE 
protein modification process regulation of cell migration 
cellular protein metabolic process positive regulation of cell differentiation 
regulation of apoptosis negative regulation of apoptosis 
regulation of programmed cell death cell part morphogenesis 
positive regulation of macromolecule 
metabolic process 
positive regulation of protein metabolic 
process 
Neurogenesis negative regulation of cell death 
positive regulation of cellular metabolic 
process 
negative regulation of programmed cell 
death 
regulation of protein metabolic process regulation of protein modification process 
Phosphorylation Proteolysis 
protein kinase cascade positive regulation of cell proliferation 
regulation of cellular protein metabolic process generation of neurons 
positive regulation of cell death neuron projection development 
protein transport cell projection morphogenesis 
positive regulation of programmed cell death neuron development 
positive regulation of transcription, DNA-
dependent 
Phospholipid metabolic process 
positive regulation of cellular protein 
metabolic process 
positive regulation of apoptosis protein catabolic process 
regulation of signal transduction inorganic anion transport 
anion transport synaptic transmission 
organ morphogenesis neuron projection morphogenesis 
intracellular signalling cascade cell migration 
induction of programmed cell death 
carboxylic acid transport 
cell morphogenesis involved in 
differentiation 
regulation of cell morphogenesis regulation of mitotic cell cycle 
cell morphogenesis negative regulation of cell proliferation 
enzyme linked receptor protein signalling 
pathway 
cellular protein catabolic process 
positive regulation of transcription, DNA-
dependent 
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Table 3.2: GO categories (biological processes 5) differentially expressed by 
normal and F305S-mutant BEST1 human ES cell-derived RPE  
Normal human ES cell-derived RPE F305S-mutant BEST1 RPE 
heart development tissue development 
carboxylic acid metabolic process positive regulation of RNA metabolic process 
regulation of cell development positive regulation of biosynthetic process 
Endocytosis positive regulation of cellular biosynthetic 
process 
regulation of transcription factor activity muscle organ development 
negative regulation of macromolecule 
metabolic process 
positive regulation of nucleobase, nucleoside, 
nucleotide and nucleic acid metabolic process 
ion homeostasis positive regulation of transcription 
negative regulation of cellular metabolic 
process 
regulation of cell cycle process 
learning or memory positive regulation of gene expression 
hexose metabolic process central nervous system development 
positive regulation of transferase activity positive regulation of nitrogen compound 
metabolic process 
 chordate embryonic development 
 embryonic appendage morphogenesis 
 embryonic limb morphogenesis 
 cell morphogenesis involved in neuron 
differentiation 
 positive regulation of macromolecule 
biosynthetic process 
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Table 3.3: PANTHER protein classes identified using GO category genes that were differentially 
expressed in normal human ES cell-derived RPE but not in F305S-mutant BEST1 RPE 
Gene Symbol Gene Name PANTHER Protein Class 
IFNB1 Interferon beta interferon superfamily 
PROK2 Prokineticin-2 peptide hormone 
TLR2 Toll-like receptor 2 receptor 
CCL23 C-C motif chemokine 23 chemokine 
HMX1 Homeobox protein HMX1 homeobox transcription factor 
HPDL 4-hydroxyphenylpyruvate dioxygenase-like protein oxygenase 
CCDC85B Coiled-coil domain-containing protein 85B - 
HHEX Hematopoietically-expressed homeobox protein HHEX - 
DHFR Dihydrofolate reductase reductase 
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Table 3.4: PANTHER protein classes identified using GO term category genes 
that were differentially expressed in F305S-mutant BEST1 RPE 
Gene 
Symbol 
Genes Name PANTHER protein class 
APOA5 Apolipoprotein A-V - 
AVP Vasopressin-neurophysin 2-copeptin neuropeptide 
BGLAP Osteocalcin extracellular matrix protein 
BMP10 Bone morphogenetic protein 10 growth factor 
C17orf47 Uncharacterized protein C17orf47 - 
C1QTNF2 Complement C1q tumor necrosis 
factor-related protein 2 
transporter 
CBFB Core-binding factor subunit beta - 
CEBPA CCAAT/enhancer-binding protein alpha transcription factor 
CHST11 Carbohydrate sulfotransferase 11 transferase 
EDF1 Endothelial differentiation-related 
factor 1 
transcription cofactor 
EGR4 Early growth response protein 4 - 
EN1 Homeobox protein engrailed-1 homeobox transcription factor 
GAS1 Growth arrest-specific protein 1 - 
GJB5 Gap junction beta-5 protein gap junction 
GPR3 G-protein coupled receptor 3 G-protein coupled receptor 
H2AFX Histone H2AX histone 
HMGB2 High mobility group protein B2 HMG box transcription factor 
HOXA5 Homeobox protein Hox-A5 homeobox transcription factor 
HOXA7 Homeobox protein Hox-A7 homeobox transcription factor 
HOXB1 Homeobox protein Hox-B1 homeobox transcription factor 
HOXB4 Homeobox protein Hox-B4 homeobox transcription factor 
HOXB6 Homeobox protein Hox-B6 homeobox transcription factor 
HOXD9 Homeobox protein Hox-D9 homeobox transcription factor 
HTR5A HEAT repeat-containing protein 5A - 
HTR5A 5-hydroxytryptamine receptor 5A G-protein coupled receptor 
IL12B Interleukin-12 subunit beta interleukin superfamily 
IL22 Interleukin-22 interleukin superfamily 
ING1 Inhibitor of growth protein 1 transcription cofactor 
ING2 Inhibitor of growth protein 2 transcription cofactor 
INS Insulin growth factor 
INS-IGF2 Insulin, isoform 2 growth factor 
IVL Involucrin - 
KLF1 Krueppel-like factor 1 - 
KRT6A Keratin, type II cytoskeletal 6A structural protein 
KRT71 Keratin, type II cytoskeletal 71 structural protein 
LCE2A Late cornified envelope protein 2A - 
LCE5A Late cornified envelope protein 5A - 
LINGO1 Leucine-rich repeat and - 
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immunoglobulin-like domain-
containing nogo receptor-interacting 
protein 1 
MAL Myelin and lymphocyte protein membrane traffic protein 
MSTN Growth/differentiation factor 8 growth factor 
MYF5 Myogenic factor 5 basic helix-loop-helix 
transcription factor 
MYL1 Myosin light chain 1/3, skeletal muscle 
isoform 
actin family cytoskeletal 
protein 
NKX2-8 Homeobox protein Nkx-2.8 homeobox transcription factor 
NRIP1 Nuclear receptor-interacting protein 1 - 
NRL Neural retina-specific leucine zipper 
protein 
transcription factor 
PAX9 Paired box protein Pax-9 homeobox transcription factor 
PKIA cAMP-dependent protein kinase 
inhibitor alpha 
kinase inhibitor 
PLG Plasminogen peptide hormone 
PMF1 Polyamine-modulated factor 1 - 
POU3F4 POU domain, class 3, transcription 
factor 4 
homeobox transcription factor 
POU4F2 POU domain, class 4, transcription 
factor 2 
homeobox transcription factor 
PRDM7 Probable histone-lysine N-
methyltransferase PRDM7 
- 
PSMC5 26S protease regulatory subunit 8 hydrolase 
PSPN Persephin neurotrophic factor 
RNF8 E3 ubiquitin-protein ligase RNF8 - 
SKAP1 Src kinase-associated phosphoprotein 1 - 
SOD1 Superoxide dismutase [Cu-Zn] oxidoreductase 
SOX3 Transcription factor SOX-3 HMG box transcription factor 
SP8 Transcription factor Sp8 - 
SPRR1B Cornifin-B - 
TERF1 Telomeric repeat-binding factor 1 nucleic acid binding 
TFAP2B Transcription factor AP-2-beta transcription factor 
TNFSF13 Tumor necrosis factor ligand 
superfamily member 13 
- 
TNKS2 Tankyrase-2 nucleotidyltransferase 
TRAF6 TNF receptor-associated factor 6 signaling molecule 
TSPY2 Testis-specific Y-encoded protein 2 phosphatase inhibitor 
YWHAE 14-3-3 protein epsilon chaperone 
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3.2.9. RPE express similar ion channel-related genes  
As ion homeostasis is a key function of the RPE, further analysis was conducted on 
the various RPE expressed gene lists to identify ion channels and ion transport-
related genes. Identification of ion channel genes using keyword searches revealed 
RPE-derived from human ES cells shared 636 out of 655 ion channel and transport-
related genes for F305S-mutant BEST1 RPE and 636 out of 640 genes for normal 
RPE. Furthermore, both normal and F305S-mutant BEST1 human ES cell-derived 
RPE revealed the expression of genes of interest relating to RPE function, they 
included: BEST1, STIM1, STIM2, ORAI1 and ORAI2 genes (Appendix Table A.2). 
GO analysis confirmed that the 636 genes were related to ion channel and ion 
transport (Appendix Table A.3). Of the 655 genes, 19 of those were differentially 
expressed by F305S-mutant BEST1 RPE and not by the normal human ES cell-
derived RPE (Table 3.5). In comparison, normal human ES cell-derived RPE 
differentially expressed 4 out of 640 ion channel genes that were not expressed by 
the F305S-mutant BEST1 RPE (Table 3.6). Therefore, these data showed that the 
F305S-mutant BEST1 RPE shared a high expression of ion channel related genes to 
normal human ES cell-derived RPE. 
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3.2.10.  Human ES cell-derived RPE and primary human RPE express common 
genes 
To determine whether normal and F305S-mutant BEST1 human ES cell-derived 
RPE is similar to published primary human fRPE than aRPE (Strunnikova et al., 
2010), all 4 gene expression profiles were compared. In these primary human RPE 
datasets fRPE was shown to express 11,198 genes common to six primary human 
fRPE samples and aRPE expressed 7,126 genes common to four primary human 
aRPE samples; together these published human foetal and aRPE datasets shared 
6,748 common genes (Figure 3.6 B). Human ES cell-derived RPE datasets were then 
compared to primary human fRPE and aRPE to identify shared gene expression. The 
results showed that normal human ES cell-derived RPE shared 9,384 out of 11,198 
of genes with human fRPE and 6,047 out of 7,126 of genes with human aRPE. In 
comparison, F305S-mutant BEST1 human ES cell-derived RPE had 9,547 out of 
11,198 of genes in common with human fRPE and 5,967 out of 6,748 of genes in 
common with human aRPE. Further comparison of shared gene expression revealed 
that RPE-derived from normal and F305S-mutant BEST1 human ES cells shared 
3,458 more genes with primary human fRPE than aRPE. Therefore, both normal and 
F305S-mutant BEST1 human ES cell-derived RPE gene expression appears to be 
more similar to primary human fRPE than aRPE. 
Ion channel-related genes expressed in normal and F305S-mutant BEST1 
RPE were compared to those expressed in primary human fRPE and aRPE. The 
results showed that human ES cell-derived RPE shared expression of 277 ion 
channel-related genes with primary human fRPE, and 205 ion channel-related genes 
with primary human aRPE (Appendix Table A.4 and A.5 respectively). A 
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comparison of ion channel shared gene expression in primary fRPE and aRPE 
revealed they shared 158 genes that were expressed by normal and F305S-mutant 
BEST1 RPE (Table 3.7). Overall, these data show that the F305S-mutant BEST1 
RPE shared a majority of ion channel and ion transport-related genes to normal 
human ES cell-derived RPE. Furthermore, they showed that both human ES cell-
derived RPE shared more ion channel-related genes with primary human fRPE, than 
aRPE. 
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Table 3.5: Ion channel-related genes differentially expressed in F305S-
mutant BEST1 human ES cell-derived RPE 
Gene 
symbol 
Gene name 
Detected in 
Primary human 
RPE (Foetal or 
Adult) 
ATP5G2 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit C2 (subunit 9) 
Adult and foetal 
ATP5J ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit F6 
Adult and foetal 
CARHSP1 calcium regulated heat stable protein 1, 24kDa Adult and foetal 
SLC19A2 solute carrier family 19 (thiamine transporter), 
member 2 
Adult and foetal 
ORAI3 ORAI calcium release-activated calcium 
modulator 3 
Foetal  
KCND3 potassium voltage-gated channel, Shal-related 
subfamily, member 3 
Foetal  
ATP5EP2 ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit pseudogene 2; ATP 
synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit 
No detection 
CAMK2N2 calcium/calmodulin-dependent protein kinase II 
inhibitor 2 
No detection 
CIB3 calcium and integrin binding family member 3 No detection 
KCNA1 potassium voltage-gated channel, shaker-related 
subfamily, member 1 (episodic ataxia with 
myokymia) 
No detection 
KCNA4 potassium voltage-gated channel, shaker-related 
subfamily, member 4 
No detection 
KCNJ12 similar to hkir2.2x; similar to inward rectifying K+ 
channel negative regulator Kir2.2v; potassium 
inwardly-rectifying channel, subfamily J, member 
12 
No detection 
KCNK18 potassium channel, subfamily K, member 18 No detection 
P2RX3 purinergic receptor P2X, ligand-gated ion channel, 3 No detection 
S100A7L2 S100 calcium binding protein A7-like 2 No detection 
SLC10A4 solute carrier family 10 (sodium/bile acid 
cotransporter family), member 4 
No detection 
SLC16A13 solute carrier family 16, member 13 
(monocarboxylic acid transporter 13) 
No detection 
SLC25A2 solute carrier family 25 (mitochondrial carrier; 
ornithine transporter) member 2 
No detection 
ZACN zinc activated ligand-gated ion channel No detection 
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Table 3.6: Ion channel-related genes differentially expressed in normal human 
ES cell-derived RPE 
Gene symbol Gene name 
Detected in 
Primary human 
RPE (Foetal or 
Adult) 
BET1 
hypothetical protein LOC100128542; blocked early 
in transport 1 homolog (S. cerevisiae) 
Adult and Foetal 
SLC39A6 solute carrier family 39 (zinc transporter), member 6 Adult and Foetal 
SCNM1 sodium channel modifier 1 Foetal  
SLC39A1 solute carrier family 39 (zinc transporter), member 1 Foetal  
 Chapter 3: Characterisation of a novel human ES cell line containing the F305S BEST1 mutation 
67 
 
  
Table 3.7: Shared expression of ion channel genes in normal and 
F305S-mutant human ES cell-derived RPE and primary human 
foetal and adult RPE  
ASNA1 ATP6V1E1 KCNT2 SLC22A8 SLC6A20 
ATP1A1 ATP6V1F KCNV2 SLC23A2 SLC6A6 
ATP1A3 ATP6V1G1 KCTD1 SLC24A1 SLC6A8 
ATP1B1 ATP6V1H KCTD10 SLC25A1 SLC7A1 
ATP1B2 ATP7A KCTD12 SLC26A2 SLC7A11 
ATP1B3 ATP7B KCTD15 SLC27A1 SLC7A2 
ATP2A2 ATP8A1 KCTD18 SLC27A2 SLC7A5 
ATP2B1 BEST1 KCTD3 SLC2A1 SLC7A6 
ATP2B2 BET1L KCTD6 SLC2A12 SLC7A8 
ATP2C1 CLCC1 KCTD7 SLC30A1 SLC8A1 
ATP5A1 CLCN3 KCTD9 SLC30A5 SLC9A3R1 
ATP5B CLCN4 MAGT1 SLC30A7 SLC9A6 
ATP5C1 CLCN5 MITD1 SLC30A9 SLCO3A1 
ATP5F1 CLCN7 NALCN SLC31A2 STIM2 
ATP5G3 CLIC1 NUTF2 SLC33A1 TMED4 
ATP5H CLIC4 NXT2 SLC35A2 TMED5 
ATP5J2 CLIC6 ORAI2 SLC35A3 TMED8 
ATP5L CLNS1A SCLT1 SLC35D1 TNPO1 
ATP5O CUTC SLC11A2 SLC39A10 TNPO3 
ATP5S FXYD3 SLC12A2 SLC39A12 TRPC1 
ATP6AP1 GOLT1B SLC12A6 SLC39A14 TRPC4AP 
ATP6AP2 IFT122 SLC12A7 SLC39A8 TRPM1 
ATP6V0A1 IFT20 SLC13A4 SLC39A9 TRPM3 
ATP6V0B IFT57 SLC16A1 SLC3A2 TRPM7 
ATP6V0C IFT80 SLC16A14 SLC40A1 VAT1 
ATP6V0D1 IFT81 SLC16A3 SLC4A4 VAT1L 
ATP6V0E1 IFT88 SLC16A4 SLC4A5 VDAC1 
ATP6V0E2 KCMF1 SLC16A6 SLC4A7 VDAC2 
ATP6V1A KCNAB1 SLC16A8 SLC5A3 VDAC3 
ATP6V1B2 KCNE3 SLC17A5 SLC6A12 VTI1B 
ATP6V1C1 KCNJ13 SLC1A4 SLC6A13 
 ATP6V1D KCNQ4 SLC20A1 SLC6A15 
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3.3. Discussion 
3.3.1. F305S-mutant BEST1 human ES cells are indistinguishable to normal 
human ES cells 
This study sought to investigate an unreported and uncharacterised human ES cell 
line, GENEA069, established by Genea Biocells. As part of routine pre-natal genetic 
diagnosis screening, the originating embryo for this pluripotent cell line had been 
shown to contain the F305S BEST1 mutation known to cause a rare, juvenile onset 
form of macular degeneration known as Best vitelliform macular dystrophy. Through 
the analyses described here, the F305S-mutant BEST1 human ES cells were shown 
to possess defining pluripotency phenotypic features (Ungrin et al., 2007) that were 
morphologically indistinguishable from the well characterised human ES cell line, 
MEL-1 (International Stem Cell et al., 2011). This includes circular growth areas 
when passaged as aggregates, cells exhibiting a high nucleus to cytoplasm ratio, high 
expression levels of key pluripotency genes (e.g., OCT4, NANOG, SOX2 and 
FOXD3), and high expression levels of accepted pluripotent cell surface antigens 
(e.g., TRA-1-60 and TRA-1-81)  
The alkaline phosphatase-based CFC assay revealed F305S-mutant BEST1 
human ES cells exhibited a CFC frequency of 4.4% ± 3.6%, which was consistent 
within the expected range for normal human pluripotent cells (O'Connor et al., 
2008). The teratoma assay was used to assess the differentiation capacity of the 
F305S-mutant BEST1 human ES cells, which demonstrated the presence of cells 
derived from all three germ layers (i.e., endoderm, mesoderm and ectoderm), thus 
demonstrating the functional capacity for tri-germ layer differentiation (Thomson et 
al., 1998, International Stem Cell et al., 2007, O'Connor et al., 2011). Together, these 
findings indicate that the F305S-mutant BEST1 human ES cells have 
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indistinguishable phenotypic and functional pluripotency characteristics compared to 
normal human ES cells, and therefore may be a useful model to investigate the 
molecular mechanisms responsible for BVMD. 
 
3.3.2. Altered BEST1 localisation in the F305S-mutant BEST1 RPE 
To more directly address the RPE differentiation capacity of the F305S-mutant 
BEST1 human ES cells, they were differentiated into RPE following an established 
method (Meyer et al., 2009). Using this approach the F305S-mutant BEST1 human 
ES cells were shown to produce pigmented cells with polygonal morphology that 
expressed mature RPE genes (e.g., BEST1, RPE65, MITF and PAX6) and proteins 
(e.g., ZO-1, BEST1 and RPE65). Of significance, all of these key RPE proteins 
except BEST1 were expressed in the same location in the F305S-mutant BEST1 RPE 
compared to normal human ES cell-derived RPE. In normal primary RPE or normal 
human ES cell-derived RPE, BEST1 is expressed predominantly at the plasma 
membrane (Milenkovic et al., 2011b, Marmorstein et al., 2000, Klimanskaya et al., 
2004). This expected pattern of BEST1 protein localisation was seen here with the 
MEL-1 (i.e., normal) human ES cell-derived RPE. In contrast, the 
immunofluorescence analysis showed that BEST1 protein in the F305S-mutant 
BEST1 human ES cell-derived RPE appeared to be localised predominantly in the 
cytoplasm of the cell rather than at the plasma membrane. This finding is significant 
since heterologous overexpression studies have shown that the F305S-mutant BEST1 
protein appears to have a trafficking defect that results in accumulation of BEST1 
within the cytoplasm compared to overexpression of wild-type BEST1 in Madin-
Darby canine kidney cells (Milenkovic et al., 2011b). 
 Chapter 3: Characterisation of a novel human ES cell line containing the F305S BEST1 mutation 
70 
 
3.3.3. F305S-mutant BEST1 RPE Affymetrix gene expression profile is highly 
similar to normal human ES cell-derived RPE 
To further understand the molecular consequences of the F305S BEST1 mutation, 
Affymetrix microarray analyses were used to provide quantitative whole-genome 
expression profiling on the human ES cell-derived RPE (Reich et al., 2006, Kuehn et 
al., 2008). Comparison of Affymetrix datasets generated from normal and F305S-
mutant BEST1 human ES cell-derived RPE showed their transcriptomes were highly 
similar, they shared expression of 19,705 common genes. GO analysis revealed that 
the human ES cell-derived RPE shared a large number of GO terms (i.e., 50) relating 
to biological processes expected of RPE. Interestingly, while 11 GO categories 
appeared specific to normal human ES cell-derived RPE and 16 appeared specific to 
F305S-mutant BEST1 RPE, further analysis revealed that almost all of the genes 
within these categories were expressed by both human ES cell-derived RPE. 
Notably, both normal and F305S-mutant BEST1 human ES cell-derived RPE 
expressed 380 genes identified in the ‘ion homeostasis’ GO category, even though 
this category was only seen in normal human ES cell RPE. This finding is significant 
as ion homeostasis is an essential RPE function, where it maintains ion homeostasis 
to the photoreceptors and choroid (Strauss, 2005, Klimanskaya et al., 2004, 
Klimanskaya, 2006, Lund et al., 2006). Of the 2 ion homeostasis genes not expressed 
by the F305S-mutant BEST1 RPE (i.e., CCL23 and PROK2), little is known of their 
role in the RPE or if they are associated with macular degeneration. 
An expected finding in the Affymetrix gene expression analyses showed that 
expression of BEST1 gene was detected in both normal and F305S-mutant BEST1 
human ES cell-derived RPE. The BEST1 gene has been reported as one of the key 
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candidate RPE genes in primary human RPE, and mutations in BEST1 are 
responsible for BVMD (Strunnikova et al., 2010, Klimanskaya et al., 2004). 
Interestingly, STIM1, STIM2, ORAI1 and ORAI2 genes were also expressed in both 
the normal and F305S-mutant BEST1 RPE and the ORAI3 gene found to be 
expressed only in F305S-mutant BEST1 RPE. ORAI proteins are members of the 
family of Ca
2+
 release-activated Ca
2+
 modulators that have been identified in 
immortalised human RPE cell lines (e.g., ARPE-19), primary human RPE and in 
RPE from other species (e.g., pig) (Gomez et al., 2013, Cordeiro and Strauss, 2011). 
The stromal interaction molecule (STIM) 1 and 2, are endoplasmic reticulum (ER) 
Ca
2+
 sensors that have been previously reported in primary human RPE and ARPE-
19 (Cordeiro and Strauss, 2011, Yang et al., 2013), as well as human PS cell-derived 
RPE (Singh et al., 2013b). A proposed function of BEST1 is that it may act as a 
regulator of Ca
2+
, and it has been reported to interact with STIM1, which in turn 
interacts with ORAI indirectly to regulate store-operated Ca
2+
 entry in the RPE 
(Gomez et al., 2013). Interestingly, these published findings are based on BEST1 
protein localising to the ER (Barro-Soria et al., 2010, Singh et al., 2013b, Gomez et 
al., 2013). Consistent with this, the data presented here shows BEST1 localises 
predominantly at or near the plasma membrane in normal RPE consistent with other 
published data (where it may be located close to the ER) (Klimanskaya et al., 2004, 
Marmorstein et al., 2000, Milenkovic et al., 2011b, Davidson et al., 2009, Bakall et 
al., 2003, Singh et al., 2013b). However, in the F305S-mutant BEST1 RPE the 
BEST1 showed intracellular localisation as reported for overexpression of BEST1 
mutant in non-RPE cells (Milenkovic et al., 2011b). Taken together, the differentially 
expressed ORAI3 gene in F305S-mutant BEST1 RPE and BEST1 intracellular 
localisation in the mutant RPE indicate that further investigation into the 
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BEST1/STIM/ORAI pathway in normal and F305S-mutant BEST1 RPE may 
provide useful information on the molecular mechanisms of BVMD.  
To investigate how similar the normal and mutant BEST1 human ES cell-
derived RPE was to primary human foetal and aRPE, the expressed gene lists were 
compared and the results revealed that human ES cell-derived RPE shared expression 
of 3,458 more genes with primary human fRPE than aRPE, suggesting they might 
function more like fRPE than aRPE. This result is not unexpected as it has been 
reported that human fRPE is the culture standard for RPE (Singh et al., 2013b, Carr 
et al., 2009). Interestingly, F305S-mutant BEST1 RPE expressed 13 genes that were 
not expressed by normal human ES cell-derived RPE or in either primary human 
foetal or aRPE datasets, further investigation showed that these genes have not been 
reported in literature in relation to RPE function or BEST1. Taken together, these 
data highlight how highly similar F305S-mutant BEST1 RPE is to normal human ES 
cell-derived RPE, and how similar the human ES cell-derived RPE is to primary 
human fRPE. The data suggests functional investigation of ion homeostasis in 
normal and F305S-mutant-BEST1 RPE will determine if the difference in expression 
of ion channel-related genes actually affects ion homeostasis in these cells.  
In summary, normal and disease-specific human PS cells are becoming 
increasingly important modern tools that have the potential to provide new molecular 
insights into normal and disease development. In this way further study of the new 
GENEA069-mutant BEST1 human ES cell line may provide an opportunity to 
identify new leads to find a treatment for BVMD. The data presented here shows that 
the GENEA069 human ES cells are pluripotent cells that appear to contain only the 
BVMD-specific F305S BEST1 mutation. Moreover, these cells can be specifically 
 Chapter 3: Characterisation of a novel human ES cell line containing the F305S BEST1 mutation 
73 
 
differentiated into cells of all three germ layers including RPE. Through the 
molecular characterisations done to date, the F305S-mutant BEST1 RPE appears 
largely similar to normal human ES cell-derived RPE, though with the striking 
exception of abnormal BEST1 protein localisation that is consistent with the 
published intracellular expression pattern of this BEST1 mutant. Furthermore, 
Affymetrix microarray data suggest that F305S-mutant BEST1 RPE gene expression 
profile is highly similar to normal human ES cell-derived RPE, with shared 
expression of genes contributing to important RPE functions such as ion 
homeostasis. The normal and F305S-mutant BEST1 human ES cell-derived RPE 
shared a large number of genes with primary human fRPE, including ion channel and 
ion transport-related genes. Analysis of the ion channel genes expressed by the 
human ES cell-derived RPE indicate further investigation of the functional properties 
of ion homeostasis could shed light on the molecular mechanisms responsible for 
BVMD development. In turn, these future studies could realistically identify new 
leads for treating this presently incurable form of juvenile blindness. 
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4.1.  Introduction 
In Chapter 3 it was shown that F305S-mutant BEST1 human ES cells have similar 
pluripotent characteristics to normal human ES cells and also have the ability to 
differentiate into RPE. The RPE-derived from F305S-mutant BEST1 human ES cells 
expressed similar RPE genes and had similar protein localisation patterns to normal 
RPE. The striking exception was the intracellular localisation of mutant BEST1 
protein, rather than the plasma membrane localisation seen with normal BEST1 RPE. 
Additionally, the Affymetrix-based gene expression analysis revealed the F305S-
mutant BEST1 RPE and the normal RPE shared a large number of genes. 
Interestingly, human ES cell-derived RPE expressed a large number of genes that 
were expressed by primary human foetal RPE (fRPE), including ion channel and ion 
transport-related genes known to contribute to important RPE functions such as ion 
homeostasis.  
To date, most human ES cell-derived RPE studies have investigated RPE 
function using in vitro phagocytosis assays or RPE transplantation into Royal 
College of Surgeon (RCS) rats (Klimanskaya et al., 2004, Carr et al., 2009, Singh et 
al., 2013b, Lund et al., 2006). However, understanding the ion homeostasis 
properties of RPE is equally as important, as one of the main RPE functions is the 
transport of fluid and ions to support and maintain surrounding tissues (i.e., 
photoreceptor outer segments and choroid) (Wimmers et al., 2007, Quinn and Miller, 
1992, Strauss, 2005). Potassium (K
+
) and sodium (Na
+
) transport of ions across the 
membrane can occur via ion channels, co-transporters, pumps and exchangers that 
are found in the RPE, and they function to maintain pH, ion and fluid homeostasis 
(Quinn and Miller, 1992, Strauss, 2009, Fox et al., 1988, Hughes and Takahira, 
1996). Voltage-gated Na
+
 and K
+
 channels have previously been described in RPE 
 Chapter 4: Voltage-gated potassium and sodium currents in human ES cell-derived RPE 
76 
 
from various species including: human (Wen et al., 1993, Fox et al., 1988, Quinn and 
Miller, 1992, Wen et al., 1994), rat (Strauss et al., 1994, Botchkin and Matthews, 
1994), cow (Bialek and Miller, 1994, Yang et al., 2003) and frog (Hughes and 
Steinberg, 1990). Voltage-gated Na
+
 and K
+
 currents have also been briefly 
demonstrated in human PS cell-derived RPE, with this study showing similar 
voltage-gated Na
+
 and K
+
 currents and membrane potential compared to human 
fRPE (Kokkinaki et al., 2011). However, little detail was provided in this study about 
the types of voltage-gated Na
+
 and K
+
 channels present within the RPE derived from 
human PS cells (Kokkinaki et al., 2011). 
This study aimed to characterise in detail the Na
+
 and K
+
 currents in normal 
and F305S-mutant BEST1 human ES cell-derived RPE using whole-cell patch clamp 
electrophysiology. The results showed similar voltage-gated Na
+
 and K
+
 currents in 
RPE derived from normal and F305S-mutant BEST1 human ES cells and that these 
currents were similar to those found in primary human RPE. 
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4.2.  Results 
4.2.1.  Localisation of key proteins similar between RPE monolayers and single 
RPE cells 
Specific localisation profiles have been reported for key proteins within RPE 
monolayers. It has been suggested that appropriate protein localisation is required for 
proper functioning of cells within the RPE (Milenkovic et al., 2011b). To determine 
whether interpretation of whole-cell patch clamp electrophysiology data from 
isolated human PS cell-derived RPE is valid, the localisation of key mature RPE 
proteins in isolated RPE cells was compared to monolayer RPE data (Chapter 3). 
Here the cellular localisation was assessed for the key and well-characterised RPE 
proteins ZO-1, RPE65 and BEST1.  
As seen with the monolayer immunofluorescence data presented in Chapter 3, 
ZO-1 was shown to be strongly expressed at the membrane in single RPE cells 
derived from both normal and F305S-mutant BEST1 human ES cells (Figure 4.1 A 
and 4.2 A). Some cytoplasmic ZO-1 staining was observed in isolated cells relative 
to monolayer staining data (Figure 3.5 A and B). However, all single cells showed 
strong ZO-1 membrane staining in both normal and F305S-mutant BEST1 RPE with 
no significant difference in localisation (Table 4.1; p = 1.000). 
Investigation of RPE65 in isolated RPE cells showed it was predominantly 
located in the cytoplasm in both normal and F305S-mutant BEST1 human ES cell-
derived RPE, with some membrane staining (Figure 4.1 B and 4.2 B). However, no 
significant difference was seen in single cells expressing membrane/cytoplasmic vs 
cytoplasmic only staining between normal and F305S-mutant BEST1 human ES cell-
derived RPE (Table 4.1; p = 0.1993). 
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In isolated RPE derived from normal human ES cells, BEST1 was found to 
be predominantly located at the cell membrane in almost all cells (Figure 4.1 C). In 
comparison, BEST1 was seen only in the cytoplasm in isolated RPE derived from 
F30S5-mutant BEST human ES cells (Figure 4.2 C). Notably, this clear difference in 
BEST1 localisation was statistically significant (Table 4.1; p = 0.0022). 
 
4.2.2. Resting membrane potential and membrane capacitance in stem cell-derived 
RPE 
As the staining profile of key RPE proteins in isolated RPE cells was similar to 
published monolayer RPE staining profiles, whole-cell patch clamp was performed 
on isolated, highly pigmented RPE cells (Figure 4.1 and 4.2). Recordings were 
conducted within 24 hours of plating and included assessment of membrane 
capacitance, resting membrane potential and voltage-dependent currents. These data 
showed that both the membrane capacitance and resting membrane potential were 
similar between normal and F305S-mutant BEST1 human ES cell-derived RPE 
(Table 4.2). The published values of primary human RPE membrane capacitance and 
resting membrane potential (Wen et al., 1993) are included in Table 4.4 for 
comparison. Comparison of the human ES cell-derived RPE obtained here and the 
published primary human RPE data showed no statistically significant difference in 
membrane capacitance or resting membrane potential, with the exception that the 
F305S-mutant BEST1 RPE had a significantly smaller membrane capacitance 
compared to primary human adult RPE (aRPE)(p = 0.0001). Taken together, these 
data showed that the normal and F305S-mutant BEST1 human ES cell-derived RPE 
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have similar membrane capacitance and resting membrane potentials to each other 
and to primary human fRPE. 
 
4.2.3. F305S-mutant BEST1 RPE has similar voltage-gated Na
+
 and K
+
 currents to 
normal RPE 
To further characterise RPE from normal and F305S-mutant BEST1 human ES cells, 
voltage-dependent currents were recorded by stepping the membrane voltage from -
130 mV to + 120 mV. The isolated RPE cells that were analysed from both the 
normal and F305S-mutant BEST1 human ES cells showed a variety of voltage-
dependent currents, with most cells displaying more than one current type (Figure 
4.3 A-D and Figure 4.4 A-D). The currents observed in both normal and F305S-
mutant BEST1 human ES cell-derived RPE were: a delayed outward current (Figure 
4.3 A and 4.4 A; Table 4.3), a sustained inward current that was always observed 
with a delayed outward current (Figure 4.3 A and 4.4 A; Table 4.3), a fast transient 
outward current (Figure 4.3 C and 4.4 C; Table 4.3), and a fast transient inward 
current (Figure 4.3 B & D and 4.4 B & D; Table 4.3). Notably, there was no 
difference in the number of isolated RPE cells displaying these different current 
types between normal and F305S-mutant BEST1 RPE (Table 4.3; p = 0.9775). 
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Figure 4.1: Isolated RPE derived from normal human ES cells show 
appropriate expression of mature RPE protein markers (left to right; 
brightfield image and fluorescent image) A) Strong ZO-1 staining at the 
membrane with some cytoplasmic staining observed. B) RPE65 showed 
localisation to the membrane and cytoplasm, and C) BEST1 protein localisation 
at the plasma membrane in normal human ES cell RPE (scale bar = 20 µm). 
A 
C 
B 
ZO-1 
RPE65 
BEST1 
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Figure 4.2: Isolated RPE derived from F305S-mutant BEST1 human ES 
cells show predicted expression of mature RPE protein markers (left to right; 
brightfield and fluorescent images) A) Strong ZO-1 staining at the membrane 
with cytoplasmic staining observed. B) RPE65 showed localisation to the 
cytoplasm with some membrane staining, and C) BEST1 protein localisation 
mainly within the cytoplasm (scale bar = 20 µm). 
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BEST1 
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 RPE cell type 
Membrane 
capacitance (pF) 
(mean ± SD) 
Resting 
potential (mV) 
(mean ± SD) 
Human ES cell-
derived RPE 
Normal RPE  
(n = 32) 
34.86 ± 14.43  -15.92 ± 13.28  
F305S BEST1 RPE 
(n = 20) 
27.14 ± 10.58*  -14.52 ± 15.47 
Primary human 
RPE 
Wen et al (1993) 
Fresh human aRPE 
(n = 21) 
59.4 ± 10 -50 ± 9  
Fresh human fRPE 
(n = 42) 
19 ± 9.0*  -34 ± 13  
Table 4.2: Membrane capacitance and resting membrane potential values 
recorded in human ES cell-derived RPE compared to primary human 
RPE (Wen, Lui et al. 1993). 
* F305S-mutant BEST1 RPE was significantly different to primary human adult RPE 
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Figure 4.3: Representative raw traces of voltage-dependent currents 
observed in normal human ES cell-derived RPE A) Delayed outward current 
with inward current, on the left the arrows indicate the direction of outward and 
inward current. B) Delayed outward current and fast transient inward current. C) 
Fast transient A-type outward current with delayed outward current and D) Fast 
transient A-type outward current with delayed outward current and fast inward 
current. A-D Voltage steps - 120 to + 120 mV, holding current at -70 mV. 
0.2 nA 
100 ms 
 Chapter 4: Voltage-gated potassium and sodium currents in human ES cell-derived RPE 
85 
 
  
Figure 4.4: Representative raw traces of voltage-dependent currents 
observed in F305S-mutant BEST1 human ES cell-derived RPE A) Delayed 
outward current with inward current. B) Delayed outward current and fast 
transient inward current. C) Fast transient A-type outward current with delayed 
outward current and D) Fast transient A-type outward current with delayed 
outward current and fast transient inward current. A-D Voltage steps - 120 to + 
120 mV, holding current at -70 mV. 
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Table 4.4: Types of  voltage-gated Na+ and K+ currents identified in 
primary human foetal and adult RPE interpreted from Wen et al 
1993 (Wen, Lui et al. 1993) 
 Chapter 4: Voltage-gated potassium and sodium currents in human ES cell-derived RPE 
88 
 
4.2.4.  Identification of Na
+
 and K
+
 current types in human ES cell-derived RPE 
 
To identify the types of ion channels responsible for the voltage-gated currents 
observed in the human ES cell-derived RPE, a selection of specific Na
+
 and K
+
 
channel blockers were applied. Use of specific K
+
 channel blockers revealed: (i) 
tetraethylammonium (TEA) significantly reduced the delayed outward current 
(Figure 4.5; p = 0.0245); and (ii) 4-Aminopyridine (4-AP) completely blocked the 
fast transient outward current to reveal a small delayed outward current (Figure 4.6; 
p = 0.0118). Taken together, these studies confirmed these particular voltage-gated 
currents in RPE derived from human ES cells were driven by K
+
. Application of the 
hyperpolarising activated cation channel blocker ZD7288 reduced the magnitude of 
the inward current (Figure 4.7). Application of the specific Na
+
 channel blocker TTX 
blocked the fast transient inward current confirming that this current was driven by 
Na
+
 (Figure 4.8; p = 0.0069). However, a small number of cells exhibited TTX-
insensitive inward currents (Figure 4.9; n = 4); this finding is consistent with primary 
human RPE (Wen et al., 1994). 
These voltage-gated Na
+
 and K
+
 currents seen in both the normal and F305S-
mutant BEST1 human ES cell-derived RPE (Table 4.3) were compared to published 
data on Na
+
 and K
+
 currents recorded from primary human RPE (Table 4.4) (Wen et 
al., 1993). This analysis revealed that RPE derived from normal and F305S-mutant 
BEST1 human ES cells shared similar voltage-gated Na
+
 and K
+
 currents compared 
to both primary human fRPE and aRPE. In particular, ~ 60% of the normal and 
F305S-mutant BEST1 RPE cells displayed a fast A-type current previously reported 
in primary human fRPE but not in primary human aRPE.  
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High expression of voltage-gated Na
+
 currents have been hypothesised to be 
caused by differences in RPE culture methods (Wen et al., 1994). Analysis here, 
compared the Na
+
 current density of human ES cell-derived RPE to primary cultured 
human RPE with similar culture medium conditions (Wen et al., 1994). This analysis 
revealed that RPE derived from human ES cells showed no difference in Na
+
 current 
densities to the primary human RPE with similar culture medium conditions method 
3 (p = 0.7173; Table 4.5). Overall, the results showed that the human ES cell-derived 
RPE displayed similar voltage-gated Na
+
 and K
+
 currents to each other and to 
primary human RPE. 
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Figure 4.5: Delayed outward currents can be blocked with K+ channel 
blocker TEA A) Representative raw trace of the delayed outward current in 
normal human ES cell-derived RPE showing a reduction in the delayed outward 
K+ current after TEA was applied. B) Current density-Voltage graph showing a 
reduction in the delayed outward current when TEA (20 mM) was applied (p 
value 0.0245; n = 6).  
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Figure 4.6: Fast A-type outward current can be blocked with K+ channel 
blocker 4-AP A) Representative raw trace of the fast A-type outward K+ current 
in normal human ES cell-derived RPE showing a reduced K+
 
current. B) Current 
density-Voltage graph showing a reduction in the fast A-type current when 4-AP 
(5 mM) was applied (p value 0.0118; n = 4). 
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Figure 4.7: Inward current can be blocked with the hyperpolarising-
activated cation channel blocker ZD7288 A) Raw trace of the inward current in 
normal human ES cell-derived RPE showing a reduction in inward currents (n = 
1). B) Current density-Voltage graph showed a reduced inward current (red box) 
when ZD7288 was applied. 
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Figure 4.8: Fast inward current can be blocked by the Na+ channel blocker 
TTX A) Representative raw trace of the fast transient inward current in normal 
human ES cell-derived RPE showing the Na+ currents being blocked by TTX. B) 
Current density-Voltage graph showing a reduction in the fast transient inward 
current when 0.5 µM TTX (Na+ blocker) was applied externally (p value 0.0069; 
n = 4). 
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Figure 4.9: TTX-insensitive currents observed in human ES cell-derived 
RPE Representative raw trace of the fast inward current in normal human ES 
cell-derived RPE were shown to display TTX-insensitive currents after 0.5 µM 
TTX was applied to fast inward currents (n = 4). 
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4.2.5.  Voltage-gated Na
+
 and K
+
 channel genes expressed by human ES cell RPE 
To investigate the specific genes/proteins responsible for the Na
+
 and K
+
 currents in 
RPE derived from human ES cells, the Affymetrix gene expression data presented in 
Chapter 3 was re-analysed to focus on specific Na
+
 and K
+
 homeostasis genes. This 
analysis revealed that normal human ES cell-derived RPE expressed 200 Na
+
 and K
+
 
channel-related genes and the F305S-mutant BEST1 RPE expressed 205 Na
+
 and K
+
 
channel-related genes. The human ES cell-derived RPE were shown to share 
expression of 199 of these Na
+
 and K
+
 ion channel-related genes (Appendix Table 
A.6). Further analysis was conducted to identify the specific voltage-gated Na
+
 and 
K
+
 genes potentially responsible for the currents recorded from the human ES cell-
derived RPE. Of the 199 shared Na
+
 and K
+
 ion channel-related genes, 56 were 
shown to be associated with the delayed outward and fast A-type K
+
 channels (Table 
4.6) (Gutman et al., 2005), 17 genes are associated with inwardly rectifying K
+
 
currents (Table 4.7) (Kubo et al., 2005), and 14 genes are associated with fast inward 
Na
+
 currents (i.e., TTX-sensitive and TTX-insensitive currents) (Table 4.8) (Ogata 
and Ohishi, 2002). 
To determine how closely this expression profile of Na
+
 and K
+
 ion channel-
related genes expressed by the human ES cell-derived RPE reflects primary RPE 
biology, the profiles were compared to primary human fRPE and aRPE (Strunnikova 
et al., 2010). The results showed the comparison of Na
+
 and K
+
 channel-related genes 
in all 4 RPE datasets revealed that both human ES cell-derived RPE shared 
expression of 35 genes with both primary human fRPE and aRPE (Table 4.9). 
Furthermore, both normal and F305S-mutant BEST1 RPE expressed an additional 16 
Na
+
 and K
+
 ion channel-related genes with primary human fRPE (Table 4.10) that 
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were not expressed by aRPE. In comparison, normal and F305S-mutant BEST1 RPE 
expressed 6 Na
+
 and K
+
 ion channel-related genes with primary human aRPE only 
(Table 4.11) and was not expressed by fRPE. Taken together, these data indicate that 
a large number of Na
+
 and K
+
 ion channel-related genes were expressed by normal 
and F305S-mutant BEST1 human ES cell-derived RPE that likely contribute to the 
voltage-dependent currents recorded in these cells This included genes for well 
characterised ion channels such as KCNQ, KCND, KCNQ (Table 4.6), KNCJ, HCN1-
4 (Table 4.7), and SCN (Table 4.8). Furthermore, both human ES cell-derived RPE 
shared more Na
+
 and K
+
 ion channel-related genes with primary human fRPE, than 
aRPE. 
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Table 4.6: Genes associated with voltage-gated K+ channels were expressed by normal and F305S-mutant BEST1 human ES cell-derived 
RPE 
Gene 
symbol Gene name 
Gene 
symbol Gene name 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 
KCNA10 potassium voltage-gated channel, shaker-related subfamily, member 10 KCNH6 potassium voltage-gated channel, subfamily H (eag-related), member 6 
KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 2 KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 
KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3 KCNH8 potassium voltage-gated channel, subfamily H (eag-related), member 8 
KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5 KCNK1 potassium channel, subfamily K, member 1 
KCNA6 potassium voltage-gated channel, shaker-related subfamily, member 6 KCNK10 potassium channel, subfamily K, member 10 
KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 KCNK13 potassium channel, subfamily K, member 13 
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 KCNK15 potassium channel, subfamily K, member 15 
KCNAB3 potassium voltage-gated channel, shaker-related subfamily, beta member 3 KCNK16 potassium channel, subfamily K, member 16 
KCNB1 potassium voltage-gated channel, Shab-related subfamily, member 1 KCNK17 potassium channel, subfamily K, member 17 
KCNB2 potassium voltage-gated channel, Shab-related subfamily, member 2 KCNK2 potassium channel, subfamily K, member 2 
KCNC1 potassium voltage-gated channel, Shaw-related subfamily, member 1 KCNK3 potassium channel, subfamily K, member 3 
KCNC2 potassium voltage-gated channel, Shaw-related subfamily, member 2 KCNK4 potassium channel, subfamily K, member 4 
KCNC3 potassium voltage-gated channel, Shaw-related subfamily, member 3 KCNK5 potassium channel, subfamily K, member 5 
KCNC4 potassium voltage-gated channel, Shaw-related subfamily, member 4 KCNK6 potassium channel, subfamily K, member 6 
KCND1 potassium voltage-gated channel, Shal-related subfamily, member 1 KCNK7 potassium channel, subfamily K, member 7 
KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 
KCNE1 potassium voltage-gated channel, Isk-related family, member 1 KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member 2 
KCNE2 potassium voltage-gated channel, Isk-related family, member 2 KCNQ3 potassium voltage-gated channel, KQT-like subfamily, member 3 
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4 
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 
KCNG1 potassium voltage-gated channel, subfamily G, member 1 KCNS1 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 
KCNG2 potassium voltage-gated channel, subfamily G, member 2 KCNS2 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 
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KCNG4 potassium voltage-gated channel, subfamily G, member 4 KCNT1 potassium channel, subfamily T, member 1 
KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1 KCNT2 potassium channel, subfamily T, member 2 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2 KCNU1 potassium channel, subfamily U, member 1 
KCNH3 potassium voltage-gated channel, subfamily H (eag-related), member 3 KCNV1 potassium channel, subfamily V, member 1 
KCNH4 potassium voltage-gated channel, subfamily H (eag-related), member 4 KCNV2 potassium channel, subfamily V, member 2 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 
KCNA10 potassium voltage-gated channel, shaker-related subfamily, member 10 KCNH6 potassium voltage-gated channel, subfamily H (eag-related), member 6 
KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 2 KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 
KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3 KCNH8 potassium voltage-gated channel, subfamily H (eag-related), member 8 
KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5 KCNK1 potassium channel, subfamily K, member 1 
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Table 4.7: Genes associated with inward currents expressed by normal and 
F305S-mutant BEST1 human ES cell-derived RPE 
Gene Symbol Gene Name  
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 
KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 
KCNJ4 potassium inwardly-rectifying channel, subfamily J, member 4 
KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5 
KCNJ6 potassium inwardly-rectifying channel, subfamily J, member 6 
KCNJ9 potassium inwardly-rectifying channel, subfamily J, member 9 
HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 
HCN2 hyperpolarization activated cyclic nucleotide-gated potassium channel 2 
HCN3 hyperpolarization activated cyclic nucleotide-gated potassium channel 3 
HCN4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 
KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1 
KCNJ10 potassium inwardly-rectifying channel, subfamily J, member 10 
KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11 
KCNJ13 potassium inwardly-rectifying channel, subfamily J, member 13 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 
KCNJ16 potassium inwardly-rectifying channel, subfamily J, member 16 
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Table 4.8: Genes associated with voltage-gated Na+ channels expressed by 
normal and F305S-mutant human ES cell-derived RPE  
Gene symbol Gene Name 
NALCN sodium leak channel, non-selective 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit 
SCN1A sodium channel, voltage-gated, type I, alpha subunit 
SCN1B sodium channel, voltage-gated, type I, beta 
SCN2A sodium channel, voltage-gated, type II, alpha subunit 
SCN2B sodium channel, voltage-gated, type II, beta 
SCN3A sodium channel, voltage-gated, type III, alpha subunit 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit 
SCN4B sodium channel, voltage-gated, type IV, beta 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit 
SCN5A sodium channel, voltage-gated, type V, alpha subunit 
SCN7A sodium channel, voltage-gated, type VII, alpha 
SCN10A sodium channel, voltage-gated, type X, alpha subunit 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit 
Genes in bold are TTX-insensitive Na+ channels (Ogata and Ohishi 2002) 
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Table 4.9: Shared K+ and Na+ channel-related genes expressed by normal 
human ES cell-derived RPE and primary human foetal and adult RPE  
Gene Symbol Gene name  
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide 
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 
KCMF1 potassium channel modulatory factor 1 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 
KCNJ13 potassium inwardly-rectifying channel, subfamily J, member 13 
KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4 
KCNT2 potassium channel, subfamily T, member 2 
KCNV2 potassium channel, subfamily V, member 2 
KCTD1 potassium channel tetramerisation domain containing 1 
KCTD10 potassium channel tetramerisation domain containing 10 
KCTD12 potassium channel tetramerisation domain containing 12 
KCTD15 potassium channel tetramerisation domain containing 15 
KCTD18 potassium channel tetramerisation domain containing 18 
KCTD3 potassium channel tetramerisation domain containing 3 
KCTD6 potassium channel tetramerisation domain containing 6 
KCTD7 potassium channel tetramerisation domain containing 7 
KCTD9 
similar to Potassium channel tetramerisation domain containing 9; 
potassium channel tetramerisation domain containing 9; similar to 
potassium channel tetramerisation domain containing 9 
NALCN sodium leak channel, non-selective 
SCLT1 sodium channel and clathrin linker 1 
SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 
SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 
SLC13A4 solute carrier family 13 (sodium/sulfate symporters), member 4 
SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 
SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
SLC4A5 solute carrier family 4, sodium bicarbonate cotransporter, member 5 
SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 
SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
SLC9A3R1 solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 
SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), member 6 
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Table 4.10:Additional K+ and Na+ channel genes expressed by human ES cell-
derived RPE and fRPE, but not in aRPE  
Gene Symbol Gene name  
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 
KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 
KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 
KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 
KCNMB4 
potassium large conductance calcium-activated channel, subfamily M, beta 
member 4 
KCTD2 potassium channel tetramerisation domain containing 2 
KCTD20 potassium channel tetramerisation domain containing 20 
KCTD5 potassium channel tetramerisation domain containing 5 
SCN5A sodium channel, voltage-gated, type V, alpha subunit 
SLC10A7 solute carrier family 10 (sodium/bile acid cotransporter family), member 7 
SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 
SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 
SLC13A3 solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 
SLC24A3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 
SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 
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Table 4.11:Additional K+ and Na+ channel genes expressed by human ES cell-
derived RPE and aRPE, but not in fRPE  
Gene Symbol Gene name  
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 
KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 
KCTD4 potassium channel tetramerisation domain containing 4 
SLC12A5 solute carrier family 12 (potassium-chloride transporter), member 5 
SLC17A7 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 7 
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4.3. Discussion 
4.3.1. Protein localisation in single RPE cells derived from human ES cells are 
similar to monolayer RPE 
This study aimed to characterise voltage-gated currents in human ES cell-derived 
RPE using whole-cell patch clamp electrophysiology. Highly pigmented individual 
RPE cells derived from both normal and F305S-mutant BEST1 human ES cells 
displayed similar protein localisation of the mature RPE proteins ZO-1, RPE65 and 
BEST1 compared to the parent RPE monolayers. Importantly, this included 
cytoplasmic localisation observed for BEST1 in the F305S-mutant BEST1 RPE 
compared to the membrane localisation seen in RPE derived from normal human ES 
cells as seen previously (Milenkovic et al., 2011b). To date RPE protein localisation 
studies have only been published for RPE monolayers, or studies in which particular 
proteins have been overexpressed in isolated non-RPE cells (Klimanskaya et al., 
2004, Marmorstein et al., 2000, Blenkinsop et al., 2015, Maminishkis et al., 2006, 
Milenkovic et al., 2011b). The immunofluorescence data presented here shows that 
for at least 24 hours after plating, key RPE proteins remain similarly located in 
isolated cells compared to cells in a RPE monolayer. These data suggest it is 
reasonable to assume that the expression profiles of key ion channels might also 
remain correctly localised within the timeframe used here, thus enabling biologically 
relevant electrophysiology data to be collected and interpreted. 
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4.3.2. F305S-mutant BEST1 human ES cell-derived RPE had similar voltage-
gated currents to normal RPE 
To begin defining the electrophysiological properties of RPE-derived from normal 
and F305S-mutant BEST1 human ES cells their membrane capacitance and resting 
membrane potentials were analysed. These features were chosen as they are 
relatively well-characterised features of primary human RPE. Here, the resting 
membrane potential measures the difference in potential between the inside and 
outside of the cell at rest, measurements were typically between -30 and -65 mV in 
primary human RPE (Wen et al., 1993, Quinn and Miller, 1992, Fox et al., 1988). 
The resting membrane potential is a consequence of the expression and conductance 
of voltage-gated channels, as well as active transporters that maintain a charge 
gradient across the plasma membrane. The normal and mutant BEST1 human ES 
cell-derived RPE were shown to have a mean membrane potential of 16 mV and 14.5 
mV respectively, compared to the published average membrane potential for primary 
human fRPE and aRPE of -34 mV and -50 mV respectively. However, the resting 
membrane potentials detected for both the normal and F305S-mutant BEST1 RPE 
showed no statistical difference with either of the primary human RPE types (Wen et 
al., 1993), suggesting they have similar expression of voltage-gated Na
+
 and K
+
 
channels and transporters to primary human RPE. Comparison of the data presented 
in this thesis and published primary human RPE data shows that the prolonged 
depolarised membrane potential of human ES cell-derived RPE does not appear to 
have an effect on the magnitudes of voltage-gated Na
+
 and K
+
 currents.  However, 
this depolarised state is known to activate voltage-gated calcium (Ca
2+
) channels that 
can lead to changes in concentration of intracellular Ca
2+
 (Ueda and Steinberg, 1995, 
Strauss et al., 1997, Rosenthal et al., 2006). Therefore, Ca
2+
-related effects of a 
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prolonged depolarised resting membrane potential would be worth investigating in 
future studies using human ES cell-derived RPE from both normal and F305S-
mutant BEST1. The second measurement recorded was the membrane capacitance; 
in primary human fRPE it is reported to be ~ 20 pF (Wen et al., 1993), and ~ 60 pF 
for primary aRPE (Wen et al., 1993). Here, the membrane capacitance of the RPE 
derived from normal human ES cells was shown to be between that of primary 
human fRPE and aRPE (Wen et al., 1993), though not statistically significantly 
different from either, except for the comparison of the F305S-mutant BEST1 RPE 
membrane capacitance which was more foetal-like and significantly different to 
primary aRPE (Wen et al., 1993). Overall, the membrane capacitance and resting 
membrane potentials of human ES cell-derived RPE suggests some cells have 
similarities with primary aRPE, but are found to be more similar to primary human 
fRPE.  
Endogenously expressed K
+
 channels have previously been detected via 
electrophysiology in primary RPE cells (Wen et al., 1993, Strauss et al., 1994, Fox et 
al., 1988, Hughes and Takahira, 1996, Strauss et al., 1993), and K
+
 channels have 
been implicated in the regulation of ions across the RPE to maintain ion, fluid and 
pH homeostasis (Fox et al., 1988, Wimmers et al., 2007, Bialek and Miller, 1994, 
Hughes and Takahira, 1996, Strauss et al., 1993). For example, K
+
 channels provide 
an efflux of K
+
 from the retina to blood in response to changes in the subretinal space 
caused by photoreceptor activity (e.g., during transitions from light to dark) (Hughes 
and Steinberg, 1990, Quinn and Miller, 1992, Bialek and Miller, 1994). In the data 
presented here, the F305S-mutant BEST1 RPE were shown to display similar 
voltage-gated Na
+
 and K
+
 currents to RPE derived from normal human ES cells. 
Importantly, both human ES cell-derived RPE types were shown to express similar 
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voltage-gated Na
+
 and K
+
 currents to primary human RPE (Wen et al., 1993, Wen et 
al., 1994, Fox et al., 1988, Strauss et al., 1993). For example, primary human RPE 
has been shown to possess a delayed outward current activated by depolarising the 
cells to voltages more positive than -30 mV that can be blocked by the specific K
+
 
channel blocker TEA (Wen et al., 1993, Strauss et al., 1993). Interestingly, the 
KCNQ1-5 genes encode for M-type K
+
 channels previously identified at the 
transcript and protein levels in RPE from various species (e.g., monkey, rat and cow) 
(Zhang et al., 2011b, Pattnaik and Hughes, 2012, Strauss et al., 2002, Zhang and 
Hughes, 2013). While the activity of these channels were not directly investigated 
here, previous studies report M-type K
+
 currents to be insensitive to the K
+
 channel 
blocker TEA (Pattnaik and Hughes, 2012). Thus a reasonable assumption is that it 
the residual delayed outward K
+
 current seen in the human ES cell-derived RPE after 
blocking with TEA might be caused by these M-type K
+
 channels. Notably, analysis 
of the human ES cell-derived RPE Affymetrix gene expression data presented in 
Chapter 3 revealed the expression of KCNQ genes in RPE derived from both normal 
and F305S-mutant BEST1 human ES cells. Therefore existing literature supports the 
findings that human ES cell-derived RPE delayed outward voltage-gated K
+
 currents 
are similar to those found in primary human RPE and suggests the KCNQ genes are 
likely to be responsible for these currents seen in RPE derived from human ES cells. 
A characteristic feature of primary human fRPE (but not aRPE) is the 
expression of the fast A-type K
+
 currents, activated by depolarisation to voltages 
more positive than -30 mV in a similar manner to the delayed outward K
+
 current 
(Wen et al., 1993). These fast A-type currents seen in the human ES cell-derived 
RPE were blocked by the K
+
 channel blocker 4-AP (Wen et al., 1993). The only fast 
A-type current gene that has been identified in the literature in relation to the RPE is 
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the KCND2 gene which encodes for Kv4.2, detected at the mRNA transcript level 
(Pinto and Klumpp, 1998). Affymetrix analysis revealed that this gene was expressed 
in both human ES cell-derived RPE and in published primary human fRPE datasets 
but not in aRPE. Additionally, both normal and F305S-mutant BEST1 human ES 
cell-derived RPE also expressed KCND1 and KCNC3-4, although these genes do not 
appear to be expressed in the primary human fRPE or aRPE datasets. Together, it is 
likely that some or all of these KCND and KCNC genes contribute to the function of 
the fast A-type K
+
 current in the RPE derived from human ES cells. These data 
similarly support the idea that human ES cell-derived RPE are more similar to 
primary human fRPE than aRPE.  
Another previously described current in primary human aRPE (but not fRPE) 
is the inwardly rectifying K
+
 current (Wen et al., 1993, Strauss et al., 1993, Hughes 
and Takahira, 1996). These inward K
+
 currents result from a family of proteins 
encoded by the KCNJ genes expressed in primary human RPE and also cow RPE 
(Yang et al., 2008, Shimura et al., 2001). Investigation of the human ES cell-derived 
RPE Affymetrix gene expression data revealed both normal and F305S-mutant 
BEST1 RPE expressed a number of KCNJ inward-rectifying K
+
 channel genes and 
HCN1-4 hyperpolarising-activated cation channel genes. The protein products of 
these genes may have contributed to the inward currents seen in ~ 15% of the human 
ES cell-derived RPE. To date, little information exists in the literature describing the 
role of HCN1-4 genes in human RPE function, thus human PS cell-derived RPE may 
provide a useful tool for these investigations in future. Overall, the combined 
electrophysiology and gene expression data provide new and highly relevant 
information on the types of K
+
 currents seen in human ES cell-derived RPE. 
Moreover, the low frequency of the sustained inward current in both normal and 
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F305S-mutant BEST1 human ES cell-derived RPE indicate more foetal-like RPE 
phenotype than adult. 
Another important ion involved in RPE homeostasis is Na
+
, particularly in 
relation to the Na
+
/K
+
/-ATPase and Na
+
/K
+
/Cl
-
 transporter that are both critical to 
RPE function (Jaffe et al., 1989, Quinn and Miller, 1992). Interestingly, both normal 
and F305S-mutant BEST1 human ES cell-derived RPE were shown to have a 
number of cells expressing a fast transient inward Na
+
 current consistent with 
cultured human RPE (Wen et al., 1994, Wen et al., 1993, Kokkinaki et al., 2011). 
The fast transient inward current was partially blocked using the Na
+
 channel blocker 
TTX, revealing both TTX-sensitive and TTX-insensitive components expressed in 
human ES cell-derived RPE. TTX-insensitive currents have been reported in cultured 
human RPE and various species (i.e., rat RPE and newt RPE), with no links to RPE-
specific function (Botchkin and Matthews, 1994, Sakai and Saito, 1996, Wen et al., 
1994). The expression of Na
+
 currents only appear to be reported in cultured primary 
human RPE, where they have been suggested to be caused by dedifferentiation as 
seen by loss of pigment and morphology, leading to a more immature RPE state 
(Wen et al., 1994). However, all RPE derived from human ES cells were highly 
pigmented, with similar Na
+
 current densities to highly pigmented cultured primary 
human RPE (Wen et al., 1994), suggesting that the appearance of Na
+
 currents might 
be caused by a response to culturing and/or culture medium conditions that can affect 
gene expression profiles. Affymetrix gene expression analysis of the human ES cell-
derived RPE revealed expression of voltage-gated Na
+
 channel-related genes that 
encode for both TTX-sensitive (i.e., SCN1-4A and SCN8-9A) and TTX-insensitive 
channels (i.e., SCN5A, SCN7A, SCN10A and SCN11A) (Ogata and Ohishi, 2002). 
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The SCN5A gene was also found in primary human fRPE but not aRPE, further 
demonstrating that the human ES cell-derived RPE is more foetal-like.  
Overall, the data presented here indicate that normal and F305S-mutant 
BEST1 RPE display similar voltage-gated Na
+
 and K
+
 currents to each other. 
Overall, these currents are consistent with published voltage-gated Na
+
 and K
+
 
currents detected in primary human RPE, particularly fRPE. Analysis of human ES 
cell-derived RPE Affymetrix gene expression data identified specific Na
+
 and K
+
 
channel-related genes that are likely responsible for the observed voltage-gated Na
+
 
and K
+
 currents. Thus further investigation of ion homeostasis using human ES cell-
derived RPE is likely to provide important and biologically relevant information on 
ion homeostasis mechanisms in normal and diseased RPE. In particular, since 
overexpression studies in non-human, non-RPE cell types suggest BEST1 may act as 
a chloride (Cl
-
) channel, investigation of Cl
-
 homeostasis in RPE derived from 
normal and F305S-mutant BEST1 human ES cells could provide new insights into 
the molecular mechanisms of BVMD.  
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5.1.  Introduction 
Best vitelliform macular dystrophy (BVMD) is known to be caused by mutations in 
the BEST1 gene, which encodes for the Bestrophin-1 (BEST1) protein normally 
localised at or near the basolateral plasma membrane of the retinal pigment 
epithelium (RPE) (Marmorstein et al., 2000, Petrukhin et al., 1998, White et al., 
2000, Kramer et al., 2000, Singh et al., 2013b, Barro-Soria et al., 2010). The BEST1 
mechanism of action in normal RPE or BVMD is unclear but data obtained through 
BEST1 overexpression studies, typically using non-RPE cell types and animal 
models, suggest it may act as; (i) a chloride (Cl
-
) channel activated by calcium (Ca
2+
) 
(Sun et al., 2002, Tsunenari et al., 2003), (ii) a regulator of voltage-dependent Ca
2+
 
channels (Xiao et al., 2008, Yu et al., 2008), (iii) a bicarbonate (HCO3
-
) anion 
channel (Qu and Hartzell, 2008), (iv) a cell volume regulator (Fischmeister and 
Hartzell, 2005, Milenkovic et al., 2015) or (v) as a multifunctional protein, where 
BEST1 may function as a Cl
-
 channel and a regulator of Ca
2+
 in a feedback loop 
(Rosenthal et al., 2006, Hartzell et al., 2008). It is widely thought that obtaining a 
more detailed understanding of how BEST1 functions in human RPE will help 
provide mechanistic links between BEST1 mutations and characteristic BVMD 
symptoms, such as an abnormal light peak seen in patient electro-oculograms and the 
accumulation of lipofuscin and fluids around the RPE and macula (Petrukhin et al., 
1998, Marchant et al., 2007, Arden and Constable, 2006, Marmorstein et al., 2006, 
Thompson et al., 2015).  
Sequence analysis and X-ray crystallography of BEST1 protein suggest it 
could act as a Cl
-
 channel activated by Ca
2+
, and a small number of studies using 
heterologous overexpression systems support this idea (Sun et al., 2002, Kane 
Dickson et al., 2014, Xiao et al., 2008, Yang et al., 2014). For example, BEST1 was 
Chapter 5: Key differences in chloride and calcium conductance in RPE derived from normal and F305S-
mutant BEST1 human ES cells 
114 
 
first shown to be able to act as a Cl
-
 channel after it was overexpressed in HEK293 
cells (Sun et al., 2002). In the same study, similar overexpression of the Y85H, 
R92C, R218S and G299E BEST1 mutants in HEK293 cells led to a significantly 
smaller whole-cell Cl
-
 conductance compared to wild-type BEST1. Notably, the Cl
-
 
conductance attributed to the overexpression of wild-type BEST1 was decreased by 
the Cl
-
 channel blocker 4,4′-Diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) 
(Sun et al., 2002), whereas the whole-cell Cl
-
 conductance was increased in the 
presence of intracellular Ca
2+
 (Sun et al., 2002). 
While these proposed BEST functions have typically been obtained in non-
RPE cell types, anion conductance (particularly Cl
-
 conductance) has been reported 
to be involved in RPE transepithelial transport (Hu et al., 1996), regulation of 
volume (Milenkovic et al., 2015, Fischmeister and Hartzell, 2005, Botchkin and 
Matthews, 1993) and generation of the light peak seen in the electro-oculogram 
(Marmorstein et al., 2002, Gallemore and Steinberg, 1989, Rosenthal et al., 2006).  
In an attempt to determine whether endogenously expressed BEST1 protein 
functions as a Cl
-
 channel in human RPE and whether this activity is Ca
2+
-dependent, 
this study investigated Cl
-
 conductance in RPE-derived from normal and F305S-
mutant BEST1 human ES cells that express endogenous levels of BEST1 protein. 
The results revealed that Cl
-
 conductance was detected in both normal and F305S-
mutant BEST1 human ES cell-derived RPE, and the Cl
-
 conductance was sensitive to 
Ca
2+
. Furthermore, the Cl
-
 conductance, Ca
2+
-dependent and -independent Cl
-
 
conductances were significantly reduced in the F305S-mutant BEST1 RPE compared 
to normal human ES cell-derived RPE. 
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5.2. Results 
5.2.1. Detection of whole-cell currents in human ES cell-derived RPE 
One of the proposed functions of BEST1 protein is that it may regulate RPE 
physiology by acting as a Ca
2+
-activated Cl
-
 channel (CaCC) (Sun et al., 2002). Here, 
whole-cell patch clamp electrophysiology was used to measure both the passive and 
voltage-dependent Cl
-
 conductance in RPE-derived from normal and F305S-mutant 
BEST1 human ES cells. The internal and external solutions were manipulated to 
eliminate Na
+
 and K
+
 currents by substituting extracellular and intracellular ions with 
TMA-Cl to allow Cl
-
 conductance to be assessed without the influence of these 
predominant membrane permeable ions. 
Under these conditions the reversal potential (i.e., no net movement of ions to 
the inside or outside of the cell) for both normal and F305S-mutant BEST1 human 
ES cell derived RPE was near zero (i.e., -2.72 ± 2.76, n = 12 and -0.79 ± 1.15, n = 12 
respectively). These values were similar to those previously reported for a cultured 
human foetal RPE (fRPE) cell line (immortalised via SV40 transformation) (Wills et 
al., 2000). Assessment of whole-cell conductance for highly pigmented normal and 
F305S-mutant BEST1 RPE showed a large current in all cells. There was no 
significant difference in the whole-cell conductance between the normal and F305S-
mutant BEST1 RPE (Figure 5.1; p = 0.4140), however the F305S-mutant BEST1 
RPE showed reduced current density across the voltage range tested compared to the 
normal BEST1 RPE. 
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5.2.2. Voltage-dependent Cl- and Ca2+ currents in human ES cell-derived RPE 
In contrast to the whole-cell currents, assessment of the voltage-dependent current 
(i.e. the remaining current after subtraction of the passive currents from the whole-
cell current), revealed a significantly reduced outward current in the F305S-mutant 
BEST1 RPE compared to RPE derived from normal human ES cells (Figure 5.2; p = 
0.0001). To test whether the outward current seen in the human ES cell-derived RPE 
was a Cl
-
 current, the Cl
-
 channel blocker 4,4'-diisothiocyanato-stilbene-2,2'-
disulphonic acid (DIDS) was applied externally at 0.5 mM. The results showed that 
DIDS completely abolished the outward Cl
-
 current in the normal RPE, and in doing 
so revealed an inward current (Figure 5.3). Application of DIDS to the F305S-mutant 
BEST1 RPE also abolished the outward current, revealing an inward current (Figure 
5.4). The difference in magnitude of the inward currents between the normal and 
F305S-mutant BEST1 RPE was not statistically significant (p = 0.1032). Taken 
together these data revealed two key findings; firstly, they show that voltage-
dependent Cl
-
 conductance in the F305S-mutant BEST1 RPE is reduced by ~ 45 - 
50% compared to normal RPE at essentially all positive voltages (Figure 5.2); this 
suggests that BEST1 is acting as a Cl
-
 channel in the human ES cell-derived RPE. 
Secondly, given the composition of the external solution, the inward current 
produced after blocking Cl
-
 conductance with DIDS was likely to be a Ca
2+
 current 
driven by Ca
2+
 entering the cell. To test this theory, the Ca
2+
 channel blocker 
cadmium chloride (CdCl2) was added to the external solution at 1 mM, after the 
addition of the Cl
-
 channel blocker DIDS. This dual inhibition of both Cl
-
 and Ca
2+
 
channels resulted in a loss of the inward current in normal RPE (Figure 5.5; p = 
0.0289), confirming the inward current was due to the movement of Ca
2+
.  
Chapter 5: Key differences in chloride and calcium conductance in RPE derived from normal and F305S-
mutant BEST1 human ES cells 
117 
 
 
 
  
-0.15
-0.1
-0.05
0
0.05
0.1
0.15
-150 -100 -50 0 50 100 150
C
u
rr
en
t 
d
en
si
ty
 (
n
A
/p
F
) 
Voltage (mV) 
Normal human
ES cell-
derived RPE
F305S-mutant
BEST1 RPE
Figure 5.1: Whole-cell current (i.e., passive and voltage-dependent currents) 
seen in normal and F305S-mutant BEST1 human ES cell-derived RPE A) 
Representative raw trace of the whole-cell current seen in both normal and 
F305S-mutant BEST1 human ES cell-derived RPE. B) Current density-Voltage 
curve showing no significant difference between normal and F305S-mutant 
BEST1 RPE (p = 0.4140; normal human ES cell-derived RPE n = 35; F305S-
mutant BEST1 RPE n = 26), however the mutant BEST1 RPE showed reduced 
current density across all voltages compared to normal RPE. 
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Figure 5.2: Voltage-dependent current seen in normal and F305S-mutant 
BEST1 human ES cell-derived RPE A) Representative raw traces of the 
voltage-dependent outward currents (after subtraction of passive currents) seen 
in both human ES cell-derived RPE. B) Current density-Voltage curve showing a 
statistically significant decrease in F305S-mutant BEST1 RPE outward current 
compared to normal RPE outward current (*p = 0.0001; normal human ES cell-
derived RPE n = 35; F305S-mutant BEST1 RPE n = 26). 
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Figure 5.3: Identification of Cl- current in normal human ES cell-derived 
RPE A) Representative raw traces before and after 0.5 mM 4,4′-
Diisothiocyanatostilbene-2,2′-disulfonic acid (DIDS) application. B) Current 
density-voltage curve of the voltage-dependent Cl- current had completely 
abolished after blocking with DIDS revealing an inward current in normal RPE 
(*p = 0.0001; n = 8).  
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Figure 5.4: Identification of the Cl- current in F305S-mutant BEST1 human 
ES cell-derived RPE A) Representative raw traces of the voltage-dependent Cl- 
current that was blocked with DIDS had revealed a smaller inward Ca2+ current 
in F305S-mutant BEST1 RPE. B) Current density-Voltage curve showed the Cl- 
channel blocker DIDS had completely abolished the outward Cl- current (*p = 
0.0001; n = 3), revealing an inward current. 
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Figure 5.5: The inward current was a Ca2+ current in human ES cell-derived 
RPE A) Representative raw traces showing the blocking of the Cl- current 
revealed an inward Ca2+ current that was blocked with 1 mM cadmium chloride 
(CdCl
2
). B) Current density-Voltage curve showed the blocking of the Cl- current 
with 0.5 mM DIDS revealed an inward current that was significantly reduced 
after external application of CdCl
2
 (*p = 0.0289; n = 3).  
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5.2.3. Cl- currents are reduced by blocking Ca2+ channels in human ES cell-
derived RPE 
As heterologous overexpression studies have shown BEST1 Cl
-
 conductance itself 
may be modulated by Ca
2+
 (Sun et al., 2002), the effects of the Ca
2+
 channel blocker 
CdCl2 was assessed with no other modification of Cl
-
 conductance (i.e., no DIDS 
present). Blocking Ca
2+
 channels via CdCl2 reduced the magnitude of the Cl
-
 
conductance in normal human ES cell-derived RPE by 60 - 70% at positive voltages 
(Figure 5.6; p = 0.0204). This data suggests that the majority of the Cl
-
 current in 
normal RPE is due to CaCCs, and that the remaining Cl
-
 currents observed are due to 
Ca
2+
-independent Cl
-
 channels. Using CdCl2 to block Ca
2+
 channels in the F305S-
mutant BEST1 RPE almost completely abolished the Cl
-
 conductance, showing 
residual Ca
2+
-independent Cl
-
 current is maintained in this mutant RPE (Figure 5.7; p 
= 0.0149). Overall, this data indicates the F305S-mutant BEST1 RPE has 
significantly reduced Ca
2+
-dependent and Ca
2+
-independent Cl
-
 currents compared to 
the normal human ES cell-derived RPE.  
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Figure 5.6: The effect of Ca2+ channel blocker on normal human ES cell-
derived RPE Cl- conductance A) Representative raw traces of the voltage-
dependent Cl- current reduced by external application of CdCl
2
. B) Current 
density-Voltage curve showing a reduction of the Cl- current when Ca2+ channel 
blocker CdCl
2
 was applied, suggesting that there are Ca2+-dependent Cl- channels 
in human ES cell-derived RPE, with Ca2+-independent Cl- currents remaining (*p 
= 0.0204; n = 5).  
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Figure 5.7: Cl- conductance was reduced by Ca2+ channel blocker in F305S-
mutant BEST1 human ES cell-derived RPE A) Representative raw traces of 
the Cl- conductance reduced by CdCl
2
. B) Current density-Voltage curve showed 
that after blocking with Ca2+ channel blocker CdCl
2
 F305S-mutant BEST1 RPE 
had reduced Ca2+-dependent Cl- conductance, with limited residual Ca2+-
independent Cl- conductance (*p = 0.0149; n = 3).  
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5.2.4. Cl- and Ca2+ homeostasis genes expressed by human ES cell-derived RPE 
To investigate the specific genes responsible for the Cl
-
 and Ca
2+
 currents in the 
human ES cell-derived RPE, the Affymetrix gene expression data presented in 
Chapter 3 was reanalysed to focus on specific Cl
-
 and Ca
2+
 homeostasis-related 
genes. This analysis revealed that both normal and F305S-mutant BEST1 human ES 
cell-derived RPE shared expression of 71 Cl
-
 homeostasis-related genes (Table 5.1), 
with none of these differentially expressed between the normal and mutant RPE. The 
Cl
-
 homeostasis genes expressed by the normal and F305S-mutant BEST1 RPE were 
compared to published Affymetrix data for primary human foetal RPE (fRPE) and 
adult RPE (aRPE) (Strunnikova et al., 2010). The results showed that both normal 
and F305S-mutant BEST1 RPE shared expression of 29 Cl
-
 homeostasis-related 
genes with primary human fRPE (Table 5.2), and 25 Cl
-
 homeostasis-related genes 
with primary human aRPE (Table 5.3). This includes the Cl
-
 channel genes BEST1, 
ANO1-10, CLCN2, CLCN3, CLCN5 and CFTR.  
 Analysis of the Ca
2+
 homeostasis-related genes showed the normal human 
ES cell-derived RPE expressed 129 Ca
2+
 homeostasis-related genes and the F305S-
mutant BEST1 RPE expressed the same 129 genes (Table 5.4) as well as 5 additional 
Ca
2+
 homeostasis-related genes that included ORAI3 (Table 5.4; font in bold). The 
Ca
2+
 homeostasis-related genes expressed by the normal and F305S-mutant BEST1 
human ES cell-derived RPE were compared to published Affymetrix data for 
primary human fRPE and aRPE (Strunnikova et al., 2010). The results showed that 
both normal and F305S-mutant BEST1 RPE shared expression of 52 Ca
2+
 
homeostasis-related genes with primary human fRPE (Table 5.5), and 36 Ca
2+
 
homeostasis-related genes with primary human aRPE (Table 5.6). These genes 
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included STIM1-2, ORAI1-3 (previously described in Chapter 3), CACNA1D, 
CACNA1C, CACNA1F and CACNA1S. Thus the Affymetrix analyses revealed that 
all Cl
-
 and almost all Ca
2+
 homeostasis-related genes were similarly expressed by 
both normal and F305S-mutant BEST1 human ES cell-derived RPE. The data also 
showed the human ES cell-derived RPE shared expression of more Cl
-
 and Ca
2+
 
homeostasis-related genes with fRPE than aRPE. Taken together, these data provide 
additional information on the genes that might contribute to the Cl
-
 and Ca
2+
 currents 
seen in these studies. 
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Table 5.1: Cl- channel-related genes expressed by both normal and F305S-mutant BEST1 human ES cell-derived RPE 
Gene 
Symbol Gene name Gene Symbol Gene name 
ANO1 anoctamin 1, calcium activated chloride channel SLC12A4 solute carrier family 12 (potassium/chloride transporters), member 4 
ANO2 anoctamin 2 SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 
ANO3 anoctamin 3 SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 
ANO4 anoctamin 4 SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 
ANO5 anoctamin 5 SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 
ANO6 anoctamin 6 SLC12A5 solute carrier family 12 (potassium-chloride transporter), member 5 
ANO7 anoctamin 7 SLC12A3 solute carrier family 12 (sodium/chloride transporters), member 3 
ANO8 anoctamin 8 SLC12A1 solute carrier family 12 (sodium/potassium/chloride transporters), member 1 
ANO9 anoctamin 9 SLC12A2 solute carrier family 12 (sodium/potassium/chloride transporters), member 2 
ANO10 anoctamin 10 SLC17A5 solute carrier family 17 (anion/sugar transporter), member 5 
BEST1 Bestrophin 1 SLC22A13 solute carrier family 22 (organic anion transporter), member 13 
BEST2 Bestrophin 2 SLC22A6 solute carrier family 22 (organic anion transporter), member 6 
BEST3 Bestrophin 3 SLC22A7 solute carrier family 22 (organic anion transporter), member 7 
BEST4 Bestrophin 4 SLC22A8 solute carrier family 22 (organic anion transporter), member 8 
CLCN1 chloride channel 1, skeletal muscle SLC22A9 solute carrier family 22 (organic anion transporter), member 9 
CLCN2 chloride channel 2 SLC22A11 solute carrier family 22 (organic anion/urate transporter), member 11 
CLCN3 chloride channel 3 SLC22A12 solute carrier family 22 (organic anion/urate transporter), member 12 
CLCN4 chloride channel 4 SLC4A1AP solute carrier family 4 (anion exchanger), member 1, adaptor protein 
CLCN5 chloride channel 5 SLC4A1 
solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane 
protein band 3, Diego blood group) 
CLCN6 chloride channel 6 SLC4A2 
solute carrier family 4, anion exchanger, member 2 (erythrocyte membrane 
protein band 3-like 1) 
CLCN7 chloride channel 7 SLC4A3 solute carrier family 4, anion exchanger, member 3 
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CLCA1 chloride channel accessory 1 SLCO1A2 solute carrier organic anion transporter family, member 1A2 
CLCA2 chloride channel accessory 2 SLCO1B1 solute carrier organic anion transporter family, member 1B1 
CLCA3P chloride channel accessory 3 (pseudogene) SLCO1B3 solute carrier organic anion transporter family, member 1B3 
CLCA4 chloride channel accessory 4 SLCO1C1 solute carrier organic anion transporter family, member 1C1 
CLCC1 chloride channel CLIC-like 1 SLCO2A1 solute carrier organic anion transporter family, member 2A1 
CLCNKA chloride channel Ka SLCO2B1 solute carrier organic anion transporter family, member 2B1 
CLCNKB chloride channel Kb SLCO3A1 solute carrier organic anion transporter family, member 3A1 
CLNS1A chloride channel, nucleotide-sensitive, 1A SLCO4A1 solute carrier organic anion transporter family, member 4A1 
CLIC1 chloride intracellular channel 1 SLCO4C1 solute carrier organic anion transporter family, member 4C1 
CLIC2 chloride intracellular channel 2 SLCO5A1 solute carrier organic anion transporter family, member 5A1 
CLIC3 chloride intracellular channel 3 SLCO6A1 solute carrier organic anion transporter family, member 6A1 
CLIC4 chloride intracellular channel 4 VDAC1 
voltage-dependent anion channel 1; similar to voltage-dependent anion 
channel 1 
CLIC5 chloride intracellular channel 5 VDAC2 voltage-dependent anion channel 2 
CLIC6 chloride intracellular channel 6 VDAC3 voltage-dependent anion channel 3 
CFTR cystic fibrosis transmembrane conductance regulator 
(ATP-binding cassette sub-family C, member 7) 
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Genes in bold are exclusively found in primary human fRPE but not in aRPE 
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Genes in bold are exclusively found in primary human aRPE but not in fRPE 
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Table 5.4: Ca2+ channel-related genes expressed by both normal and F305S-mutant BEST1 human ES cell-derived RPE 
Gene 
Symbol Gene name 
Gene 
Symbol Gene name 
CAMK2N2 calcium/calmodulin-dependent protein kinase II inhibitor 2 EFCAB4A EF-hand calcium binding domain 4A 
C2CD2 C2 calcium-dependent domain containing 2 EFCAB4B EF-hand calcium binding domain 4B 
C2CD3 C2 calcium-dependent domain containing 3 EFCAB5 EF-hand calcium binding domain 5 
CAB39 calcium binding protein 39 EFCAB6 EF-hand calcium binding domain 6 
CAB39L calcium binding protein 39-like EFCAB7 EF-hand calcium binding domain 7 
CABP1 calcium binding protein 1 EFCAB9 EF-hand calcium binding domain 9 
CABP2 calcium binding protein 2 GCA grancalcin, EF-hand calcium binding protein 
CABP4 calcium binding protein 4 HRC histidine rich calcium binding protein 
CABP5 calcium binding protein 5 KCNMA1 
potassium large conductance calcium-activated channel, subfamily M, alpha member 
1 
CABP7 calcium binding protein 7 KCNMB1 
potassium large conductance calcium-activated channel, subfamily M, beta member 
1 
CABYR calcium binding tyrosine-(Y)-phosphorylation regulated KCNMB2 
potassium large conductance calcium-activated channel, subfamily M, beta member 
2 
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit KCNMB3 potassium large conductance calcium-activated channel, subfamily M beta member 3 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit KCNMB4 
potassium large conductance calcium-activated channel, subfamily M, beta member 
4 
CACNA1C 
hypothetical protein LOC100131098; calcium channel, voltage-
dependent, L type, alpha 1C subunit 
KCNN1 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 1 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit KCNN2 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 2 
CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit KCNN3 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 3 
CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit KCNN4 
potassium intermediate/small conductance calcium-activated channel, subfamily N, 
member 4 
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CACNA1G calcium channel, voltage-dependent, T type, alpha 1G subunit NECAB1 N-terminal EF-hand calcium binding protein 1 
CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit NECAB2 N-terminal EF-hand calcium binding protein 2 
CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit NECAB3 N-terminal EF-hand calcium binding protein 3 
CACNA1S calcium channel, voltage-dependent, L type, alpha 1S subunit NOX5 NADPH oxidase, EF-hand calcium binding domain 5 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 ORAI1 ORAI calcium release-activated calcium modulator 1 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 ORAI2 ORAI calcium release-activated calcium modulator 2 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 ORAI3 ORAI calcium release-activated calcium modulator 3 
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 
CACNB1 calcium channel, voltage-dependent, beta 1 subunit PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) 
CACNB3 calcium channel, voltage-dependent, beta 3 subunit PPEF1 protein phosphatase, EF-hand calcium binding domain 1 
CACNB4 calcium channel, voltage-dependent, beta 4 subunit PPEF2 protein phosphatase, EF-hand calcium binding domain 2 
CACNG1 calcium channel, voltage-dependent, gamma subunit 1 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
CACNG2 calcium channel, voltage-dependent, gamma subunit 2 RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) 
CACNG3 calcium channel, voltage-dependent, gamma subunit 3 RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 
CACNG4 calcium channel, voltage-dependent, gamma subunit 4 RCN1 reticulocalbin 1, EF-hand calcium binding domain 
CACNG5 calcium channel, voltage-dependent, gamma subunit 5 RCN2 reticulocalbin 2, EF-hand calcium binding domain 
CACNG6 calcium channel, voltage-dependent, gamma subunit 6 RCN3 reticulocalbin 3, EF-hand calcium binding domain 
CACNG7 calcium channel, voltage-dependent, gamma subunit 7 S100A1 S100 calcium binding protein A1 
CACNG8 calcium channel, voltage-dependent, gamma subunit 8 S100A10 S100 calcium binding protein A10 
CALCOCO1 calcium binding and coiled-coil domain 1 S100A11 S100 calcium binding protein A11; S100 calcium binding protein A11 pseudogene 
CALCOCO2 calcium binding and coiled-coil domain 2 S100A12 S100 calcium binding protein A12 
CALHM1 calcium homeostasis modulator 1 S100A13 S100 calcium binding protein A13 
CALHM2 calcium homeostasis modulator 2 S100A14 S100 calcium binding protein A14 
CALHM3 calcium homeostasis modulator 3 S100A16 S100 calcium binding protein A16 
CAMK1 calcium/calmodulin-dependent protein kinase I S100A2 S100 calcium binding protein A2 
CAMK1D calcium/calmodulin-dependent protein kinase ID S100A3 S100 calcium binding protein A3 
CAMK1G calcium/calmodulin-dependent protein kinase IG S100A4 S100 calcium binding protein A4 
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CAMK2A calcium/calmodulin-dependent protein kinase II alpha S100A5 S100 calcium binding protein A5 
CAMK2B calcium/calmodulin-dependent protein kinase II beta S100A6 S100 calcium binding protein A6 
CAMK2D calcium/calmodulin-dependent protein kinase II delta S100A7 S100 calcium binding protein A7 
CAMK2G calcium/calmodulin-dependent protein kinase II gamma S100A7A S100 calcium binding protein A7A 
CAMK4 calcium/calmodulin-dependent protein kinase IV S100A7L2 S100 calcium binding protein A7-like 2 
CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha S100A8 S100 calcium binding protein A8 
CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta S100A9 S100 calcium binding protein A9 
CAMLG calcium modulating ligand S100B S100 calcium binding protein B 
CANT1 calcium activated nucleotidase 1 S100P S100 calcium binding protein P 
CARHSP1 calcium regulated heat stable protein 1, 24kDa S100Z S100 calcium binding protein Z 
CASK 
calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) 
SCGN secretagogin, EF-hand calcium binding protein 
CASR calcium-sensing receptor SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 
CCBE1 collagen and calcium binding EGF domains 1 SLC24A2 solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 
CFTR 
cystic fibrosis transmembrane conductance regulator (ATP-
binding cassette sub-family C, member 7) 
SLC24A3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 
CHERP calcium homeostasis endoplasmic reticulum protein SLC24A4 solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 
CIB1 calcium and integrin binding 1 (calmyrin) SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
CIB2 calcium and integrin binding family member 2 SLC8A2 solute carrier family 8 (sodium/calcium exchanger), member 2 
CIB3 calcium and integrin binding family member 3 SLC8A3 solute carrier family 8 (sodium/calcium exchanger), member 3 
CIB4 calcium and integrin binding family member 4 SMOC1 SPARC related modular calcium binding 1 
EFCAB1 EF-hand calcium binding domain 1 SMOC2 SPARC related modular calcium binding 2 
EFCAB10 EF-hand calcium binding domain 10 STIM1 stromal interaction molecule 1 
EFCAB2 EF-hand calcium binding domain 2 STIM2 stromal interaction molecule 2 
EFCAB3 similar to hypoxia-inducible protein 2; EF-hand calcium binding domain 3 
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Table 5.5: Ca2+ channel-related genes expressed by both normal and F305S-mutant BEST1 human ES cell-derived RPE and primary 
foetal RPE 
Gene Symbol Gene Name  Gene Symbol Gene Name  
C2CD2 C2 calcium-dependent domain containing 2 EFCAB2 EF-hand calcium binding domain 2 
C2CD3 C2 calcium-dependent domain containing 3 EFCAB4A EF-hand calcium binding domain 4A 
CAB39 calcium binding protein 39 EFCAB7 EF-hand calcium binding domain 7 
CAB39L calcium binding protein 39-like GCA grancalcin, EF-hand calcium binding protein 
CABYR calcium binding tyrosine-(Y)-phosphorylation regulated KCNMB4 potassium large conductance calcium-activated channel, 
subfamily M, beta member 4 
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit NECAB1 N-terminal EF-hand calcium binding protein 1 
CACNA1C hypothetical protein LOC100131098; calcium channel, voltage-
dependent, L type, alpha 1C subunit NECAB2 N-terminal EF-hand calcium binding protein 2 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit NECAB3 N-terminal EF-hand calcium binding protein 3 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 ORAI2 ORAI calcium release-activated calcium modulator 2 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
CACNB4 calcium channel, voltage-dependent, beta 4 subunit RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 
CALCOCO1 calcium binding and coiled-coil domain 1 RCN1 reticulocalbin 1, EF-hand calcium binding domain 
CALCOCO2 calcium binding and coiled-coil domain 2 RCN2 reticulocalbin 2, EF-hand calcium binding domain 
CAMK2B calcium/calmodulin-dependent protein kinase II beta S100A10 S100 calcium binding protein A10 
CAMK2D calcium/calmodulin-dependent protein kinase II delta S100A13 S100 calcium binding protein A13 
CAMK2G calcium/calmodulin-dependent protein kinase II gamma S100A16 S100 calcium binding protein A16 
CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta S100A6 S100 calcium binding protein A6 
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CAMLG calcium modulating ligand S100B S100 calcium binding protein B 
CANT1 calcium activated nucleotidase 1 SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 1 
CASK calcium/calmodulin-dependent serine protein kinase (MAGUK 
family) SLC24A3 
solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 3 
CCBE1 collagen and calcium binding EGF domains 1 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
CHERP calcium homeostasis endoplasmic reticulum protein SMOC2 SPARC related modular calcium binding 2 
CIB1 calcium and integrin binding 1 (calmyrin) STIM1 stromal interaction molecule 1 
CIB2 calcium and integrin binding family member 2 STIM2 stromal interaction molecule 2 
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Genes in bold in this list are exclusively found in primary human aRPE but not in fRPE 
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5.3. Discussion 
5.3.1. Reduced Cl- and Ca2+ conductance in F305S-mutant BEST1 RPE  
This study investigated the effect of the F305S BEST1 mutation on Cl
-
 conductance 
via whole-cell patch clamp electrophysiology in human ES cell-derived RPE 
expressing endogenous levels of normal or F305S-mutant BEST1. Published studies 
on RPE Cl
-
 channels have shown these channels are important for RPE function 
(Strauss, 2005) and can be activated in a variety of ways including through 
phosphorylation regulated by protein phosphatase 2A (Marmorstein et al., 2002), or 
by cell swelling (Botchkin and Matthews, 1993, Milenkovic et al., 2015). 
Studies using non-RPE cells have shown that BEST1 overexpression results 
in whole-cell currents that can be blocked by the Cl
-
 channel blocker DIDS (Qu and 
Hartzell, 2008, Sun et al., 2002, Liu et al., 2015). Furthermore, overexpression of 
mutant BEST1 in non-RPE resulted in reduced whole-cell Cl
-
 currents (Sun et al., 
2002, Qu and Hartzell, 2008, Marmorstein et al., 2015). This decrease in whole-cell 
Cl
-
 current was observed with a range of different disease-causing BEST1 mutations 
including: Y85H, R92C, W93C, R218S, G299E, ΔI295, D312N, E119Q and A146K 
(Sun et al., 2002, Qu and Hartzell, 2008, Yu et al., 2007b, Marmorstein et al., 2015). 
The data presented in this chapter did not find a significant decrease in the F305S-
mutant BEST1 RPE whole-cell conductance compared to the normal human ES cell-
derived RPE. This is likely due to endogenous BEST1 expression, with lower 
physiologically-relevant levels of BEST1 activity, rather than overexpression 
systems that show larger BEST1 activity. However, when assessing only voltage-
dependent Cl
-
 currents, the data revealed a significant decrease in Cl
-
 currents in the 
F305S-mutant BEST1 RPE compared to normal human ES cell-derived RPE.  
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An additional feature of BEST1 Cl
-
 currents seen in overexpression systems 
is that it can be activated by Ca
2+ 
(Sun et al., 2002, Kane Dickson et al., 2014). 
Interestingly, the data presented here revealed the Ca
2+
 blocker CdCl2 reduced the Cl
-
 
conductance in both normal and F305S-mutant BEST1 RPE, suggesting there are 
CaCCs present in human ES cell-derived RPE. Strikingly, the F305S-mutant BEST1 
RPE CaCC current was significantly reduced compared to normal RPE. A study 
using liposomes reconstituted with BEST1cryst (chicken BEST1 crystal construct 
containing amino acids 1-405) performed an anion flux assay to determine if BEST1 
functions as a CaCC (Kane Dickson et al., 2014). These studies showed Cl
-
 fluxes 
increased with increasing Ca
2+
 concentrations, suggesting that BEST1 is a Cl
-
 
channel activated by the direct binding of Ca
2+
 (Kane Dickson et al., 2014). Further 
evidence that BEST1 is highly permeable to anions and is Ca
2+
-dependent came from 
a study of 13 BEST1 mutations compared to wild-type BEST1 using a heterologous 
overexpression system; this study included analysis of the clinically-relevant disease-
causing F305S BEST1 mutation (Milenkovic et al., 2011b). In that study, 
measurement of Ca
2+
-dependent anion fluxes via fluorescence intensity showed 
decreased anion permeability in the different BEST1 mutations, including the F305S 
BEST1 mutation in comparison to wild-type BEST1, despite the presence of Ca
2+
. 
(Milenkovic et al., 2011b). Furthermore, the BEST1-induced whole-cell Cl
-
 current 
observed in published overexpression studies has been shown to increase with the 
release of intracellular Ca
2+
, further demonstrating BEST1 may act as a CaCC (Sun 
et al., 2002). To date, only three CaCCs have been identified in the literature: 
anoctamin 1 (ANO1), also known as TMEM16A; ANO2 (TMEM16B); and BEST1 
(Huang et al., 2012, Kunzelmann et al., 2011, Liu et al., 2015, Kunzelmann et al., 
2009, Stohr et al., 2009, Schroeder et al., 2008). Affymetrix analysis revealed the 
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ANO1-10 genes were expressed by both normal and F305S-mutant BEST1 human 
ES cell-derived RPE. Comparison with published primary human RPE data showed 
ANO2, 5, 6 and 10 are expressed by fRPE but not aRPE. These data suggest that one 
or more of the ANO family of CaCCs could be responsible for the CaCC activity in 
both human ES cell-derived RPE. Together, these data indicate that the reduction in 
F305S-mutant BEST1 CaCC is likely due to reduced BEST1 activity. Future studies 
could investigate the contribution of these other CaCCs, by using blockers with 
differing activities for BEST1, ANO1 and ANO2. For example, DIDS was shown to 
reduce the whole-cell CaCC magnitude similarly for both BEST1 and ANO1 activity 
(Liu et al., 2015, Sun et al., 2002). Whereas niflumic acid and T16Ainh-A01 have 
been shown to have a larger effect on ANO1 Cl
-
 conductance compared to BEST1 
Cl
-
 conductance (Liu et al., 2015), although ANO2 has also been shown to be 
blocked by niflumic acid similarly to ANO1 (Stephan et al., 2009, Liu et al., 2015). 
Other ANO family members expressed by both normal and F305S-mutant BEST1 
RPE have not been well studied and their functions as CaCCs are yet to be defined 
(Ferrera et al., 2011, Stohr et al., 2009, Hartzell et al., 2009). 
 
5.3.2. F305S-mutant BEST1 RPE has reduced Ca2+-dependent and Ca2+-
independent Cl
-
 conductance compared to normal RPE 
The data presented here also show that, after blocking with the Ca
2+
 channel blocker 
CdCl2, the F305S-mutant BEST1 RPE had reduced Ca
2+
-independent Cl
-
 currents 
compared to the normal human ES cell-derived RPE. Although evidence suggests 
BEST1 is a CaCC, it is possible that BEST1 may somehow affect the activity of 
Ca
2+
-independent Cl
-
 channels in human RPE. In primary human RPE Ca
2+
-
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independent Cl
-
 channels have been observed including: CFTR, CLCN2, CLCN3 
and CLCN5 (Weng et al., 2002, Wills et al., 2000). These genes were detected at the 
mRNA level in primary human RPE (Weng et al., 2002). Additionally, CFTR, 
CLCN3 and CLCN5 have been detected at the protein level, suggesting they may 
play a role in the whole-cell Cl
-
 current seen in human RPE (Weng et al., 2002, Wills 
et al., 2000). In support of there being Ca
2+
-independent Cl
-
 channels in the human 
ES cell-derived RPE, analysis of the Affymetrix gene expression data revealed both 
normal and F305S-mutant BEST1 RPE expressed the same set of Cl
-
 channel-related 
genes including: CLC2, 3 and 5, as well as CFTR. Together, these data suggests that 
the effects of BEST1 mutation also reduce Ca
2+
-independent Cl
-
 channel activity. 
Therefore the F305S-mutant BEST1 human ES cell-derived RPE can provide a 
useful system to study the mechanism of mutant BEST1 and its activity on these 
Ca
2+
-independent Cl
-
 channels. 
An additional finding from this study was that the F305S BEST1 mutation 
reduced Ca
2+
 currents in human RPE. Literature reports suggest that BEST1 might 
regulate voltage-dependent Ca
2+
 channels (VDCC) (Muller et al., 2014, Reichhart et 
al., 2010, Rosenthal et al., 2006, Yu et al., 2008). One type of Ca
2+
 channel that has 
been described in the RPE is a VDCC, specifically the voltage-dependent L-type 
Ca
2+
 channel, that is important in Ca
2+
 signalling (Rosenthal et al., 2006, Wimmers et 
al., 2008, Reichhart et al., 2010, Marmorstein et al., 2006). In heterologous 
expression systems co-immunoprecipitation and co-localisation studies have shown 
that BEST1 and the L-type Ca
2+
 channel β-subunits bind and form a complex with 
CaV1.3, with localisation at the plasma membrane (Yu et al., 2008, Milenkovic et al., 
2011a). This suggests BEST1 may regulate L-type Ca
2+
 channels through these 
interactions (Milenkovic et al., 2011a, Yu et al., 2008, Muller et al., 2014). 
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Furthermore, it has been demonstrated that the C-terminus of BEST1 has a proline 
rich region, and within this region are predicted SH3 binding domains (Yu et al., 
2008, Milenkovic et al., 2011a, Reichhart et al., 2010). The BEST1 predicted SH3 
binding domain has been suggested to bind to the L-type Ca
2+
 channel CaV1.3/β-
subunit complex to regulate these channels (Milenkovic et al., 2008, Yu et al., 2008). 
Affymetrix analyses presented here revealed that both the normal and F305S-mutant 
BEST1 human ES cell-derived RPE, as well as primary human fRPE and aRPE 
express the CACNA1D gene that encodes for the CaV1.3 L-type Ca
2+
 channel 
(Milenkovic et al., 2011a, Reichhart et al., 2010, Rosenthal et al., 2006). It is 
therefore possible that the reduced Ca
2+
 current seen in the F305S-mutant BEST1 
RPE is due to impaired interaction with or regulation of the CaV1.3 L-type Ca
2+
 
channel. Additionally, both the normal and F305S-mutant BEST1 human ES cell-
derived RPE expressed CACNA1C that is also expressed by primary human fRPE. 
Interestingly, the VDCC subunit genes CACNA1F and CACNA1S appear to be 
expressed by human ES cell-derived RPE but not by either primary human RPE cell 
types. Little is known about the role of these genes in macular dystrophy or in RPE 
function, thus further investigation is required to see if these VDCC subunits might 
affect BEST1 interaction with CaV1.3 L-type Ca
2+
 channels in human ES cell-
derived RPE. Therefore, both the normal and F305S mutant BEST1 RPE system 
could provide useful insight into their role in normal and diseased RPE biology.  
Additionally, as mentioned in Chapter 4, the depolarised resting membrane 
potential could affect Ca
2+
 currents in normal and F305S-mutant human ES cell-
derived RPE. The human ES cell-derived RPE had membrane potentials averaging ~ 
15 mV in comparison to primary RPE (averaging ~ 40 mV). Studies have shown that 
voltage-gated inward Ca
2+
 currents in RPE are activated at potentials more positive 
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than -30 mV (Ueda and Steinberg, 1995, Rosenthal et al., 2006, Strauss et al., 1997). 
A depolarised resting membrane potential of approximately ~ -15 mV could result in 
a continuous increased intracellular Ca
2+
 concentration that could lead to altered Ca
2+
 
buffering mechanisms within the RPE derived from both normal and F305S mutant 
human ES cells. As a consequence, the regulation of intracellular Ca
2+
 through 
different pathways such as voltage-gated Ca
2+
 channels, Ca
2+
 release from organelles 
or phosphorylation dependent pathways (i.e. protein tyrosine kinase or ATP) could 
be altered (Murchison and Griffith, 2007, Armstrong and Eckert, 1987, Peterson et 
al., 1997, Strauss et al., 1997, Gilabert, 2012). Therefore both normal and F305S-
mutant BEST1 human ES cell-derived RPE can provide a useful system to study 
these pathways that may alter Ca
2+
 ions and the effect on the mechanism of BEST1 
and its activity. 
This chapter has demonstrated that endogenous expression levels of the 
F305S-mutant BEST1 protein localised within the RPE cells rather than in or near 
the plasma membrane, results in reduced Cl
-
 and Ca
2+
 currents in human ES cell-
derived RPE. Thus a better understanding of the molecular consequences of these 
reduced ion currents could indicate how BVMD develops and might also provide 
insights into the development of potential treatments. For example, Ca
2+
 and Cl
-
 are 
thought to play key roles in phagocytosis of shed photoreceptor outer segments 
(POS) and the generation of the electro-oculogram light peak respectively. The 
importance of phagocytosis in RPE is highlighted by experiments conducted in 
human induced PS cell-derived RPE containing the A146K and N296H BEST1 
mutations (Singh et al., 2015, Singh et al., 2013b). These data show that RPE 
containing BEST1 mutations have delayed degradation of POS as seen by an 
accumulation of autofluorescent POS material within the mutant RPE (Singh et al., 
Chapter 5: Key differences in chloride and calcium conductance in RPE derived from normal and F305S-
mutant BEST1 human ES cells 
143 
 
2013b). Additionally, knock-down of BEST1 in pig RPE showed a slight increase in 
the uptake of POS, suggesting that it might be both POS uptake and POS degradation 
that are affected by BEST1 mutations (Muller et al., 2014). Currently, it is not known 
how BEST1 mutations cause protein degradation changes; however, it has been 
hypothesised to be a result of altered Cl
-
 and Ca
2+
 homeostasis (Singh et al., 2015). 
As discussed above, there is evidence that BEST1 is required for the regulation of 
intracellular Ca
2+
 through interactions with the L-type Ca
2+
 channel, and this 
interaction is thought to trigger phagocytosis of shed POS via the proteolytic 
pathway (Muller et al., 2014, Singh et al., 2015). The blocking of the CaV1.3 L-type 
Ca
2+
 channel showed reduced phagocytosis activity, suggesting that L-type channels 
activate phagocytosis in the RPE (Muller et al., 2014, Strauss et al., 2016). Thus the 
impaired Ca
2+
 signalling seen here with the F305S BEST1 mutation could change the 
regulation of photoreceptor degradation therefore leading to the accumulation of 
lipofuscin seen in BVMD patients (Strauss et al., 2016, Singh et al., 2013b). Notably, 
in RPE derived from human induced PS cells containing the A146K and N296H 
BEST1 mutations showed reduced accumulation of autofluorescence after treatment 
with valproic acid (i.e., a histone deacetylase inhibitor that increases protein 
degradation) (Singh et al., 2015). While this substance is not suitable for treating 
patients, the study demonstrates the potential to increase the degradation of POS as a 
possible treatment for BVMD patients (Singh et al., 2015). Therefore further 
investigation into the mechanisms and consequences of the altered Cl
-
 and Ca
2+
 
currents in F305S-mutant BEST1 RPE could identify potential treatment options for 
BVMD patients (Singh et al., 2015). 
In addition to POS processing and degradation, Cl
-
 and Ca
2+
 channels are 
thought to be involved in generating the electro-oculogram light peak that is altered 
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in BVMD patients (Gallemore and Steinberg, 1989, Gallemore and Steinberg, 1993). 
The BEST1 Cl
-
 channel has been proposed as the candidate to play a role in the 
generation of the light peak by regulating L-type Ca
2+
 channels (Rosenthal et al., 
2006, Reichhart et al., 2010, Tsunenari et al., 2003, Milenkovic et al., 2011a, 
Marmorstein et al., 2006). A study has suggested a possible feedback loop, where 
BEST1 regulates Ca
2+
 through L-type Ca
2+
 channels, which in turn increases the 
plasma membrane Cl
-
 conductance via a CaCC (with the candidate CaCC being 
BEST1), therefore generating the light peak (Rosenthal et al., 2006). The expression 
of CaV1.3 L-type Ca
2+
 channel genes by both normal and F305S-mutant BEST1 RPE 
suggests an interaction between these proteins within the human ES cell-derived RPE 
is possible, and that BEST1 could regulate the activity of the VDCC CaV1.3 L-type 
Ca
2+
 channel pore function (Milenkovic et al., 2011a). Further investigation of these 
proteins using the human ES cell system could provide an improved molecular 
understanding of how the light peak is affected in the electro-oculogram of BVMD 
patients (Marmorstein et al., 2006, Rosenthal et al., 2006). 
Overall, the data presented here show that the clinically-relevant F305S-
mutant BEST1 reduces Cl
-
 conductance, Ca
2+
-dependent Cl
-
 conductance and Ca
2+
-
independent Cl
-
 conductance in human ES cell-derived RPE. The data presented here 
is consistent with that reported for heterologous overexpression systems in non-RPE 
cell types, but is more physiologically-relevant as it was obtained from a human RPE 
cell type expressing endogenous levels of BEST1. The analysis of human ES cell-
derived RPE Affymetrix gene expression data revealed both types of human ES cell-
derived RPE shared a large number of Cl
-
 and Ca
2+
 channel-related genes that are 
likely to contribute to the Cl
-
 and Ca
2+
 conductance displayed in these cells. Further 
investigations to define the molecular pathways affected by normal and altered Cl
-
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and Ca
2+
 conductance (as a consequence of normal or mutant BEST1) could provide 
key mechanistic links between BEST1 function and characteristic BVMD symptoms 
such as lipofuscin and fluid accumulation, as well as the decreased light peak seen in 
the electro-oculogram. 
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6.1. Human ES cell-derived RPE: a valuable tool to study normal and disease 
development 
The data in this study has contributed to our understanding of Bestrophin-1 (BEST1) 
function through the use of human embryonic stem (ES) cell-derived retinal pigment 
epithelium (RPE) from both normal and F305S-mutant BEST1 cell lines. The data 
presented in this thesis also demonstrate that investigation of RPE derived from 
normal and disease specific human ES cells provides an improved system compared 
to heterologous overexpression studies using non-RPE cell types.  
Best vitelliform macular dystrophy (BVMD) is an incurable form of 
congenital blindness that results from mutations of the BEST1 gene. BVMD can also 
be a model for the more common form of macular dystrophy, age-related macular 
degeneration. Both diseases share characteristics such as the abnormal accumulation 
of water and lipofuscin (i.e., protein and lipid products) within the retina that results 
in a loss of visual acuity (Marquardt et al., 1998, Bressler et al., 1988, Stone et al., 
1992). The BEST1 mutations that cause BVMD require further investigation to 
understand the phenotype-genotype relationship in BVMD patients and to identify 
potential treatment avenues. While the exact function of BEST1 within human RPE 
has until now remained elusive, there are multiple overexpression studies in human 
and non-human, non-RPE cells that link BEST1 with anion channel activity and/or 
homeostasis of Cl
-
 and Ca
2+
 ions (Kane Dickson et al., 2014, Marmorstein et al., 
2015, Yang et al., 2014, Yu et al., 2008, Barro-Soria et al., 2010, Fischmeister and 
Hartzell, 2005, Gomez et al., 2013, Muller et al., 2014, Reichhart et al., 2010, 
Rosenthal et al., 2006, Sun et al., 2002). Therefore, further investigation is necessary 
to define pathways that link the consequences of BEST1 mutations with key BVMD 
symptoms, such as the accumulation of fluid and lipofuscin and decreased electro-
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oculogram light peak. This information will provide much-needed new targets for 
BVMD and potentially age-related macular degeneration.  
Human ES cells can provide a powerful and unique tool to investigate the 
molecular mechanisms that underpin normal development and disease progression 
due to their capacity to generate an unlimited source of any cell type in the human 
body (Thomson et al., 1998). Published studies have demonstrated that the in vitro 
production of RPE from human ES cells involves molecular events similar to those 
that occur during embryonic RPE development (Meyer et al., 2009, Brandl et al., 
2014, Buchholz et al., 2009, Idelson et al., 2009, Klimanskaya et al., 2004). The 
work presented here in this thesis is the first study to report the characterisation of 
any human pluripotent cell line containing the F305S BEST1 mutation found to 
cause BVMD. 
This study showed the F305S-mutant BEST1 human ES cells had phenotypic 
and functional pluripotent characteristics indistinguishable from those reported for 
normal human ES cell lines, such as the well characterised MEL1 cells (International 
Stem Cell et al., 2011). The molecular characterisation of F305S-mutant BEST1 
human ES cells showed that they possessed the same morphology, expressed key 
pluripotent genes and cell surface antigens, were able to self-renew and differentiate 
into other cell types through teratoma formation, similarly to normal human ES cells 
(Thomson et al., 1998, O'Connor et al., 2011, O'Connor et al., 2008, Ungrin et al., 
2007, International Stem Cell et al., 2007).  
The F305S-mutant BEST1 human ES cells can be differentiated into RPE 
cells that display features of primary human RPE including: pigmentation, polygonal 
morphology, expression of key RPE genes and appropriate localisation for key 
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proteins such as ZO-1 and RPE65 (Klimanskaya et al., 2004, Meyer et al., 2009, 
Brandl et al., 2014, Buchholz et al., 2009, Idelson et al., 2009). One striking 
difference was the abnormal intracellular localisation of BEST1 protein within the 
F305S-mutant BEST1 RPE. Notably, this finding is consistent with the published 
intracellular expression pattern of this BEST1 mutant when overexpressed in non-
human, non-RPE cells (Milenkovic et al., 2011b). However, studies suggest that 
different human PS cells show differences in differentiation propensities due to 
genetic variability (Osafune et al., 2008, Leach et al., 2016, Toivonen et al., 2013). 
For example, their efficiency to differentiate into particular cell types or differences 
in gene expression can vary between human PS cell lines (Osafune et al., 2008, 
Toivonen et al., 2013, Leach et al., 2016). Further investigation using several normal 
and BEST1 mutant cells lines may provide an increased understanding of the 
differences and or similarities in the RPE derived from normal and F305S-mutant 
BEST human ES cells. Overall, these data suggest that the RPE derived from F305S-
mutant BEST1 human ES cells will provide a valuable model to study the function of 
endogenously expressed BEST1 in comparison to RPE derived from normal human 
ES cells. 
BEST1 protein has been implicated in chloride (Cl
-
) and calcium (Ca
2+
) 
homeostasis in the RPE as suggested by overexpression studies in non-RPE cell 
types (Kane Dickson et al., 2014, Marmorstein et al., 2015, Yang et al., 2014, Yu et 
al., 2008, Barro-Soria et al., 2010, Fischmeister and Hartzell, 2005, Gomez et al., 
2013, Muller et al., 2014, Reichhart et al., 2010, Rosenthal et al., 2006, Sun et al., 
2002). In Chapter 4, whole-cell patch clamp electrophysiology was used to initially 
assess sodium (Na
+
) and potassium (K
+
) currents in RPE derived from normal and 
F305S-mutant BEST1 human ES cells. The data showed that voltage-gated Na
+
 and 
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K
+
 currents in both normal and F305S-mutant BEST1 RPE were functionally similar 
to one another and to primary human RPE in particular foetal RPE (Wen et al., 
1993).  
 
6.2. Molecular function of BEST1 in human RPE: Cl
-
 and Ca
2+
 transport 
The data in the final experimental chapter suggests that BEST1 may act as a Ca
2+
-
activated Cl
-
 channel (CaCC) in human RPE. The data show that RPE containing the 
clinically-relevant F305S BEST1 mutation has reduced Ca
2+
-dependent Cl
-
 
conductance compared to normal human ES cell-derived RPE. Moreover, the human 
ES cell-derived RPE containing the F305S BEST1 mutation also resulted in reduced 
Ca
2+
-independent Cl
-
 conductance. These data are consistent with published data 
obtained from heterologous BEST1 overexpression systems that suggest BEST1 acts 
as a CaCC, and that BEST1 can regulate the activity of Ca
2+
 channels within the RPE 
(Kane Dickson et al., 2014, Liu et al., 2015, Sun et al., 2002, Yu et al., 2008, 
Tsunenari et al., 2003). Analysis of the human ES cell-derived RPE Affymetrix gene 
expression data presented here revealed the normal and F305S-mutant BEST1 RPE 
share expression of a large number of Cl
-
 and Ca
2+
 channel-related genes that are 
likely to contribute to the Cl
-
 and Ca
2+
 conductance displayed in these cells. Thus 
further investigations to define the molecular pathways affected by normal and 
altered Cl
-
 and Ca
2+
 conductance in RPE derived from normal and F305S-mutant 
BEST1 human ES cells could provide key mechanistic links between BEST1 
function and characteristic BVMD symptoms. This idea is reinforced by published 
data that suggest Cl
-
 and Ca
2+
 ions might play key roles in RPE functions such as 
phagocytosis of shed photoreceptor outer segments (POS) and the generation of the 
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light peak seen in the electro-oculogram (Muller et al., 2014, Singh et al., 2013b, 
Marmorstein et al., 2006).  
 
6.2.1. BEST1 involved in POS processing  
BEST1 mutations are highly variable as different BVMD patients within the same 
family can show a number of clinical manifestations (Cohn et al., 2011, Seddon et 
al., 2003, Wabbels et al., 2006). It is suggested that BVMD is caused by cumulative 
effects of one or more subtle disruptions in RPE physiology (Singh et al., 2013b). 
This has led to the suggestion that the function of BEST1 as a Cl
-
 channel might not 
completely explain the phenotypes/symptoms of BVMD. This idea is supported by 
other data that suggest BEST1 can perform additional functions that may contribute 
to BVMD (Hartzell et al., 2008). One hypothesis is that BEST1 may be a 
multifunctional protein, where it is a Cl
-
 channel that regulates L-type Ca
2+
 channels 
(Rosenthal et al., 2006, Muller et al., 2014). Therefore, if an imbalance in Cl
-
 and/or 
Ca
2+
 homeostasis occurs it could affect POS processing and degradation leading to 
the accumulation of lipofuscin within and beneath the RPE (Muller et al., 2014, 
Singh et al., 2013b, Marmorstein et al., 2006). For example, a study investigated 
Ca
2+
 fluorescence and lipofuscin fluorescence intensity in human RPE cells fed with 
POS showed increased Ca
2+
 fluorescence intensity caused by an accumulation of 
lipofuscin that was associated with POS processing in the RPE (Zhang et al., 2011a). 
This increase in Ca
2+
 is hypothesised to regulate POS degradation in RPE cells 
(Zhang et al., 2011a, Muller et al., 2014). Furthermore, human induced PS cells 
containing the A146K and N296H BEST1 mutations showed delayed degradation of 
POS as seen by an accumulation of autofluorescent POS material within the mutant 
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RPE (Singh et al., 2015, Singh et al., 2013b). Additionally, knock-down of BEST1 in 
pig RPE showed a slight increase in the uptake of POS, suggesting that it might be 
both POS uptake and POS degradation that are affected by BEST1 mutations (Muller 
et al., 2014). Therefore, it may be reasonable to assume that the reduced Ca
2+
 
conductance seen in the F305S-mutant BEST1 RPE may lead to reduced degradation 
of POS causing an accumulation of lipofuscin in these cells. Therefore, future 
investigation of POS processing and degradation with the addition of specific Ca
2+
 
and Cl
-
 channel inhibitors in RPE derived from F305S-mutant BEST1 human ES 
cells compared to normal BEST1 RPE, will likely provide useful insights into the 
role of Ca
2+
 and Cl
-
 homeostasis within this process.  
 
6.2.2. Generation of the light peak by BEST1 
Light energy causes the depolarisation of the RPE basolateral membrane which in 
turn generates the light peak seen in the electro-oculogram (Gallemore and 
Steinberg, 1993, Arden and Constable, 2006). RPE function is detected using an 
electro-oculogram and is used to examine the light peak in patients with BVMD 
(Whatham et al., 2014, Arden and Constable, 2006). One candidate thought to cause 
the abnormal BVMD light peak Cl
-
 conductance is a disruption to BEST1 activity 
(Sun et al., 2002, Marmorstein et al., 2002, Qu et al., 2003). Importantly, the light 
peak associated with most BVMD patients is thought to be mediated via a second 
messenger (Arden and Constable, 2006). The BEST1 Cl
-
 channel has been proposed 
as the candidate to play a role in the generation of the light peak by regulating L-type 
Ca
2+
 channels (Rosenthal et al., 2006, Reichhart et al., 2010, Tsunenari et al., 2003, 
Milenkovic et al., 2011a, Marmorstein et al., 2006).  
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It has been hypothesised that an increase in cytosolic Ca
2+
 is activated by 
extracellular ATP at the apical RPE membrane via purinergic G protein-coupled 
receptors (i.e., P2Y), this increase in cytosolic Ca
2+
 subsequently activates Cl
- 
conductance in the basolateral membrane (Marmorstein et al., 2006, Peterson et al., 
1997). A study investigating BEST1 as a Ca
2+
 channel regulator in BEST1
-/-
 mice 
and BEST1
+/+
 mice found no difference in Cl
-
 channel conductance, but did show an 
increase in intracellular Ca
2+
 when stimulated by ATP (Marmorstein et al., 2006). 
Furthermore, a study conducted in human induced pluripotent stem cells containing 
N296H and A146K BEST1 mutations showed an increase in intracellular Ca
2+
 when 
stimulated by external ATP. This suggests that BEST1 mutations can demonstrate a 
gain-of-function mechanism (i.e., mutation enhances the BEST1 activity) in BVMD 
(Singh et al., 2013b). Thus, future investigation into BEST1 function and its 
interactions with L-type Ca
2+
 channels using RPE derived from normal and F305S-
mutant BEST1 human ES cells would be important in gaining a better understanding 
of BEST1 activity. These investigations could utilise whole-cell patch clamp 
electrophysiology, cellular localisation studies (e.g., differentiation centrifugation 
coupled with Western blotting) and Ca
2+
 imaging, together with known light peak 
activators (e.g., ATP) and inhibitors (e.g., nimodipine). These studies will aid in 
defining how BEST1-mediated Cl
-
 and Ca
2+
 conductance are involved in producing 
the normal and abnormal light peak seen in the electro-oculogram and in turn provide 
information for potential treatment avenues for BVMD patients.  
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6.2.3. Does BEST1 regulate cell volume in the RPE? 
A key function of the RPE is fluid homeostasis, where it functions to maintain the 
extracellular fluid and ionic environment of the subretinal space between the RPE 
and the photoreceptors (Botchkin and Matthews, 1993, Adorante and Miller, 1990). 
The homeostatic processes required to balance the movement of water and ions 
involves ion channels and other forms of transport within the RPE. For example, it 
has been shown that exposure to a hypotonic solution causes cell swelling, and this is 
quickly followed by the process of regulatory volume decrease (RVD) that attempts 
to return the cell volume to its previous level. In contrast, when the cell shrinks, a 
regulatory volume increase (RVI) occurs; this process allows water and ions to move 
into the cell (Nilius et al., 1997, Adorante and Miller, 1990, Kennedy, 1994).  
It has been proposed that BEST1 may act as a volume regulated anion 
channel (VRAC), with Cl
-
 being the main anion driving these channels or be a 
counterpart of VRACs (Chien & Hartzell, 2007; Fischmeister & Hartzell, 2005; 
Hartzell et al., 2008; A. Milenkovic et al., 2015). Additionally, these VRACs are 
thought to be both Ca
2+
 and volume sensitive (Fischmeister and Hartzell, 2005, 
Milenkovic et al., 2015, Hartzell et al., 2008, Chien and Hartzell, 2007). Studies 
examined volume sensitivity of BEST1 in HEK293 cells, mouse RPE and human 
induced pluripotent stem cell-derived RPE. These studies showed activation of the 
Cl
-
 current in hypotonic solution and a reduced Cl
-
 current in a hypertonic solution 
(Milenkovic et al., 2015, Fischmeister and Hartzell, 2005, Chien and Hartzell, 2007). 
Furthermore, studies of human induced pluripotent stem cell-derived RPE containing 
the A243V BEST1 mutation showed a reduced VRAC current (Milenkovic et al., 
2015). This suggests that BEST1 Cl
-
 conductance can be regulated by Ca
2+
 and cell 
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volume (Fischmeister and Hartzell, 2005, Chien and Hartzell, 2007, Milenkovic et 
al., 2015). The reduced Cl
-
 and Ca
2+
 conductance observed in F305S-mutant BEST1 
RPE might also be affected by different osmotic solutions. Thus, future investigation 
should be aimed at determining whether the effects of the F305S BEST1 mutation on 
Cl
-
 and Ca
2+
 conductance seen here will be affected by different osmotic solutions. 
This can be investigated through application of Cl
-
 and Ca
2+
 channel blockers at 
different osmotic solutions in RPE derived from normal and F305S-mutant BEST1 
human ES cells. By doing so, a more complete molecular understanding of BEST1 
mutation on RPE function will be obtained. The F305S-mutant BEST1 RPE will 
provide a highly suitable model to further investigate the consequence of RPE 
volume regulation on BEST1 activity. 
 
6.3. Summary 
In conclusion, this study showed the RPE derived from F305S-mutant BEST1 human 
ES cells had reduced Ca
2+
-dependent and Ca
2+
-independent Cl
-
 currents to normal 
RPE. Furthermore, the RPE derived from F305S-mutant BEST1 human ES cells 
provides a physiologically-relevant system that express endogenous levels of BEST1 
to conduct future investigations. These data indicate further investigation of how 
altered Ca
2+
 and Cl
-
 homeostasis may affect key RPE functions such as (i) POS 
processing, degradation and elimination, (ii) generation of the light peak, and (iii) 
volume regulation, will provide insights into the molecular mechanism of BVMD 
and potentially age-related macular degeneration.  
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Appendix Table A.1: The GO term ‘ion homeostasis’ genes expressed in both normal and F305S-mutant BEST1 human ES cell-derived RPE 
 
Gene Symbol Gene name Gene Symbol Gene name 
AFG3L2 AFG3 ATPase family gene 3-like 2 (yeast) APLP2 amyloid beta (A4) precursor-like protein 2 
ATP5B 
ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
polypeptide AGTR1 angiotensin II receptor, type 1 
ABCB6 ATP-binding cassette, sub-family B (MDR/TAP), member 6 AGT angiotensinogen (serpin peptidase inhibitor, clade A, member 8) 
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 ANXA7 annexin A7 
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 MFI2 
antigen p97 (melanoma associated) identified by monoclonal 
antibodies 133.2 and 96.5 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 AIFM3 apoptosis-inducing factor, mitochondrion-associated, 3 
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 AQP11 aquaporin 11 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 AVPR1A arginine vasopressin receptor 1A 
ATP7A ATPase, Cu++ transporting, alpha polypeptide ASNA1 arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) 
ATP7B ATPase, Cu++ transporting, beta polypeptide ATXN1 ataxin 1 
ATP6V0E2 ATPase, H+ transporting V0 subunit e2 BEST2 bestrophin 2 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H BDKRB1 bradykinin receptor B1 
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 BDKRB2 bradykinin receptor B2 
ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 CALCR calcitonin receptor 
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 CALCA calcitonin-related polypeptide alpha 
ATP4A ATPase, H+/K+ exchanging, alpha polypeptide CALCB calcitonin-related polypeptide beta 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 
ATP1A4 ATPase, Na+/K+ transporting, alpha 4 polypeptide CACNA1G calcium channel, voltage-dependent, T type, alpha 1G subunit 
BCL2 B-cell CLL/lymphoma 2 CACNB4 calcium channel, voltage-dependent, beta 4 subunit 
BAK1 BCL2-antagonist/killer 1; BCL2-like 7 pseudogene 1 CACNG2 calcium channel, voltage-dependent, gamma subunit 2 
BAX BCL2-associated X protein CASR calcium-sensing receptor 
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BCL2L1 BCL2-like 1 CAMK2D calcium/calmodulin-dependent protein kinase II delta 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 CALR calreticulin 
BUD31 BUD31 homolog (S. cerevisiae) CPS1 carbamoyl-phosphate synthetase 1, mitochondrial 
CD38 CD38 molecule CAV1 caveolin 1, caveolae protein, 22kDa 
CD52 CD52 molecule CAV3 caveolin 3 
CD55 
CD55 molecule, decay accelerating factor for complement (Cromer blood 
group) CLN3 ceroid-lipofuscinosis, neuronal 3 
CD9 CD9 molecule CLN5 ceroid-lipofuscinosis, neuronal 5 
CHRFAM7A  
CHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5-10) and 
FAM7A (family with sequence similarity 7A, exons A-E) fusion  CLN6 ceroid-lipofuscinosis, neuronal 6, late infantile, variant 
CHRNA7 cholinergic receptor, nicotinic, alpha 7   
FKBP1B FK506 binding protein 1B, 12.6 kDa CP ceruloplasmin (ferroxidase) 
FXYD1 FXYD domain containing ion transport regulator 1 XCR1 chemokine (C motif) receptor 1 
CHRND cholinergic receptor, nicotinic, delta GPR12 G protein-coupled receptor 12 
CHRNE cholinergic receptor, nicotinic, epsilon GPR6 G protein-coupled receptor 6 
CHRNG cholinergic receptor, nicotinic, gamma GIMAP1 GTPase, IMAP family member 1 
CLDN1 claudin 1 GIMAP5 GTPase, IMAP family member 5 
CLDN11 claudin 11 JAK2 Janus kinase 2 
CLDN16 claudin 16 MON1A MON1 homolog A (yeast) 
F2 coagulation factor II (thrombin) NDUFS1 
NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-
coenzyme Q reductase) 
F2R coagulation factor II (thrombin) receptor NOX1 NADPH oxidase 1 
F2RL1 coagulation factor II (thrombin) receptor-like 1 NAB1 NGFI-A binding protein 1 (EGR1 binding protein 1) 
CCDC47 coiled-coil domain containing 47 NAB2 NGFI-A binding protein 2 (EGR1 binding protein 2) 
C3AR1 complement component 3a receptor 1 NDFIP1 Nedd4 family interacting protein 1 
C5AR1 complement component 5a receptor 1 POU3F1 POU class 3 homeobox 1 
C7 complement component 7 POU3F2 POU class 3 homeobox 2 
CKB creatine kinase, brain PTK2B PTK2B protein tyrosine kinase 2 beta 
CUL5 cullin 5 PARK7 Parkinson disease (autosomal recessive, early onset) 7 
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CUTC cutC copper transporter homolog (E. coli) RHCG Rh family, C glycoprotein 
CCR6 chemokine (C-C motif) receptor 6 RHAG Rh-associated glycoprotein 
CDK5 cyclin-dependent kinase 5 SCO1 SCO cytochrome oxidase deficient homolog 1 (yeast) 
CSRP3 cysteine and glycine-rich protein 3 (cardiac LIM protein) SCO2 SCO cytochrome oxidase deficient homolog 2 (yeast) 
CYSLTR1 cysteinyl leukotriene receptor 1 SBF2 SET binding factor 2 
CYP11B2 cytochrome P450, family 11, subfamily B, polypeptide 2 SMAD7 SMAD family member 7 
CYP27B1 cytochrome P450, family 27, subfamily B, polypeptide 1 WFS1 Wolfram syndrome 1 (wolframin) 
DHH desert hedgehog homolog (Drosophila) ACO1 aconitase 1, soluble 
DLD dihydrolipoamide dehydrogenase ACSBG1 acyl-CoA synthetase bubblegum family member 1 
DRD1 dopamine receptor D1 ADORA1 adenosine A1 receptor 
DRD2 dopamine receptor D2 ADORA2A adenosine A2a receptor 
DRD3 dopamine receptor D3 AMIGO1 adhesion molecule with Ig-like domain 1 
DRD4 dopamine receptor D4 ADM adrenomedullin 
DRD5 dopamine receptor D5 AMELX amelogenin (amelogenesis imperfecta 1, X-linked) 
DMPK dystrophia myotonica-protein kinase ALAS2 aminolevulinate, delta-, synthase 2 
EGR2 early growth response 2 APP amyloid beta (A4) precursor protein 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 EIF2B2 eukaryotic translation initiation factor 2B, subunit 2 beta, 39kDa 
CCL5 chemokine (C-C motif) ligand 5 EIF2B4 eukaryotic translation initiation factor 2B, subunit 4 delta, 67kDa 
CCR1 chemokine (C-C motif) receptor 1 EIF2B5 eukaryotic translation initiation factor 2B, subunit 5 epsilon, 82kDa 
CCR10 chemokine (C-C motif) receptor 10 ERCC2 
excision repair cross-complementing rodent repair deficiency, 
complementation group 2 
CCR2 chemokine (C-C motif) receptor 2 FTMT ferritin mitochondrial 
CCR3 chemokine (C-C motif) receptor 3 FGF23 fibroblast growth factor 23 
CCR5 chemokine (C-C motif) receptor 5 FXN frataxin 
CCR7 chemokine (C-C motif) receptor 7 FZD2 frizzled homolog 2 (Drosophila) 
CCR8 chemokine (C-C motif) receptor 8 GAL3ST1 galactose-3-O-sulfotransferase 1 
CCR9 chemokine (C-C motif) receptor 9 GALR2 galanin receptor 2 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) GJD2 gap junction protein, delta 2, 36kDa 
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CXCL13 chemokine (C-X-C motif) ligand 13 GJC3 gap junction protein, gamma 3, 30.2kDa 
CXCR4 chemokine (C-X-C motif) receptor 4 GIPR gastric inhibitory polypeptide receptor 
CLCN3 chloride channel 3 GHRL ghrelin/obestatin prepropeptide 
CCK cholecystokinin GCM2 glial cells missing homolog 2 (Drosophila) 
CCKAR cholecystokinin A receptor GLP1R glucagon-like peptide 1 receptor 
CCKBR cholecystokinin B receptor GRIN1 glutamate receptor, ionotropic, N-methyl D-aspartate 1 
CHRNA1 cholinergic receptor, nicotinic, alpha 1 (muscle) GRIN2A glutamate receptor, ionotropic, N-methyl D-aspartate 2A 
CHRNA3 cholinergic receptor, nicotinic, alpha 3 GRIN2B glutamate receptor, ionotropic, N-methyl D-aspartate 2B 
CHRNA4 cholinergic receptor, nicotinic, alpha 4 GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 
CHRNA6 cholinergic receptor, nicotinic, alpha 6 GRID2 glutamate receptor, ionotropic, delta 2 
CHRNB1 cholinergic receptor, nicotinic, beta 1 (muscle) GRIK1 glutamate receptor, ionotropic, kainate 1 
CHRNB2 cholinergic receptor, nicotinic, beta 2 (neuronal) GRIK2 glutamate receptor, ionotropic, kainate 2 
CHRNB4 cholinergic receptor, nicotinic, beta 4 NTF3 neurotrophin 3 
GRIK3 glutamate receptor, ionotropic, kainate 3 NR3C2 nuclear receptor subfamily 3, group C, member 2 
GCLC glutamate-cysteine ligase, catalytic subunit OLIG2 oligodendrocyte lineage transcription factor 2 
GCLM glutamate-cysteine ligase, modifier subunit OPRL1 opiate receptor-like 1 
GLRA1 glycine receptor, alpha 1 OTC ornithine carbamoyltransferase 
GLRB glycine receptor, beta OXTR oxytocin receptor 
GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) OXT oxytocin, prepropeptide 
GNA13 guanine nucleotide binding protein (G protein), alpha 13 PPT1 palmitoyl-protein thioesterase 1 
GNA15 guanine nucleotide binding protein (G protein), alpha 15 (Gq class) PTH parathyroid hormone 
GNB1 guanine nucleotide binding protein (G protein), beta polypeptide 1 PTH1R parathyroid hormone 1 receptor 
GNG3 guanine nucleotide binding protein (G protein), gamma 3 PRX periaxin 
GNAQ guanine nucleotide binding protein (G protein), q polypeptide PMP22 peripheral myelin protein 22 
HP haptoglobin PRDX3 peroxiredoxin 3 
HPR haptoglobin-related protein PPARD peroxisome proliferator-activated receptor delta 
HSP90B1 heat shock protein 90kDa beta (Grp94), member 1 PIK3CB phosphoinositide-3-kinase, catalytic, beta polypeptide 
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HMOX1 heme oxygenase (decycling) 1 PLN phospholamban 
HFE hemochromatosis PLCE1 phospholipase C, epsilon 1 
HPX hemopexin PLCG2 phospholipase C, gamma 2 (phosphatidylinositol-specific) 
HAMP hepcidin antimicrobial peptide PYGM phosphorylase, glycogen, muscle 
HEXA hexosaminidase A (alpha polypeptide) PLLP plasma membrane proteolipid (plasmolipin) 
HEXB hexosaminidase B (beta polypeptide) PKD2 polycystic kidney disease 2 (autosomal dominant) 
HRH3 histamine receptor H3 P2RX1 purinergic receptor P2X, ligand-gated ion channel, 1 
HRC histidine rich calcium binding protein P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 
LTF lactotransferrin P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 
LGI4 leucine-rich repeat LGI family, member 4 P2RY2 purinergic receptor P2Y, G-protein coupled, 2 
LCK lymphocyte-specific protein tyrosine kinase QKI quaking homolog, KH domain RNA binding (mouse) 
LPAR1 lysophosphatidic acid receptor 1 RGN regucalcin (senescence marker protein-30) 
LPAR2 lysophosphatidic acid receptor 2 RYR1 ryanodine receptor 1 (skeletal) 
LPAR3 lysophosphatidic acid receptor 3 RYR2 ryanodine receptor 2 (cardiac) 
MCHR1 melanin-concentrating hormone receptor 1 RYR3 ryanodine receptor 3 
MGEA5 meningioma expressed antigen 5 (hyaluronidase) SCARA5 scavenger receptor class A, member 5 (putative) 
MT1H metallothionein 1H SERINC5 serine incorporator 5 
MT2A metallothionein 2A SAA2 serum amyloid A2 
MT3 metallothionein 3 FTL similar to ferritin, light polypeptide; ferritin, light polypeptide 
MTL5 metallothionein-like 5, testis-specific (tesmin) TPT1 
similar to tumor protein, translationally-controlled 1; tumor protein, 
translationally-controlled 1 
MBP myelin basic protein SCN8A sodium channel, voltage gated, type VIII, alpha subunit 
MPZ myelin protein zero SCN1A sodium channel, voltage-gated, type I, alpha subunit 
NPPB natriuretic peptide precursor B SLC1A6 
solute carrier family 1 (high affinity aspartate/glutamate transporter), 
member 6 
NPR1 
natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide 
receptor A) SLC11A1 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 1 
NEDD4L neural precursor cell expressed, developmentally down-regulated 4-like SLC11A2 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2 
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NF1 neurofibromin 1 SLC12A5 solute carrier family 12 (potassium-chloride transporter), member 5 
NLGN3 neuroligin 3 SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 
NMUR2 neuromedin U receptor 2 KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11 
NPY1R neuropeptide Y receptor Y1 KCNMB3 
potassium large conductance calcium-activated channel, subfamily M 
beta member 3 
HERPUD1 
homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-
like domain member 1 KCNMA1 
potassium large conductance calcium-activated channel, subfamily 
M, alpha member 1 
HTT huntingtin KCNMB2 
potassium large conductance calcium-activated channel, subfamily 
M, beta member 2 
HCN2 hyperpolarization activated cyclic nucleotide-gated potassium channel 2 KCNMB4 
potassium large conductance calcium-activated channel, subfamily 
M, beta member 4 
APOE hypothetical LOC100129500; apolipoprotein E KCNE1 potassium voltage-gated channel, Isk-related family, member 1 
CACNA1C 
hypothetical protein LOC100131098; calcium channel, voltage-dependent, 
L type, alpha 1C subunit KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 
IBTK inhibitor of Bruton agammaglobulinemia tyrosine kinase KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 
ITPR1 inositol 1,4,5-triphosphate receptor, type 1 KCNA5 
potassium voltage-gated channel, shaker-related subfamily, member 
5 
ITPR3 inositol 1,4,5-triphosphate receptor, type 3 KCNH2 
potassium voltage-gated channel, subfamily H (eag-related), member 
2 
ILK integrin-linked kinase PSEN1 presenilin 1 
IFI6 interferon, alpha-inducible protein 6 PRNP prion protein 
IL1B interleukin 1, beta PROK2 prokineticin 2 
IL2 interleukin 2 PTGER3 prostaglandin E receptor 3 (subtype EP3) 
IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) PRKCA protein kinase C, alpha 
IREB2 iron-responsive element binding protein 2 PRKCB protein kinase C, beta 
JPH1 junctophilin 1 PRKCZ protein kinase C, zeta 
JPH2 junctophilin 2 PPP3CA protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 
JPH3 junctophilin 3 PPP3CB protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform 
JPH4 junctophilin 4 PTPRC protein tyrosine phosphatase, receptor type, C 
KLK6 kallikrein-related peptidase 6 PLP1 proteolipid protein 1 
KDR kinase insert domain receptor (a type III receptor tyrosine kinase) SLC24A2 solute carrier family 24 (sodium/potassium/calcium exchanger), 
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member 2 
KNG1 kininogen 1 SLC24A3 
solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 3 
TF transferrin SLC26A4 solute carrier family 26, member 4 
TFRC transferrin receptor (p90, CD71) SLC26A9 solute carrier family 26, member 9 
TFR2 transferrin receptor 2 SLC30A1 solute carrier family 30 (zinc transporter), member 1 
TGFB1 transforming growth factor, beta 1 SLC30A4 solute carrier family 30 (zinc transporter), member 4 
TGM2 
transglutaminase 2 (C polypeptide, protein-glutamine-gamma-
glutamyltransferase) SLC30A5 solute carrier family 30 (zinc transporter), member 5 
TRPC1 transient receptor potential cation channel, subfamily C, member 1 SLC30A8 solute carrier family 30 (zinc transporter), member 8 
TRPC6 transient receptor potential cation channel, subfamily C, member 6 SLC34A1 solute carrier family 34 (sodium phosphate), member 1 
TRPM8 transient receptor potential cation channel, subfamily M, member 8 SLC34A2 solute carrier family 34 (sodium phosphate), member 2 
TRPV4 transient receptor potential cation channel, subfamily V, member 4 SLC34A3 solute carrier family 34 (sodium phosphate), member 3 
TMPRSS3 transmembrane protease, serine 3 SLC39A4 solute carrier family 39 (zinc transporter), member 4 
TRIM24 tripartite motif-containing 24 SLC4A1 
solute carrier family 4, anion exchanger, member 1 (erythrocyte 
membrane protein band 3, Diego blood group) 
TNNI3 troponin I type 3 (cardiac) SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 10 
TSC1 tuberous sclerosis 1 SLC4A11 solute carrier family 4, sodium borate transporter, member 11 
TP53 tumor protein p53 SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 
UPK3A uroplakin 3A SLC7A8 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 8 
UTS2R urotensin 2 receptor SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) SLC9A1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) SLC9A2 solute carrier family 9 (sodium/hydrogen exchanger), member 2 
VDR vitamin D (1,25- dihydroxyvitamin D3) receptor SLC9A3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
XIRP1 xin actin-binding repeat containing 1 CCL1 chemokine (C-C motif) ligand 1 
CNTF 
zinc finger protein 91 homolog (mouse); ZFP91-CNTF readthrough 
transcript; ciliary neurotrophic factor CCL13 chemokine (C-C motif) ligand 13 
SLC9A3R1 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 
1 CCL14 chemokine (C-C motif) ligand 14 
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SLC9A4 solute carrier family 9 (sodium/hydrogen exchanger), member 4 CCL15 chemokine (C-C motif) ligand 15 
SLC9A5 solute carrier family 9 (sodium/hydrogen exchanger), member 5 CCL19 chemokine (C-C motif) ligand 19 
SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), member 6 CCL2 chemokine (C-C motif) ligand 2 
SLC9A7 solute carrier family 9 (sodium/hydrogen exchanger), member 7 CCL23 chemokine (C-C motif) ligand 23 
SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger), member 8 CCL28 chemokine (C-C motif) ligand 28 
SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 CCL3 chemokine (C-C motif) ligand 3 
SRI sorcin ELANE elastase, neutrophil expressed 
S1PR1 sphingosine-1-phosphate receptor 1 EDN1 endothelin 1 
S1PR3 sphingosine-1-phosphate receptor 3 EDN2 endothelin 2 
S1PR4 sphingosine-1-phosphate receptor 4 EDNRA endothelin receptor type A 
STC1 stanniocalcin 1 EDNRB endothelin receptor type B 
STIM2 stromal interaction molecule 2 EPHX2 epoxide hydrolase 2, cytoplasmic 
SOD2 superoxide dismutase 2, mitochondrial EPB42 erythrocyte membrane protein band 4.2 
SV2A synaptic vesicle glycoprotein 2A EPOR erythropoietin receptor 
SYPL2 synaptophysin-like 2 
  SNCA synuclein, alpha (non A4 component of amyloid precursor) 
  TACR1 tachykinin receptor 1 
  TAC1 tachykinin, precursor 1 
  TTC7A tetratricopeptide repeat domain 7A 
  TRHR thyrotropin-releasing hormone receptor 
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Appendix Table A.2: Ion channel genes expressed in both normal and F305S-mutant BEST1 human ES cell-derived RPE 
 
Gene Symbol Gene name  Gene Symbol Gene name  
ANO1 anoctamin 1, calcium activated chloride channel ATP5S 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s 
(factor B) 
ASNA1 arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 
ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide ATP6AP1L ATPase, H+ transporting, lysosomal accessory protein 1-like 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide ATP6AP2 ATPase, H+ transporting, lysosomal accessory protein 2 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 
ATP1A4 ATPase, Na+/K+ transporting, alpha 4 polypeptide ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
ATP1B4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 
ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP6V0E2 ATPase, H+ transporting V0 subunit e2 
ATP2A3 ATPase, Ca++ transporting, ubiquitous ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
ATP2B3 ATPase, Ca++ transporting, plasma membrane 3 ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 ATP6V1C2 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 ATP6V1D ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
ATP5A1 
ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, 
cardiac muscle 
ATP6V1E2 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F 
  Appendix   
180 
 
ATP5C1 
ATP synthase, H+ transporting, mitochondrial F1 complex, gamma 
polypeptide 1 
ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 ATP6V1G2 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G2 
ATP5G1 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1 
(subunit 9) 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 
ATP5G3 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C3 
(subunit 9) 
ATP7A ATPase, Cu++ transporting, alpha polypeptide 
ATP5H ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d ATP7B ATPase, Cu++ transporting, beta polypeptide 
ATP5J2 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 ATP8A1 
ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 
1 
ATP5L ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G ATP8A2 ATPase, aminophospholipid transporter-like, class I, type 8A, member 2 
ATP5L2 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G2 
pseudogene 
BEST1 bestrophin 1 
ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit BEST2 bestrophin 2 
BEST3 bestrophin 3 CACNG3 calcium channel, voltage-dependent, gamma subunit 3 
BEST4 bestrophin 4 CACNG4 calcium channel, voltage-dependent, gamma subunit 4 
BET1L blocked early in transport 1 homolog (S. cerevisiae)-like CACNG5 calcium channel, voltage-dependent, gamma subunit 5 
C2CD2 C2 calcium-dependent domain containing 2 CACNG6 calcium channel, voltage-dependent, gamma subunit 6 
C2CD3 C2 calcium-dependent domain containing 3 CACNG7 calcium channel, voltage-dependent, gamma subunit 7 
CAB39 calcium binding protein 39 CACNG8 calcium channel, voltage-dependent, gamma subunit 8 
CAB39L calcium binding protein 39-like CALCOCO1 calcium binding and coiled-coil domain 1 
CABP1 calcium binding protein 1 CALCOCO2 calcium binding and coiled-coil domain 2 
CABP2 calcium binding protein 2 CALHM1 calcium homeostasis modulator 1 
CABP4 calcium binding protein 4 CALHM2 calcium homeostasis modulator 2 
CABP5 calcium binding protein 5 CALHM3 calcium homeostasis modulator 3 
CABP7 calcium binding protein 7 CAMK1 calcium/calmodulin-dependent protein kinase I 
CABYR calcium binding tyrosine-(Y)-phosphorylation regulated CAMK1D calcium/calmodulin-dependent protein kinase ID 
CACNA1A calcium channel, voltage-dependent, P/Q type, alpha 1A subunit CAMK1G calcium/calmodulin-dependent protein kinase IG 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit CAMK2A calcium/calmodulin-dependent protein kinase II alpha 
CACNA1C hypothetical protein LOC100131098; calcium channel, voltage-dependent, CAMK2B calcium/calmodulin-dependent protein kinase II beta 
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L type, alpha 1C subunit 
CACNA1D calcium channel, voltage-dependent, L type, alpha 1D subunit CAMK2D calcium/calmodulin-dependent protein kinase II delta 
CACNA1E calcium channel, voltage-dependent, R type, alpha 1E subunit CAMK2G calcium/calmodulin-dependent protein kinase II gamma 
CACNA1F calcium channel, voltage-dependent, L type, alpha 1F subunit CAMK4 calcium/calmodulin-dependent protein kinase IV 
CACNA1G calcium channel, voltage-dependent, T type, alpha 1G subunit CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha 
CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta 
CACNA1I calcium channel, voltage-dependent, T type, alpha 1I subunit CAMLG calcium modulating ligand 
CACNA1S calcium channel, voltage-dependent, L type, alpha 1S subunit CANT1 calcium activated nucleotidase 1 
CACNA2D1 calcium channel, voltage-dependent, alpha 2/delta subunit 1 CASK calcium/calmodulin-dependent serine protein kinase (MAGUK family) 
CACNA2D2 calcium channel, voltage-dependent, alpha 2/delta subunit 2 CASR calcium-sensing receptor 
CACNA2D3 calcium channel, voltage-dependent, alpha 2/delta subunit 3 CATSPER1 cation channel, sperm associated 1 
CACNA2D4 calcium channel, voltage-dependent, alpha 2/delta subunit 4 CATSPER2 cation channel, sperm associated 2 
CACNB1 calcium channel, voltage-dependent, beta 1 subunit CATSPER2P1 cation channel, sperm associated 2 pseudogene 1 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit CATSPER3 cation channel, sperm associated 3 
CACNB3 calcium channel, voltage-dependent, beta 3 subunit CATSPER4 cation channel, sperm associated 4 
CACNB4 calcium channel, voltage-dependent, beta 4 subunit CATSPERB cation channel, sperm-associated, beta 
CACNG1 calcium channel, voltage-dependent, gamma subunit 1 CCBE1 collagen and calcium binding EGF domains 1 
CACNG2 calcium channel, voltage-dependent, gamma subunit 2 CHAC1 ChaC, cation transport regulator homolog 1 (E. coli) 
CHAC2 ChaC, cation transport regulator homolog 2 (E. coli) EFCAB5 EF-hand calcium binding domain 5 
CHERP calcium homeostasis endoplasmic reticulum protein EFCAB6 EF-hand calcium binding domain 6 
CIB1 calcium and integrin binding 1 (calmyrin) EFCAB7 EF-hand calcium binding domain 7 
CIB2 calcium and integrin binding family member 2 EFCAB9 EF-hand calcium binding domain 9 
CIB4 calcium and integrin binding family member 4 FCGRT Fc fragment of IgG, receptor, transporter, alpha 
CLCA1 chloride channel accessory 1 FXYD1 FXYD domain containing ion transport regulator 1 
CLCA2 chloride channel accessory 2 FXYD3 FXYD domain containing ion transport regulator 3 
CLCA3P chloride channel accessory 3 (pseudogene) FXYD4 FXYD domain containing ion transport regulator 4 
CLCA4 chloride channel accessory 4 FXYD5 FXYD domain containing ion transport regulator 5 
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CLCC1 chloride channel CLIC-like 1 FXYD6 FXYD domain containing ion transport regulator 6 
CLCN1 chloride channel 1, skeletal muscle FXYD7 FXYD domain containing ion transport regulator 7 
CLCN2 chloride channel 2 GCA grancalcin, EF-hand calcium binding protein 
CLCN3 chloride channel 3 GHRL ghrelin/obestatin prepropeptide 
CLCN4 chloride channel 4 GOLT1A golgi transport 1 homolog A (S. cerevisiae) 
CLCN5 chloride channel 5 GOLT1B golgi transport 1 homolog B (S. cerevisiae) 
CLCN6 chloride channel 6 HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 
CLCN7 chloride channel 7 HCN2 hyperpolarization activated cyclic nucleotide-gated potassium channel 2 
CLCNKA chloride channel Ka HCN3 hyperpolarization activated cyclic nucleotide-gated potassium channel 3 
CLCNKB chloride channel Kb HCN4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 
CLIC1 chloride intracellular channel 1 HRC histidine rich calcium binding protein 
CLIC2 chloride intracellular channel 2 IFT122 intraflagellar transport 122 homolog (Chlamydomonas) 
CLIC3 chloride intracellular channel 3 IFT140 intraflagellar transport 140 homolog (Chlamydomonas) 
CLIC4 chloride intracellular channel 4 IFT172 intraflagellar transport 172 homolog (Chlamydomonas) 
CLIC5 chloride intracellular channel 5 IFT20 intraflagellar transport 20 homolog (Chlamydomonas) 
CLIC6 chloride intracellular channel 6 IFT52 intraflagellar transport 52 homolog (Chlamydomonas) 
CLNS1A chloride channel, nucleotide-sensitive, 1A IFT57 intraflagellar transport 57 homolog (Chlamydomonas) 
CUTC cutC copper transporter homolog (E. coli) IFT74 intraflagellar transport 74 homolog (Chlamydomonas) 
EFCAB1 EF-hand calcium binding domain 1 IFT80 intraflagellar transport 80 homolog (Chlamydomonas) 
EFCAB10 EF-hand calcium binding domain 10 IFT81 intraflagellar transport 81 homolog (Chlamydomonas) 
EFCAB2 EF-hand calcium binding domain 2 IFT88 intraflagellar transport 88 homolog (Chlamydomonas) 
EFCAB3 similar to hypoxia-inducible protein 2; EF-hand calcium binding domain 3 KCMF1 potassium channel modulatory factor 1 
EFCAB4A EF-hand calcium binding domain 4A KCNA10 potassium voltage-gated channel, shaker-related subfamily, member 10 
EFCAB4B EF-hand calcium binding domain 4B KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 2 
KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3 KCNJ13 potassium inwardly-rectifying channel, subfamily J, member 13 
KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5 KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 
KCNA6 potassium voltage-gated channel, shaker-related subfamily, member 6 KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 
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KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 KCNJ16 potassium inwardly-rectifying channel, subfamily J, member 16 
KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 
KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 
KCNAB3 potassium voltage-gated channel, shaker-related subfamily, beta member 3 KCNJ4 potassium inwardly-rectifying channel, subfamily J, member 4 
KCNB1 potassium voltage-gated channel, Shab-related subfamily, member 1 KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5 
KCNB2 potassium voltage-gated channel, Shab-related subfamily, member 2 KCNJ6 potassium inwardly-rectifying channel, subfamily J, member 6 
KCNC1 potassium voltage-gated channel, Shaw-related subfamily, member 1 KCNJ9 potassium inwardly-rectifying channel, subfamily J, member 9 
KCNC2 potassium voltage-gated channel, Shaw-related subfamily, member 2 KCNK1 potassium channel, subfamily K, member 1 
KCNC3 potassium voltage-gated channel, Shaw-related subfamily, member 3 KCNK10 potassium channel, subfamily K, member 10 
KCNC4 potassium voltage-gated channel, Shaw-related subfamily, member 4 KCNK13 potassium channel, subfamily K, member 13 
KCND1 potassium voltage-gated channel, Shal-related subfamily, member 1 KCNK15 potassium channel, subfamily K, member 15 
KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 KCNK16 potassium channel, subfamily K, member 16 
KCNE1 potassium voltage-gated channel, Isk-related family, member 1 KCNK17 potassium channel, subfamily K, member 17 
KCNE2 potassium voltage-gated channel, Isk-related family, member 2 KCNK2 potassium channel, subfamily K, member 2 
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 KCNK3 potassium channel, subfamily K, member 3 
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 KCNK4 potassium channel, subfamily K, member 4 
KCNG1 potassium voltage-gated channel, subfamily G, member 1 KCNK5 potassium channel, subfamily K, member 5 
KCNG2 potassium voltage-gated channel, subfamily G, member 2 KCNK6 potassium channel, subfamily K, member 6 
KCNG4 potassium voltage-gated channel, subfamily G, member 4 KCNK7 potassium channel, subfamily K, member 7 
KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1 KCNMA1 
potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2 KCNMB1 
potassium large conductance calcium-activated channel, subfamily M, beta 
member 1 
KCNH3 potassium voltage-gated channel, subfamily H (eag-related), member 3 KCNMB2 
potassium large conductance calcium-activated channel, subfamily M, beta 
member 2 
KCNH4 potassium voltage-gated channel, subfamily H (eag-related), member 4 KCNMB3 
potassium large conductance calcium-activated channel, subfamily M beta 
member 3 
KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 KCNMB4 
potassium large conductance calcium-activated channel, subfamily M, beta 
member 4 
KCNH6 potassium voltage-gated channel, subfamily H (eag-related), member 6 KCNN1 potassium intermediate/small conductance calcium-activated channel, 
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subfamily N, member 1 
KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 KCNN2 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 2 
KCNH8 potassium voltage-gated channel, subfamily H (eag-related), member 8 KCNN3 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 3 
KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1 KCNN4 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4 
KCNJ10 potassium inwardly-rectifying channel, subfamily J, member 10 KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 
KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11 KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member 2 
KCNQ3 potassium voltage-gated channel, KQT-like subfamily, member 3 NECAB1 N-terminal EF-hand calcium binding protein 1 
KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4 NECAB2 N-terminal EF-hand calcium binding protein 2 
KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 NECAB3 N-terminal EF-hand calcium binding protein 3 
KCNS1 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 NKAIN1 Na+/K+ transporting ATPase interacting 1 
KCNS2 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 NKAIN2 Na+/K+ transporting ATPase interacting 2 
KCNT1 potassium channel, subfamily T, member 1 NKAIN3 Na+/K+ transporting ATPase interacting 3 
KCNT2 potassium channel, subfamily T, member 2 NKAIN4 Na+/K+ transporting ATPase interacting 4 
KCNU1 potassium channel, subfamily U, member 1 NOX5 NADPH oxidase, EF-hand calcium binding domain 5 
KCNV1 potassium channel, subfamily V, member 1 NUTF2 nuclear transport factor 2 
KCNV2 potassium channel, subfamily V, member 2 NXT2 nuclear transport factor 2-like export factor 2 
KCTD1 potassium channel tetramerisation domain containing 1 ORAI1 ORAI calcium release-activated calcium modulator 1 
KCTD10 potassium channel tetramerisation domain containing 10 ORAI2 ORAI calcium release-activated calcium modulator 2 
KCTD11 potassium channel tetramerisation domain containing 11 P2RX1 purinergic receptor P2X, ligand-gated ion channel, 1 
KCTD12 potassium channel tetramerisation domain containing 12 P2RX2 purinergic receptor P2X, ligand-gated ion channel, 2 
KCTD15 potassium channel tetramerisation domain containing 15 P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4 
KCTD16 potassium channel tetramerisation domain containing 16 P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5 
KCTD17 potassium channel tetramerisation domain containing 17 P2RX6 purinergic receptor P2X, ligand-gated ion channel, 6 
KCTD18 potassium channel tetramerisation domain containing 18 P2RX6P purinergic receptor P2X, ligand-gated ion channel, 6 pseudogene 
KCTD19 potassium channel tetramerisation domain containing 19 P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7 
KCTD2 potassium channel tetramerisation domain containing 2 PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 
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KCTD20 potassium channel tetramerisation domain containing 20 PLA2G4C phospholipase A2, group IVC (cytosolic, calcium-independent) 
KCTD3 potassium channel tetramerisation domain containing 3 PLA2G6 phospholipase A2, group VI (cytosolic, calcium-independent) 
KCTD4 potassium channel tetramerisation domain containing 4 PPEF1 protein phosphatase, EF-hand calcium binding domain 1 
KCTD5 potassium channel tetramerisation domain containing 5 PPEF2 protein phosphatase, EF-hand calcium binding domain 2 
KCTD6 potassium channel tetramerisation domain containing 6 RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
KCTD7 potassium channel tetramerisation domain containing 7 RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) 
KCTD8 potassium channel tetramerisation domain containing 8 RASGRP3 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 
KCTD9 
similar to Potassium channel tetramerisation domain containing 9; 
potassium channel tetramerisation domain containing 9; similar to 
potassium channel tetramerisation domain containing 9 
RCN1 reticulocalbin 1, EF-hand calcium binding domain 
LOC284379 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 3 pseudogene 
RCN2 reticulocalbin 2, EF-hand calcium binding domain 
MAGT1 magnesium transporter 1 RCN3 reticulocalbin 3, EF-hand calcium binding domain 
MITD1 MIT, microtubule interacting and transport, domain containing 1 RGP1 RGP1 retrograde golgi transport homolog (S. cerevisiae) 
MMGT1 membrane magnesium transporter 1 RTP1 receptor (chemosensory) transporter protein 1 
NALCN sodium leak channel, non-selective RTP2 receptor (chemosensory) transporter protein 2 
RTP3 receptor (chemosensory) transporter protein 3 SCN7A sodium channel, voltage-gated, type VII, alpha 
RTP4 receptor (chemosensory) transporter protein 4 SCN8A sodium channel, voltage gated, type VIII, alpha subunit 
S100A1 S100 calcium binding protein A1 SCN9A sodium channel, voltage-gated, type IX, alpha subunit 
S100A10 S100 calcium binding protein A10 SCNN1A sodium channel, nonvoltage-gated 1 alpha 
S100A11 
S100 calcium binding protein A11; S100 calcium binding protein A11 
pseudogene 
SCNN1B sodium channel, nonvoltage-gated 1, beta 
S100A12 S100 calcium binding protein A12 SCNN1D sodium channel, nonvoltage-gated 1, delta 
S100A13 S100 calcium binding protein A13 SCNN1G sodium channel, nonvoltage-gated 1, gamma 
S100A14 S100 calcium binding protein A14 SLC10A1 solute carrier family 10 (sodium/bile acid cotransporter family), member 1 
S100A16 S100 calcium binding protein A16 SLC10A2 solute carrier family 10 (sodium/bile acid cotransporter family), member 2 
S100A2 S100 calcium binding protein A2 SLC10A3 solute carrier family 10 (sodium/bile acid cotransporter family), member 3 
S100A3 S100 calcium binding protein A3 SLC10A6 solute carrier family 10 (sodium/bile acid cotransporter family), member 6 
S100A4 S100 calcium binding protein A4 SLC10A7 solute carrier family 10 (sodium/bile acid cotransporter family), member 7 
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S100A5 S100 calcium binding protein A5 SLC11A1 
solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 1 
S100A6 S100 calcium binding protein A6 SLC11A2 
solute carrier family 11 (proton-coupled divalent metal ion transporters), 
member 2 
S100A7 S100 calcium binding protein A7 SLC12A1 
solute carrier family 12 (sodium/potassium/chloride transporters), member 
1 
S100A7A S100 calcium binding protein A7A SLC12A2 
solute carrier family 12 (sodium/potassium/chloride transporters), member 
2 
S100A8 S100 calcium binding protein A8 SLC12A3 solute carrier family 12 (sodium/chloride transporters), member 3 
S100A9 S100 calcium binding protein A9 SLC12A4 solute carrier family 12 (potassium/chloride transporters), member 4 
S100B S100 calcium binding protein B SLC12A5 solute carrier family 12 (potassium-chloride transporter), member 5 
S100P S100 calcium binding protein P SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 
S100Z S100 calcium binding protein Z SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 
SCGN secretagogin, EF-hand calcium binding protein SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 
SCLT1 sodium channel and clathrin linker 1 SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 
SCN10A sodium channel, voltage-gated, type X, alpha subunit SLC13A1 solute carrier family 13 (sodium/sulfate symporters), member 1 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit SLC13A2 
solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 2 
SCN1A sodium channel, voltage-gated, type I, alpha subunit SLC13A3 
solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 3 
SCN1B sodium channel, voltage-gated, type I, beta SLC13A4 solute carrier family 13 (sodium/sulfate symporters), member 4 
SCN2A sodium channel, voltage-gated, type II, alpha subunit SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 
SCN2B sodium channel, voltage-gated, type II, beta SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 
SCN3A sodium channel, voltage-gated, type III, alpha subunit SLC14A2 solute carrier family 14 (urea transporter), member 2 
SCN4A sodium channel, voltage-gated, type IV, alpha subunit SLC15A1 solute carrier family 15 (oligopeptide transporter), member 1 
SCN4B sodium channel, voltage-gated, type IV, beta SLC15A2 solute carrier family 15 (H+/peptide transporter), member 2 
SCN5A sodium channel, voltage-gated, type V, alpha subunit SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 
SLC16A10 solute carrier family 16, member 10 (aromatic amino acid transporter) SLC22A16 solute carrier family 22 (organic cation/carnitine transporter), member 16 
SLC16A12 solute carrier family 16, member 12 (monocarboxylic acid transporter 12) SLC22A18AS solute carrier family 22 (organic cation transporter), member 18 antisense 
SLC16A14 solute carrier family 16, member 14 (monocarboxylic acid transporter 14) SLC22A2 solute carrier family 22 (organic cation transporter), member 2 
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SLC16A2 solute carrier family 16, member 2 (monocarboxylic acid transporter 8) SLC22A3 solute carrier family 22 (extraneuronal monoamine transporter), member 3 
SLC16A3 solute carrier family 16, member 3 (monocarboxylic acid transporter 4) SLC22A4 
solute carrier family 22 (organic cation/ergothioneine transporter), member 
4 
SLC16A4 solute carrier family 16, member 4 (monocarboxylic acid transporter 5) SLC22A5 solute carrier family 22 (organic cation/carnitine transporter), member 5 
SLC16A5 
similar to MCT; solute carrier family 16, member 5 (monocarboxylic acid 
transporter 6) 
SLC22A6 solute carrier family 22 (organic anion transporter), member 6 
SLC16A6 
solute carrier family 16, member 6 (monocarboxylic acid transporter 7); 
similar to solute carrier family 16, member 6 
SLC22A7 solute carrier family 22 (organic anion transporter), member 7 
SLC16A7 solute carrier family 16, member 7 (monocarboxylic acid transporter 2) SLC22A8 solute carrier family 22 (organic anion transporter), member 8 
SLC16A8 solute carrier family 16, member 8 (monocarboxylic acid transporter 3) SLC22A9 solute carrier family 22 (organic anion transporter), member 9 
SLC16A9 solute carrier family 16, member 9 (monocarboxylic acid transporter 9) SLC23A1 solute carrier family 23 (nucleobase transporters), member 1 
SLC17A1 solute carrier family 17 (sodium phosphate), member 1 SLC23A2 solute carrier family 23 (nucleobase transporters), member 2 
SLC17A2 solute carrier family 17 (sodium phosphate), member 2 SLC23A3 solute carrier family 23 (nucleobase transporters), member 3 
SLC17A3 solute carrier family 17 (sodium phosphate), member 3 SLC24A1 solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 
SLC17A4 solute carrier family 17 (sodium phosphate), member 4 SLC24A2 solute carrier family 24 (sodium/potassium/calcium exchanger), member 2 
SLC17A5 solute carrier family 17 (anion/sugar transporter), member 5 SLC24A3 solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 
SLC17A6 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 6 
SLC24A4 solute carrier family 24 (sodium/potassium/calcium exchanger), member 4 
SLC17A7 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 7 
SLC25A1 
solute carrier family 25 (mitochondrial carrier; citrate transporter), member 
1 
SLC17A8 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 
SLC25A10 
solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), 
member 10 
SLC19A1 solute carrier family 19 (folate transporter), member 1 SLC25A15 
solute carrier family 25 (mitochondrial carrier; ornithine transporter) 
member 15 
SLC1A1 
solute carrier family 1 (neuronal/epithelial high affinity glutamate 
transporter, system Xag), member 1 
SLC26A1 solute carrier family 26 (sulfate transporter), member 1 
SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 SLC26A2 solute carrier family 26 (sulfate transporter), member 2 
SLC1A3 solute carrier family 1 (glial high affinity glutamate transporter), member 3 SLC27A1 solute carrier family 27 (fatty acid transporter), member 1 
SLC1A4 
solute carrier family 1 (glutamate/neutral amino acid transporter), member 
4 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 
SLC1A5 solute carrier family 1 (neutral amino acid transporter), member 5 SLC27A3 solute carrier family 27 (fatty acid transporter), member 3 
SLC1A6 solute carrier family 1 (high affinity aspartate/glutamate transporter), SLC27A4 solute carrier family 27 (fatty acid transporter), member 4 
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member 6 
SLC1A7 solute carrier family 1 (glutamate transporter), member 7 SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 
SLC20A1 solute carrier family 20 (phosphate transporter), member 1 SLC27A6 solute carrier family 27 (fatty acid transporter), member 6 
SLC20A2 solute carrier family 20 (phosphate transporter), member 2 SLC28A1 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
1 
SLC22A1 solute carrier family 22 (organic cation transporter), member 1 SLC28A2 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
2 
SLC22A11 solute carrier family 22 (organic anion/urate transporter), member 11 SLC28A3 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
3 
SLC22A12 solute carrier family 22 (organic anion/urate transporter), member 12 SLC29A1 solute carrier family 29 (nucleoside transporters), member 1 
SLC22A13 solute carrier family 22 (organic anion transporter), member 13 SLC29A2 solute carrier family 29 (nucleoside transporters), member 2 
SLC29A3 
solute carrier family 29 (nucleoside transporters), member 3; Sp9 
transcription factor homolog (mouse) 
SLC35A2 solute carrier family 35 (UDP-galactose transporter), member A2 
SLC29A4 
solute carrier family 29 (nucleoside transporters), member 4; similar to 
solute carrier family 29 (nucleoside transporters), member 4 
SLC35A3 
solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) 
transporter), member A3 
SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 SLC35D1 
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1 
SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 SLC37A1 solute carrier family 37 (glycerol-3-phosphate transporter), member 1 
SLC2A11 solute carrier family 2 (facilitated glucose transporter), member 11 SLC37A2 solute carrier family 37 (glycerol-3-phosphate transporter), member 2 
SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12 SLC37A3 solute carrier family 37 (glycerol-3-phosphate transporter), member 3 
SLC2A13 solute carrier family 2 (facilitated glucose transporter), member 13 SLC37A4 solute carrier family 37 (glucose-6-phosphate transporter), member 4 
SLC2A14 solute carrier family 2 (facilitated glucose transporter), member 14 SLC39A10 solute carrier family 39 (zinc transporter), member 10 
SLC2A2 solute carrier family 2 (facilitated glucose transporter), member 2 SLC39A11 solute carrier family 39 (metal ion transporter), member 11 
SLC2A3 solute carrier family 2 (facilitated glucose transporter), member 3 SLC39A12 solute carrier family 39 (zinc transporter), member 12 
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 SLC39A13 solute carrier family 39 (zinc transporter), member 13 
SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 SLC39A14 solute carrier family 39 (zinc transporter), member 14 
SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 SLC39A2 solute carrier family 39 (zinc transporter), member 2 
SLC2A7 solute carrier family 2 (facilitated glucose transporter), member 7 SLC39A3 solute carrier family 39 (zinc transporter), member 3 
SLC2A8 solute carrier family 2 (facilitated glucose transporter), member 8 SLC39A4 solute carrier family 39 (zinc transporter), member 4 
SLC2A9 solute carrier family 2 (facilitated glucose transporter), member 9 SLC39A5 solute carrier family 39 (metal ion transporter), member 5 
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SLC30A1 solute carrier family 30 (zinc transporter), member 1 SLC39A7 solute carrier family 39 (zinc transporter), member 7 
SLC30A2 solute carrier family 30 (zinc transporter), member 2 SLC39A8 solute carrier family 39 (zinc transporter), member 8 
SLC30A3 solute carrier family 30 (zinc transporter), member 3 SLC39A9 solute carrier family 39 (zinc transporter), member 9 
SLC30A4 solute carrier family 30 (zinc transporter), member 4 SLC3A1 
solute carrier family 3 (cystine, dibasic and neutral amino acid 
transporters, activator of cystine, dibasic and neutral amino acid transport), 
member 1 
SLC30A5 solute carrier family 30 (zinc transporter), member 5 SLC3A2 
solute carrier family 3 (activators of dibasic and neutral amino acid 
transport), member 2 
SLC30A6 solute carrier family 30 (zinc transporter), member 6 SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 
SLC30A7 solute carrier family 30 (zinc transporter), member 7 SLC46A1 solute carrier family 46 (folate transporter), member 1 
SLC30A8 solute carrier family 30 (zinc transporter), member 8 SLC48A1 solute carrier family 48 (heme transporter), member 1 
SLC30A9 solute carrier family 30 (zinc transporter), member 9 SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 10 
SLC31A1 solute carrier family 31 (copper transporters), member 1 SLC4A11 solute carrier family 4, sodium borate transporter, member 11 
SLC31A2 solute carrier family 31 (copper transporters), member 2 SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
SLC32A1 solute carrier family 32 (GABA vesicular transporter), member 1 SLC4A5 solute carrier family 4, sodium bicarbonate cotransporter, member 5 
SLC33A1 solute carrier family 33 (acetyl-CoA transporter), member 1 SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 
SLC34A1 solute carrier family 34 (sodium phosphate), member 1 SLC4A8 solute carrier family 4, sodium bicarbonate cotransporter, member 8 
SLC34A2 solute carrier family 34 (sodium phosphate), member 2 SLC4A9 solute carrier family 4, sodium bicarbonate cotransporter, member 9 
SLC34A3 solute carrier family 34 (sodium phosphate), member 3 SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 
SLC35A1 solute carrier family 35 (CMP-sialic acid transporter), member A1 SLC5A10 solute carrier family 5 (sodium/glucose cotransporter), member 10 
SLC5A11 solute carrier family 5 (sodium/glucose cotransporter), member 11 SLC7A3 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 3 
SLC5A12 solute carrier family 5 (sodium/glucose cotransporter), member 12 SLC7A4 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 4 
SLC5A2 solute carrier family 5 (sodium/glucose cotransporter), member 2 SLC7A5 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 5 
SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 SLC7A6 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 6 
SLC5A4 solute carrier family 5 (low affinity glucose cotransporter), member 4 SLC7A7 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 7 
SLC5A5 solute carrier family 5 (sodium iodide symporter), member 5 SLC7A8 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 8 
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SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 SLC7A9 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 9 
SLC5A7 solute carrier family 5 (choline transporter), member 7 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
SLC5A8 solute carrier family 5 (iodide transporter), member 8 SLC8A2 solute carrier family 8 (sodium/calcium exchanger), member 2 
SLC5A9 solute carrier family 5 (sodium/glucose cotransporter), member 9 SLC8A3 solute carrier family 8 (sodium/calcium exchanger), member 3 
SLC6A1 solute carrier family 6 (neurotransmitter transporter, GABA), member 1 SLC9A1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 
SLC6A10P 
solute carrier family 6 (neurotransmitter transporter, creatine), member 10 
(pseudogene); similar to solute carrier family 6 member 8 
SLC9A2 solute carrier family 9 (sodium/hydrogen exchanger), member 2 
SLC6A11 solute carrier family 6 (neurotransmitter transporter, GABA), member 11 SLC9A3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
SLC6A12 
solute carrier family 6 (neurotransmitter transporter, betaine/GABA), 
member 12 
SLC9A3R1 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 
1 
SLC6A13 solute carrier family 6 (neurotransmitter transporter, GABA), member 13 SLC9A3R2 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 
2 
SLC6A14 solute carrier family 6 (amino acid transporter), member 14 SLC9A4 solute carrier family 9 (sodium/hydrogen exchanger), member 4 
SLC6A15 solute carrier family 6 (neutral amino acid transporter), member 15 SLC9A5 solute carrier family 9 (sodium/hydrogen exchanger), member 5 
SLC6A19 solute carrier family 6 (neutral amino acid transporter), member 19 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), member 6 
SLC6A2 
solute carrier family 6 (neurotransmitter transporter, noradrenalin), 
member 2 
SLC9A7 solute carrier family 9 (sodium/hydrogen exchanger), member 7 
SLC6A20 solute carrier family 6 (proline IMINO transporter), member 20 SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger), member 8 
SLC6A3 solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 
SLC6A4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 SLCO1A2 solute carrier organic anion transporter family, member 1A2 
SLC6A5 solute carrier family 6 (neurotransmitter transporter, glycine), member 5 SLCO1B1 solute carrier organic anion transporter family, member 1B1 
SLC6A6 solute carrier family 6 (neurotransmitter transporter, taurine), member 6 SLCO1B3 solute carrier organic anion transporter family, member 1B3 
SLC6A7 solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 SLCO1C1 solute carrier organic anion transporter family, member 1C1 
SLC6A8 solute carrier family 6 (neurotransmitter transporter, creatine), member 8 SLCO2A1 solute carrier organic anion transporter family, member 2A1 
SLC6A9 solute carrier family 6 (neurotransmitter transporter, glycine), member 9 SLCO2B1 solute carrier organic anion transporter family, member 2B1 
SLC7A1 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 1 
SLCO3A1 solute carrier organic anion transporter family, member 3A1 
SLC7A10 
solute carrier family 7, (neutral amino acid transporter, y+ system) member 
10 
SLCO4A1 solute carrier organic anion transporter family, member 4A1 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) SLCO4C1 solute carrier organic anion transporter family, member 4C1 
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member 11 
SLC7A13 
solute carrier family 7, (cationic amino acid transporter, y+ system) 
member 13 
SLCO5A1 solute carrier organic anion transporter family, member 5A1 
SLC7A14 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 14 
SLCO6A1 solute carrier organic anion transporter family, member 6A1 
SLC7A2 
solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 
SMOC1 SPARC related modular calcium binding 1 
SMOC2 SPARC related modular calcium binding 2 TRPM8 transient receptor potential cation channel, subfamily M, member 8 
STIM1 stromal interaction molecule 1 TRPV1 transient receptor potential cation channel, subfamily V, member 1 
STIM2 stromal interaction molecule 2 TRPV2 transient receptor potential cation channel, subfamily V, member 2 
TACSTD2 tumor-associated calcium signal transducer 2 TRPV3 transient receptor potential cation channel, subfamily V, member 3 
TAP1 transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) TRPV4 transient receptor potential cation channel, subfamily V, member 4 
TAP2 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) TRPV5 transient receptor potential cation channel, subfamily V, member 5 
TCIRG1 
T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 
subunit A3 
VAT1 vesicle amine transport protein 1 homolog (T. californica) 
TICAM2 
transmembrane emp24 protein transport domain containing 7; toll-like 
receptor adaptor molecule 2 
VAT1L vesicle amine transport protein 1 homolog (T. californica)-like 
TMED1 transmembrane emp24 protein transport domain containing 1 VDAC1 
voltage-dependent anion channel 1; similar to voltage-dependent anion 
channel 1 
TMED3 transmembrane emp24 protein transport domain containing 3 VDAC2 voltage-dependent anion channel 2 
TMED4 transmembrane emp24 protein transport domain containing 4 VDAC3 voltage-dependent anion channel 3 
TMED5 transmembrane emp24 protein transport domain containing 5 VTI1A vesicle transport through interaction with t-SNAREs homolog 1A (yeast) 
TMED6 transmembrane emp24 protein transport domain containing 6 VTI1B vesicle transport through interaction with t-SNAREs homolog 1B (yeast) 
TMED8 transmembrane emp24 protein transport domain containing 8 
  
TNPO1 transportin 1 
  
TNPO2 transportin 2 
  
TNPO3 transportin 3 
  
TRPA1 transient receptor potential cation channel, subfamily A, member 1 
 
TRPC1 transient receptor potential cation channel, subfamily C, member 1 
  
TRPC2 
transient receptor potential cation channel, subfamily C, member 2 
(pseudogene)  
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TRPC3 transient receptor potential cation channel, subfamily C, member 3 
  
TRPC4 transient receptor potential cation channel, subfamily C, member 4 
  
TRPC4AP 
transient receptor potential cation channel, subfamily C, member 4 
associated protein  
TRPC5 transient receptor potential cation channel, subfamily C, member 5 
  
TRPC6 transient receptor potential cation channel, subfamily C, member 6 
  
TRPC7 transient receptor potential cation channel, subfamily C, member 7 
  
TRPM1 transient receptor potential cation channel, subfamily M, member 1 
 
TRPM2 transient receptor potential cation channel, subfamily M, member 2 
 
TRPM3 transient receptor potential cation channel, subfamily M, member 3 
 
TRPM4 transient receptor potential cation channel, subfamily M, member 4 
 
TRPM5 transient receptor potential cation channel, subfamily M, member 5 
 
TRPM6 transient receptor potential cation channel, subfamily M, member 6 
 
TRPM7 transient receptor potential cation channel, subfamily M, member 7 
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Appendix Table 3: Identification of ion channel genes using GO term analysis in human ES cell-derived RPE  
GO Term biological processes Benjamini GO Term biological processes Benjamini 
cation transport 3.50E-242 acidic amino acid transport 1.10E-04 
metal ion transport 2.90E-237 response to calcium ion 1.10E-04 
monovalent inorganic cation transport 1.50E-179 regulation of heart contraction 4.10E-04 
di-, tri-valent inorganic cation transport 1.20E-45 ATP synthesis coupled proton transport 4.80E-04 
anion transport 4.90E-32 energy coupled proton transport, down electrochemical gradient 4.80E-04 
carboxylic acid transport 2.60E-30 hexose transport 5.30E-04 
amino acid transport 3.70E-23 aspartate transport 6.00E-04 
organic anion transport 5.10E-19 monosaccharide transport 6.30E-04 
ion homeostasis 1.90E-17 cell volume homeostasis 8.10E-04 
inorganic anion transport 9.00E-15 L-amino acid transport 9.50E-04 
dicarboxylic acid transport 5.10E-09 amino acid import 1.00E-03 
cellular chemical homeostasis 1.20E-08 L-amino acid import 1.00E-03 
synaptic transmission 1.70E-08 nucleobase, nucleoside and nucleotide biosynthetic process 1.30E-03 
regulation of membrane potential 2.30E-08 nucleobase, nucleoside, nucleotide and nucleic acid biosynthetic process 1.30E-03 
nucleoside triphosphate biosynthetic process 3.90E-07 regulation of action potential in neuron 3.60E-03 
proton transport 1.00E-06 cellular cation homeostasis 4.10E-03 
purine nucleoside triphosphate metabolic process 5.30E-06 D-amino acid transport 4.80E-03 
ribonucleotide biosynthetic process 6.40E-06 quaternary ammonium group transport 5.90E-03 
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ion transmembrane transport 6.20E-06 L-glutamate transport 1.10E-02 
regulation of ion transport 8.40E-06 monocarboxylic acid transport 1.10E-02 
nucleoside transport 1.70E-05 monoamine transport 2.30E-02 
purine ribonucleotide metabolic process 2.50E-05 positive regulation of ion transport 2.40E-02 
regulation of metal ion transport 2.40E-05 D-aspartate import 4.30E-02 
excretion 3.00E-05 D-aspartate transport 4.30E-02 
neutral amino acid transport 5.10E-05 neurotransmitter uptake 4.30E-02 
purine nucleotide biosynthetic process 5.70E-05 positive regulation of calcium ion transport 4.30E-02 
two-component signal transduction system (phosphorelay) 7.70E-05 nucleoside phosphate metabolic process 4.50E-02 
organic cation transport 9.10E-05 
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Appendix Table A.4: Common ion channel and ion transport genes in 
human ES cell-derived RPE with primary human foetal RPE 
ASNA1 ATP6V1G1 CLCN5 KCTD12 SLC12A9 SLC30A1 SLC6A6 
ATP1A1 ATP6V1H CLCN7 KCTD15 SLC13A3 SLC30A4 SLC6A8 
ATP1A3 ATP7A CLIC1 KCTD18 SLC16A1 SLC30A5 SLC7A1 
ATP1B1 ATP7B CLIC4 KCTD2 SLC16A10 SLC30A6 SLC7A10 
ATP1B2 ATP8A1 CLIC6 KCTD20 SLC16A14 SLC30A7 SLC7A11 
ATP1B3 ATP8A2 CLNS1A KCTD3 SLC16A2 SLC30A9 SLC7A2 
ATP2A2 ATP8B1 CUTC KCTD5 SLC16A3 SLC31A1 SLC7A5 
ATP2B1 BEST1 EFCAB2 KCTD6 SLC16A4 SLC31A2 SLC7A6 
ATP2B2 BET1L EFCAB4A KCTD7 SLC16A5 SLC33A1 SLC7A8 
ATP2B4 C2CD2 EFCAB7 KCTD9 SLC16A6 SLC35A1 SLC8A1 
ATP2C1 C2CD3 FCGRT MAGT1 SLC16A7 SLC35A2 SLCO3A1 
ATP2C2 CAB39 FXYD1 MITD1 SLC16A8 SLC35A3 SMOC2 
ATP5A1 CAB39L FXYD3 MMGT1 SLC16A9 SLC35D1 STIM1 
ATP5B CABYR FXYD6 NECAB1 SLC17A5 SLC37A3 STIM2 
ATP5C1 CACNA1A GCA NECAB2 SLC19A1 SLC37A4 TMED1 
ATP5F1 CACNA1C GOLT1B NECAB3 SLC1A4 SLC39A10 TMED3 
ATP5G1 CACNA1D IFT122 NUTF2 SLC20A1 SLC39A11 TMED4 
ATP5G3 CACNA2D1 IFT140 NXT2 SLC20A2 SLC39A12 TMED5 
ATP5H CACNA2D2 IFT172 ORAI2 SLC22A3 SLC39A13 TMED8 
ATP5J2 CACNA2D4 IFT20 P2RX4 SLC22A5 SLC39A14 TNPO1 
ATP5L CACNB2 IFT52 PLA2G4A SLC22A8 SLC39A3 TNPO2 
ATP5O CACNB4 IFT57 PLA2G6 SLC23A2 SLC39A4 TNPO3 
ATP5S CALCOCO1 IFT74 RASGRP1 SLC24A1 SLC39A8 TRPC1 
ATP6AP1 CALCOCO2 IFT80 RASGRP3 SLC24A3 SLC39A9 TRPC4 
ATP6AP1L CAMK2B IFT81 RCN1 SLC25A1 SLC3A1 TRPC4AP 
ATP6AP2 CAMK2D IFT88 RCN2 SLC25A10 SLC3A2 TRPM1 
ATP6V0A1 CAMK2G KCMF1 RGP1 SLC25A15 SLC40A1 TRPM3 
ATP6V0A2 CAMKK2 KCNAB1 RICTOR SLC26A2 SLC46A1 TRPM4 
ATP6V0B CAMLG KCNAB2 S100A10 SLC27A1 SLC48A1 TRPM6 
ATP6V0C CANT1 KCND2 S100A13 SLC27A2 SLC4A1AP TRPM7 
ATP6V0D1 CASK KCNE3 S100A16 SLC27A3 SLC4A2 VAT1 
ATP6V0E1 CCBE1 KCNH5 S100A6 SLC27A6 SLC4A4 VAT1L 
ATP6V0E2 CHAC2 KCNJ13 S100B SLC29A1 SLC4A5 VDAC1 
ATP6V1A CHERP KCNJ3 SLC10A7 SLC29A2 SLC4A7 VDAC2 
ATP6V1B2 CIB1 KCNMB4 SLC11A2 SLC29A4 SLC5A3 VDAC3 
ATP6V1C1 CIB2 KCNQ4 SLC12A1 SLC2A1 SLC5A6 VTI1A 
ATP6V1C2 CLCC1 KCNT2 SLC12A2 SLC2A10 SLC6A12 VTI1B 
ATP6V1D CLCN2 KCNV2 SLC12A6 SLC2A11 SLC6A13 
 ATP6V1E1 CLCN3 KCTD1 SLC12A7 SLC2A12 SLC6A15 
 ATP6V1F CLCN4 KCTD10 SLC12A8 SLC2A13 SLC6A20 
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Appendix Table A.5: Common ion channel and ion transport 
genes in human ES cell-derived RPE with primary human adult 
RPE 
ASNA1 ATP8B1 IFT80 SLC12A6 SLC4A1AP 
ATP1A1 BEST1 IFT81 SLC12A7 SLC4A4 
ATP1A2 BET1L IFT88 SLC16A1 SLC4A5 
ATP1A3 C2CD2 KCMF1 SLC16A14 SLC4A7 
ATP1B1 CAB39 KCNAB1 SLC16A3 SLC5A3 
ATP1B2 CAB39L KCNE3 SLC16A4 SLC6A12 
ATP1B3 CACNA1A KCNH7 SLC16A6 SLC6A13 
ATP2A2 CACNA1D KCNJ13 SLC16A8 SLC6A15 
ATP2B1 CACNA2D1 KCNJ14 SLC17A5 SLC6A20 
ATP2B2 CACNA2D4 KCNQ4 SLC17A7 SLC6A6 
ATP2C1 CACNB2 KCNT2 SLC1A4 SLC6A8 
ATP5A1 CALCOCO2 KCNV2 SLC1A7 SLC7A1 
ATP5B CAMK2D KCTD1 SLC20A1 SLC7A11 
ATP5C1 CAMK2G KCTD10 SLC22A8 SLC7A2 
ATP5F1 CAMKK1 KCTD12 SLC23A2 SLC7A5 
ATP5G3 CAMLG KCTD15 SLC24A1 SLC7A6 
ATP5H CANT1 KCTD18 SLC25A1 SLC7A8 
ATP5J2 CASK KCTD3 SLC26A2 SLC8A1 
ATP5L CHERP KCTD4 SLC27A1 SLCO1A2 
ATP5O CIB1 KCTD6 SLC27A2 SLCO1C1 
ATP5S CLCC1 KCTD7 SLC2A1 SLCO3A1 
ATP6AP1 CLCN3 KCTD9 SLC2A12 SLCO4A1 
ATP6AP2 CLCN4 MAGT1 SLC2A3 SMOC2 
ATP6V0A1 CLCN5 MITD1 SLC2A9 STIM2 
ATP6V0B CLCN7 NECAB3 SLC30A1 TAP2 
ATP6V0C CLIC1 NUTF2 SLC30A5 TMED4 
ATP6V0D1 CLIC4 NXT2 SLC30A7 TMED5 
ATP6V0D2 CLIC5 ORAI2 SLC30A8 TMED8 
ATP6V0E1 CLIC6 PLA2G6 SLC30A9 TNPO1 
ATP6V0E2 CLNS1A RASGRP1 SLC31A2 TNPO3 
ATP6V1A CUTC RCN1 SLC33A1 TRPC1 
ATP6V1B2 EFCAB2 RCN2 SLC35A2 TRPC4AP 
ATP6V1C1 EFCAB4B RICTOR SLC35A3 TRPM1 
ATP6V1D EFCAB7 S100A10 SLC35D1 TRPM3 
ATP6V1E1 FXYD3 S100A12 SLC39A10 TRPM7 
ATP6V1F FXYD5 S100A6 SLC39A12 VAT1 
ATP6V1G1 GCA S100A8 SLC39A14 VAT1L 
ATP6V1H GOLT1B S100A9 SLC39A8 VDAC1 
ATP7A IFT122 SLC11A2 SLC39A9 VDAC2 
ATP7B IFT20 SLC12A2 SLC3A2 VDAC3 
ATP8A1 IFT57 SLC12A5 SLC40A1 VTI1B 
  
  Appendix   
197 
 
Appendix Table A.6: Shared expression of K+ and Na+ genes in normal and F305S-mutant BEST1 human ES cell-derived RPE 
Gene symbol Gene name Gene symbol Gene name 
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 polypeptide SLC13A4 solute carrier family 13 (sodium/sulfate symporters), member 4 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide SLC17A7 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 7 
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide SLC24A1 
solute carrier family 24 (sodium/potassium/calcium exchanger), member 
1 
ATP1B1 ATPase, Na+/K+ transporting, beta 1 polypeptide SLC4A4 solute carrier family 4, sodium bicarbonate cotransporter, member 4 
ATP1B2 ATPase, Na+/K+ transporting, beta 2 polypeptide SLC4A5 solute carrier family 4, sodium bicarbonate cotransporter, member 5 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide SLC4A7 solute carrier family 4, sodium bicarbonate cotransporter, member 7 
KCMF1 potassium channel modulatory factor 1 SLC5A3 solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 
KCNAB1 
potassium voltage-gated channel, shaker-related subfamily, beta member 
1 SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 
KCNE3 potassium voltage-gated channel, Isk-related family, member 3 SLC9A3R1 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 
1 
KCNH7 potassium voltage-gated channel, subfamily H (eag-related), member 7 SLC9A6 solute carrier family 9 (sodium/hydrogen exchanger), member 6 
KCNJ13 potassium inwardly-rectifying channel, subfamily J, member 13 ATP12A ATPase, H+/K+ transporting, nongastric, alpha polypeptide 
KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14 ATP1A4 ATPase, Na+/K+ transporting, alpha 4 polypeptide 
KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4 ATP1B4 ATPase, (Na+)/K+ transporting, beta 4 polypeptide 
KCNT2 potassium channel, subfamily T, member 2 HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1 
KCNV2 potassium channel, subfamily V, member 2 HCN2 hyperpolarization activated cyclic nucleotide-gated potassium channel 2 
KCTD1 potassium channel tetramerisation domain containing 1 HCN3 hyperpolarization activated cyclic nucleotide-gated potassium channel 3 
KCTD10 potassium channel tetramerisation domain containing 10 HCN4 hyperpolarization activated cyclic nucleotide-gated potassium channel 4 
KCTD12 potassium channel tetramerisation domain containing 12 KCNA10 potassium voltage-gated channel, shaker-related subfamily, member 10 
KCTD15 potassium channel tetramerisation domain containing 15 KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 2 
KCTD18 potassium channel tetramerisation domain containing 18 KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3 
KCTD3 potassium channel tetramerisation domain containing 3 KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5 
KCTD4 potassium channel tetramerisation domain containing 4 KCNA6 potassium voltage-gated channel, shaker-related subfamily, member 6 
KCTD6 potassium channel tetramerisation domain containing 6 KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7 
KCTD7 potassium channel tetramerisation domain containing 7 KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 
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2 
KCTD9 
similar to Potassium channel tetramerisation domain containing 9; 
potassium channel tetramerisation domain containing 9; similar to 
potassium channel tetramerisation domain containing 9 KCNAB3 
potassium voltage-gated channel, shaker-related subfamily, beta member 
3 
NALCN sodium leak channel, non-selective KCNB1 potassium voltage-gated channel, Shab-related subfamily, member 1 
SCLT1 sodium channel and clathrin linker 1 KCNB2 potassium voltage-gated channel, Shab-related subfamily, member 2 
SLC12A2 
solute carrier family 12 (sodium/potassium/chloride transporters), 
member 2 KCNC1 potassium voltage-gated channel, Shaw-related subfamily, member 1 
SLC12A5 solute carrier family 12 (potassium-chloride transporter), member 5 KCNC2 potassium voltage-gated channel, Shaw-related subfamily, member 2 
SLC12A6 solute carrier family 12 (potassium/chloride transporters), member 6 KCNC3 potassium voltage-gated channel, Shaw-related subfamily, member 3 
SLC12A7 solute carrier family 12 (potassium/chloride transporters), member 7 KCNC4 potassium voltage-gated channel, Shaw-related subfamily, member 4 
KCND1 potassium voltage-gated channel, Shal-related subfamily, member 1 KCNK3 potassium channel, subfamily K, member 3 
KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2 KCNK4 potassium channel, subfamily K, member 4 
KCNE1 potassium voltage-gated channel, Isk-related family, member 1 KCNK5 potassium channel, subfamily K, member 5 
KCNE2 potassium voltage-gated channel, Isk-related family, member 2 KCNK6 potassium channel, subfamily K, member 6 
KCNE4 potassium voltage-gated channel, Isk-related family, member 4 KCNK7 potassium channel, subfamily K, member 7 
KCNG1 potassium voltage-gated channel, subfamily G, member 1 KCNMA1 
potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1 
KCNG2 potassium voltage-gated channel, subfamily G, member 2 KCNMB1 
potassium large conductance calcium-activated channel, subfamily M, 
beta member 1 
KCNG4 potassium voltage-gated channel, subfamily G, member 4 KCNMB2 
potassium large conductance calcium-activated channel, subfamily M, 
beta member 2 
KCNH1 potassium voltage-gated channel, subfamily H (eag-related), member 1 KCNMB3 
potassium large conductance calcium-activated channel, subfamily M 
beta member 3 
KCNH2 potassium voltage-gated channel, subfamily H (eag-related), member 2 KCNMB4 
potassium large conductance calcium-activated channel, subfamily M, 
beta member 4 
KCNH3 potassium voltage-gated channel, subfamily H (eag-related), member 3 KCNN1 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 1 
KCNH4 potassium voltage-gated channel, subfamily H (eag-related), member 4 KCNN2 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 2 
KCNH5 potassium voltage-gated channel, subfamily H (eag-related), member 5 KCNN3 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 3 
KCNH6 potassium voltage-gated channel, subfamily H (eag-related), member 6 KCNN4 
potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4 
KCNH8 potassium voltage-gated channel, subfamily H (eag-related), member 8 KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 
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KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1 KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member 2 
KCNJ10 potassium inwardly-rectifying channel, subfamily J, member 10 KCNQ3 potassium voltage-gated channel, KQT-like subfamily, member 3 
KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11 KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5 
KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 KCNS1 
potassium voltage-gated channel, delayed-rectifier, subfamily S, member 
1 
KCNJ16 potassium inwardly-rectifying channel, subfamily J, member 16 KCNS2 
potassium voltage-gated channel, delayed-rectifier, subfamily S, member 
2 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 KCNT1 potassium channel, subfamily T, member 1 
KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3 KCNU1 potassium channel, subfamily U, member 1 
KCNJ4 potassium inwardly-rectifying channel, subfamily J, member 4 KCNV1 potassium channel, subfamily V, member 1 
KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5 KCTD11 potassium channel tetramerisation domain containing 11 
KCNJ6 potassium inwardly-rectifying channel, subfamily J, member 6 KCTD16 potassium channel tetramerisation domain containing 16 
KCNJ9 potassium inwardly-rectifying channel, subfamily J, member 9 KCTD17 potassium channel tetramerisation domain containing 17 
KCNK1 potassium channel, subfamily K, member 1 KCTD19 potassium channel tetramerisation domain containing 19 
KCNK10 potassium channel, subfamily K, member 10 KCTD2 potassium channel tetramerisation domain containing 2 
KCNK13 potassium channel, subfamily K, member 13 KCTD20 potassium channel tetramerisation domain containing 20 
KCNK15 potassium channel, subfamily K, member 15 KCTD5 potassium channel tetramerisation domain containing 5 
KCNK16 potassium channel, subfamily K, member 16 KCTD8 potassium channel tetramerisation domain containing 8 
KCNK17 potassium channel, subfamily K, member 17 NKAIN1 Na+/K+ transporting ATPase interacting 1 
KCNK2 potassium channel, subfamily K, member 2 NKAIN2 Na+/K+ transporting ATPase interacting 2 
NKAIN3 Na+/K+ transporting ATPase interacting 3 SLC17A1 solute carrier family 17 (sodium phosphate), member 1 
NKAIN4 Na+/K+ transporting ATPase interacting 4 SLC17A2 solute carrier family 17 (sodium phosphate), member 2 
SCN10A sodium channel, voltage-gated, type X, alpha subunit SLC17A3 solute carrier family 17 (sodium phosphate), member 3 
SCN11A sodium channel, voltage-gated, type XI, alpha subunit SLC17A4 solute carrier family 17 (sodium phosphate), member 4 
SCN1A sodium channel, voltage-gated, type I, alpha subunit SLC17A6 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 6 
SCN1B sodium channel, voltage-gated, type I, beta SLC17A8 
solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 8 
SCN2A sodium channel, voltage-gated, type II, alpha subunit SLC24A2 
solute carrier family 24 (sodium/potassium/calcium exchanger), member 
2 
SCN2B sodium channel, voltage-gated, type II, beta SLC24A3 
solute carrier family 24 (sodium/potassium/calcium exchanger), member 
3 
SCN3A sodium channel, voltage-gated, type III, alpha subunit SLC24A4 
solute carrier family 24 (sodium/potassium/calcium exchanger), member 
4 
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SCN4A sodium channel, voltage-gated, type IV, alpha subunit SLC28A1 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
1 
SCN4B sodium channel, voltage-gated, type IV, beta SLC28A2 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
2 
SCN5A sodium channel, voltage-gated, type V, alpha subunit SLC28A3 
solute carrier family 28 (sodium-coupled nucleoside transporter), member 
3 
SCN7A sodium channel, voltage-gated, type VII, alpha SLC34A1 solute carrier family 34 (sodium phosphate), member 1 
SCN8A sodium channel, voltage gated, type VIII, alpha subunit SLC34A2 solute carrier family 34 (sodium phosphate), member 2 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit SLC34A3 solute carrier family 34 (sodium phosphate), member 3 
SCNN1A sodium channel, nonvoltage-gated 1 alpha SLC4A10 solute carrier family 4, sodium bicarbonate transporter, member 10 
SCNN1B sodium channel, nonvoltage-gated 1, beta SLC4A11 solute carrier family 4, sodium borate transporter, member 11 
SCNN1D sodium channel, nonvoltage-gated 1, delta SLC4A8 solute carrier family 4, sodium bicarbonate cotransporter, member 8 
SCNN1G sodium channel, nonvoltage-gated 1, gamma SLC4A9 solute carrier family 4, sodium bicarbonate cotransporter, member 9 
SLC10A1 
solute carrier family 10 (sodium/bile acid cotransporter family), member 
1 SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 
SLC10A2 
solute carrier family 10 (sodium/bile acid cotransporter family), member 
2 SLC5A10 solute carrier family 5 (sodium/glucose cotransporter), member 10 
SLC10A3 
solute carrier family 10 (sodium/bile acid cotransporter family), member 
3 SLC5A11 solute carrier family 5 (sodium/glucose cotransporter), member 11 
SLC10A6 
solute carrier family 10 (sodium/bile acid cotransporter family), member 
6 SLC5A12 solute carrier family 5 (sodium/glucose cotransporter), member 12 
SLC10A7 
solute carrier family 10 (sodium/bile acid cotransporter family), member 
7 SLC5A2 solute carrier family 5 (sodium/glucose cotransporter), member 2 
SLC12A1 
solute carrier family 12 (sodium/potassium/chloride transporters), 
member 1 SLC5A5 solute carrier family 5 (sodium iodide symporter), member 5 
SLC12A3 solute carrier family 12 (sodium/chloride transporters), member 3 SLC5A6 solute carrier family 5 (sodium-dependent vitamin transporter), member 6 
SLC12A4 solute carrier family 12 (potassium/chloride transporters), member 4 SLC5A9 solute carrier family 5 (sodium/glucose cotransporter), member 9 
SLC12A8 solute carrier family 12 (potassium/chloride transporters), member 8 SLC8A2 solute carrier family 8 (sodium/calcium exchanger), member 2 
SLC12A9 solute carrier family 12 (potassium/chloride transporters), member 9 SLC8A3 solute carrier family 8 (sodium/calcium exchanger), member 3 
SLC13A1 solute carrier family 13 (sodium/sulfate symporters), member 1 SLC9A1 solute carrier family 9 (sodium/hydrogen exchanger), member 1 
SLC13A2 
solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 2 SLC9A2 solute carrier family 9 (sodium/hydrogen exchanger), member 2 
SLC13A3 
solute carrier family 13 (sodium-dependent dicarboxylate transporter), 
member 3 SLC9A3 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
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SLC13A5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 SLC9A3R2 
solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 
2 
SLC9A4 solute carrier family 9 (sodium/hydrogen exchanger), member 4     
SLC9A5 solute carrier family 9 (sodium/hydrogen exchanger), member 5     
SLC9A7 solute carrier family 9 (sodium/hydrogen exchanger), member 7     
SLC9A8 solute carrier family 9 (sodium/hydrogen exchanger), member 8     
SLC9A9 solute carrier family 9 (sodium/hydrogen exchanger), member 9     
